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Abstract 


T cell infiltration into tumours is essential for tumour antigen recognition and tumour cell 
elimination. The aim of this study was to develop a better understanding of T cell infiltration 
into tumours, focusing on two opposing arms of an immune response, anti-tumour CD8 T 
cells and Regulatory T cells (Tregs). Activated CD4 T helper cells are also of importance but 
could not be studied due to the time constraints of the project. The effect of T cell signalling 
at the immunological synapse following interactions between T cells and APCs presenting 
cognate antigen have been well studied [1]. The endothelium is neither a stereotypical APC 
nor simply a passive filter barrier for non-cognate infiltrating T cells. The endothelium can 
actively influence the development of an inflammatory response depending on the functional 
state of both the endothelium and interacting T cells (resting versus recently activated T cells) 
and the type of interactions (cognate versus non-cognate). The hypothesis was that 
recognition of antigens presented in the context of major histocompatibility complex (MHC) 
molecules by endothelium aids T cell transmigration and hence infiltration into tissues, 
including into tumours. 
 
In this study, the data highlights that high avidity TRP-2 specific CD8 T cell transmigration 
across murine lung endothelium requires recognition of TRP-2 peptide presented by the 
endothelium, aiding recruitment of antigen-specific T cells into tissues in the absence of 
endothelial cell killing.  In order for antigen specific T cells to migrate into the tumour, the 
tumour endothelium therefore needs to present tumour antigens.  
 
In addition to CD8 T cells, high numbers of Tregs have been found within tumours but the 
key mediators for this recruitment remain uncertain. The data shows a novel mechanism for 
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Treg transmigration where cognate antigen-specific recognition of self-peptides was required 
for transmigration with preferential transmigration of Tregs across syngeneic rather than 
allogeneic endothelium. Upregulation of major histocompatibility complex (MHC) class II 
and adhesion molecules, by IFN-γ and TNF-α, together with a gradient of the tumour-
associated chemokine CXCL12 were also pre-requisites for efficient Treg transmigration. 
Previous studies have shown that high CXCL12 expression can induce fugetaxis of tumour 
cells leading to efficient metastatic spread and a poor prognosis. These results would suggest 
that low levels of CXCL12 and recognition of self peptides presented by self MHC on 
endothelial cells allows efficient migration of Tregs whereas higher levels of CXCL12 may 
promote tumour metastases and lead to fugetaxis of the Tregs leading to an even worse 
prognosis.  
 
In conclusion recognition of cognate antigen presented by endothelium enhances antigen-
specific transmigration of CD8 and Regulatory T cells. This study therefore reports a novel 
mechanism for T cell subset infiltration into tumours where high avidity CD8 T cells require 
recognition of cognate tumour antigen presented on tumour endothelium in the context of 
MHC class I and conversely regulatory T cell infiltration into tumours depends on the 
repertoire of self-peptides presented on tumour endothelium in the context of MHC class II. 
Alteration of antigen presentation or MHC expression on tumour endothelium therefore 
represents a mechanism whereby T cell infiltration can be altered to re-direct anti-tumour 
immune responses. 
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Chapter 1: Introduction 

Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing 
an immune response. The aim of cancer immunotherapy is to reject tumours by stimulating 
the patient's immune system to attack the malignant tumour cells that are responsible for the 
disease. The identification of tumour antigens, has allowed the development of antigen-
specific vaccines and a number of these are to self antigens. However, the immune system is 
inherently programmed to regulate immune response to self-antigens in order to prevent 
autoimmunity. The effectiveness of anti-tumour vaccines is also limited by the evasion 
strategies evolved by tumours. The ultimate goal of a cancer vaccine is to stimulate the 
immune system and generate effector T cells that localise and kill tumours. This thesis 
investigates the mechanisms of immune migration into tumours and signals that alter the 
tumour environment.  

1.1 Immunity – The lymphoid system 
 
The adaptive immune response allows immunological memory to develop towards a 
particular antigen resulting in a more rapid response on second exposure. The development of 
effective cancer vaccines relies on the formation of this immunological memory against 
tumour antigens. Lymphocytes are divided into T and B cells, which bear antigen specific 
receptors on their surface, however this introduction will focus on T lymphocytes. 
 
1.1.1 T lymphocytes 
 
T lymphocytes are derived from the bone marrow and migrate to the thymus for maturation. 
T cells express a membrane receptor for antigen known as the T cell receptor (TCR). Unlike 
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B cells, T cells are unable to recognise native antigen and instead recognise short peptide 
sequences presented by the MHC on the surface of an antigen presenting cells (APC) forming 
an immunological synapse [1]. The TCR molecule exists as a heterodimer and the majority of 
T cells possess alpha (α) and beta (β) chains, although gamma (γ) and delta (δ) forms also 
exist. Each chain of a TCR contains a variable and constant region where the variable 
domains are responsible for recognition of peptide via three complementarity determining 
regions (CDRs).Associated with the TCR on the cell surface are co-receptors such as CD3 
which activate intracellular signalling pathways upon TCR binding to cognate peptide 
presented via MHC molecules (peptide:MHC complexes) [2]. There are two main types of T 
cells which are dependent on the surface expression of further co-receptors CD4 and CD8 
which also contribute to the MHC restriction of the T cell [3].  Helper T cells are denoted by 
a CD4+CD8-T cell phenotype and recognise only antigen presented in association with MHC 
class II. Conversely, CD4-CD8+ T cells recognise only antigen presented in association with 
MHC class I and are known as cytotoxic T cells (CTLs) [4]. Due to the different antigen 
processing pathways leading to antigen presentation in association with MHC class I and II, 
CD4+ and CD8+ T cells primarily respond to exogenous and endogenous antigens 
respectively. This difference in antigen specificity contributes to the diverse effector 
functions of these two sub types of T cells.
 
1.1.2 The Major Histocompatibility Complex 
 
The major histocompatibility complex contains genes essential for the normal function and 
diversity of the immune response where MHC molecules are cell surface glycoproteins that 
present protein fragments (peptides) on the cell surface. The MHC complex can therefore 
influence immune recognition during infection and is involved in other biological processes 
such as mating preferences, kin recognition and pregnancy [5,6].  
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The MHC complex in man is called the human leukocyte antigen (HLA) system, HLA class I 
antigens are denoted as HLA-A, B and C with minor antigens E, F and G also present [7]. 
Major HLA class II genes include HLA-DP, DQ and DR. Within mice the MHC complex is 
called H-2 and also contains MHC class I and II molecules where class I contains two major 
types, H-2K and D and the class II contains H-2A and E formed by one alpha and one beta 
chain to make one class II molecule [8]. The murine class II MHC complex is also referred to 
as the I region or Ia antigens. Homozygous mouse strains are specific for one haplotype such 
that the haplotype for C57Bl/6 mice is H2
b
 and for Balb/c it is H2
d
. With the advance of 
transgenic mice it is now possible to generate murine models expressing human MHC 
molecules to aid research into organ transplantations, infectious disease, autoimmunity and 
cancer [9]. 

1.1.3 T cell education and differentiation 
 
Burnet first proposed the idea of tolerance to self, when he suggested that autoreactive T cells 
are generated randomly and deleted during development of the immune system [10]. T cell 
education occurs within the thymus and ensures that developing T cells encounter antigens 
presented on self MHC molecules. This process determines the available repertoire of T cells 
subsequently present in the periphery as during thymic selection few of T cells that enter the 
thymus actually leave. Thymic selection can be divided into two main components: positive 
and negative selection where around 95% of the developing thymocytes are eliminated 
generating central tolerance of T cells to autoantigens in the periphery [11]. Positive selection 
results in T cells with a functional TCR [12], followed by negative selection to ensure that the 
TCR does not strongly recognise self antigens [13]. During development in the thymus the 
recognition of self peptide by CD8+CD4+ pre T cell thymocytes  occurs by interaction with 
thymic stromal cells [14] and thymic education is determined by the affinity of this self 
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peptide recognition. The high rate of elimination of developing T cells is due to most 
thymocytes (80−90%) either failing to express a functional TCR or synthesising TCRs with 
little affinity for self peptide:MHC complexes which therefore die by ‘neglect’ due to lack of 
signalling to maintain cellular homeostasis [15].  
 
A model of activation thresholds has been proposed for the generation of T cells in the 
thymus that depends on a threshold for T cell activation [16]. The strength (affinity) of the 
interaction between a TCR and MHC on an APC determines a T cells fate.  If the affinity of 
the interaction is too low and fails to reach the threshold of activation the T cell is eliminated 
(positive selection). Alternatively, if the affinity is too high and therefore over the threshold 
of activation, the T cell is eliminated by negative selection. Natural T regulatory cells (Tregs) 
in the thymus are generated as a result of an interaction with self antigen that is between 
thresholds for positive selection and clonal deletion, insufficient to reach the threshold for 
thymic deletion but is insufficient for full activation of the thymocytes [17].  In this way 
natural Tregs form a suppressive T cell population able to regulate peripheral immune 
responses and prevent autoimmuity [18]. Within the periphery, just as in the thymus, 
activation thresholds determine T cell fate where activation over a threshold leads to an 
effector T cell phenotype whereas if activation falls under a threshold this results in 
incomplete activation and may lead to regulatory functions [19]. Defective T cell education 
could lead to hyperproliferation of T cells causing problems such as severe immune 
deficiency and autoimmune diseases dependent of T cell subsets affected. 
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1.1.4 T cell activation  
 
Mature but antigen inexperienced (naive) T cells leave primary lymphoid organs and 
circulate between the blood and secondary lymphoid tissues [20]. T cells interact with antigen 
displayed on APCs within T cell dependent areas of these secondary lymphoid tissues.  
Bretscher and Cohn suggested that naive precursor T cells require the generation of two 
signals for full activation [21]; signal 1 is generated after the interaction of the T cell receptor 
with its ligand, (MHC:peptide), whereas signal 2 is generated via an interaction between 
costimulatory molecules on the antigen-presenting cell and counter receptors on the T cell 
[22].  More recently a third component has been included forming signal 3 which is generated 
via the presence of cytokines such as IL-12. Signal 3, although not essential for T cell 
activation and proliferation where high antigen stimulus is present, has been shown to be 
necessary for full development of T cell effector function [23].  For CD8 T cells the third 
signal is provided by IL-12 which is necessary for proliferation and development of cytolytic 
function following stimulation with antigen and B7 cosimulation. 
Stimulation of T cells via TCR interaction with cognate peptide presented in the context of 
MHC class I results in activation of the Src family kinase Lck is leading to the 
phosphorylation of ITAMs (immune-receptor tyrosine-based activation motifs) on the 
subunits (CD3-ε,δ,γ and ζ) of the TCR [24]. This interaction results in activation of the 
tyrosine kinase ZAP-70 and subsequently activation of the Ras signalling pathway allowing 
cell proliferation, cytokine production and cytotoxicity [25]. The classical secondary co-
stimulatory signal is formed by binding of CD28 on a T cell to CD80 and CD86 (B7 
molecules) on activated dendritic cells (DCs). CD28 signalling initiates activation of 
signalling cascades, phosphorylation of a tyrosine residues and activation of PI3K [26]. The 
PI3K-dependent signalling pathway regulates functions such as cell cycle progression, 
apoptosis, cellular metabolism, and IL-2 transcription ( 	). The absence of CD28 
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engagement causes T cells to become anergic [27]. The formation of an ‘immunological 
synapse’ between a T cell and an APC also includes adhesion molecule interactions, LFA-1 
(lymphocyte function-associated antigen-1) and CD2 on T cells which bind to ICAM-1 
(intercellular adhesion molecule type-1) and LFA-3 on APCs [28]. These same co-
stimulatory cell adhesion molecules are also involved with T cell interaction with endothelial 
cells (ECs) and hence T cell trans-endothelial migration.  
 
 
 


	
	
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
		
	[26] .  
Tyrosine phosphorylation of the YMNM motif via Src family kinases initiates the binding of the p85 subunit of 
PI3K. PI3K activity leads to the production of D-3 lipids, which recruit proteins via their pleckstrin homology 
domain (PH), including PDK1 and PKB/Akt. Once PKB is phosphorylated by PDK1, PKB phosphorylates its 
downstream targets including mTOR, IκB, GSK3β and Bad. Active mTOR and IκB result in increased NF-κB 
transcriptional activity whereas the phosphorylation of Bad and GSK3β results in increased survival and NFAT 
transcriptional regulation, respectively. The activation of NF-κB and NFAT (indicated by the dotted lines) 
induces the transcription of both Bcl-XL, a prosurvival factor, and IL-2, an important T-cell cytokine required 
for proliferation as well as other genes. 
 
 
Negative regulators of T cell activation exist such as CTLA-4 [29], which also binds to B7 
molecules on antigen presenting cells, and PD-1 also a member of the extended 
CD28/CTLA-4 family of T cell regulators [30]. CTLA-4 and PD-1 regulate T cell activation 
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by causing inhibition of protein kinase B (PKB/AKT) phosphorylation, however PD-1 
signalling inhibits Akt phosphorylation by preventing CD28-mediated activation of 
phosphatidylinositol 3-kinase (PI3K) [31]. PKB/AKT phosphorylates the pro-apoptotic 
protein BAD [32], a pro-apoptotic member of the BcL-2 protein family, promoting apoptosis 
through heterodimerisation with anti-apoptotic proteins such as BcL-2 and BcL-XL [33].  

1.2 CD4 and CD8 T lymphocyte subpopulations 
 
In a simple view, MHC class I molecules present peptides from intracellular source proteins 
to CD8 T cells, whereas MHC class II molecules present antigenic peptides from exogenous 
and membrane proteins to CD4 T cells.

1.2.1 Antigen processing within CD4 T cells. 
Class II molecules display exogenous peptides from proteins phago/pinocytosed and 
degraded in lysosomes and late endosomes. Crosstalk can occur between these two pathways 
and peptide presentation alters considerably upon induction of cell component degradation 
(autophagy). The presentation of peptides from intracellular and lysosomal source proteins 
has been shown to be strongly increased on MHC class II in contrast with peptides from 
membrane and secreted proteins [34]. MHC class II proteins contain α and β chains and they 
present antigen fragments to T helper cells by binding to the CD4 receptor [35]. Within T 
helper cells MHC class II α and β chains assemble in the endoplasmic reticulum (ER) and, 
together with a glycoprotein called the invariant chain (Ii), form nonameric (αβ-Ii)3  
complexes [36]. Nonamers are then targeted to compartments of the endocytic pathway 
called MIICs (MHC class II compartments) where peptide loading occurs [37].  Following 
proteolysis Ii forms peptides called CLIP which occupy the peptide-binding groove of class II 
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αβ dimers and until replacement with tightly bound antigenic peptides derived from 
internalised antigens or endogenous proteins [38].  

1.2.2 Helper CD4+ T cell subsets 
 
Helper (Th) CD4+ T cells help both the adaptive and innate immune response by the release 
of different cytokine profiles designated as Th1 or Th2 type CD4 T cell subsets. The 
differentiation of Th1/Th2 cells is influenced by many factors such as the type and strength of 
co-stimulation, the dose of antigen and the cytokine milieu within the immediate 
microenvironment [39].  DCs influence the differentiation of Th1/Th2 effector CD4 T cells by 
the cytokines they produce, following CD40 or TLR ligation IL-12p70 is produced, which 
induces IFN-γ production and leads to a Th1 phenotype [40]. Stimulation in the absence of 
IL-12p70  leads to a Th2 phenotype, characterised by down regulation of Th1 responses and 
the production of cytokines such as IL-12p40, IL-6, or IL-10 [41]. Th2 polarisation, while 
occurring in the absence of IL-12, can occur in the presence of cytokines such as IL-4 [42]. 
In addition to different cytokine expression patterns, Th1 differentiation from naive cells is 
driven by TCR signalling and subsequent phosphorylation of STAT1 which induces the 
expression of T-bet leading to cytokine production and responsiveness to IL-12 [43]. Th1 
responses producing IL-12 and IFN-γ are pro-inflammatory and essential for cell-mediated (T 
cell) immunity and activation of CTL responses. IFN-γ has many effects on immune 
responses, including upregulation of MHC class I leading to increased antigen expression on 
APCs and therefore improving recognition and cytotoxicity of CTLs [44].  Th2 differentiation 
from naive cells is also driven by STAT6 phosphorylation and leads to the induction of the 
transcription factor GATA3 activating production of cytokines IL-4, IL-5 and IL-13 and 
simultaneously down regulating STAT4 and IL-2 receptor [45]. Th2 responses help to drive 
humoral (antibody) responses through secretion of cytokines such as IL-4, IL-5 and IL-6 [46]. 
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More recently further subsets such as Th17 have been defined. Th17 cells differentiate from 
naive cells via TGF-β and IL-6 and although this process does not require IL-23 it is essential 
for Th17 expansion and maintenance [47]. The orphan nuclear receptor RORγt is the key 
transcription factor that causes the differentiation of this effector Th17 cell lineage and is 
required for their expression in response to IL-6 and TGF-β enabling release of IL-17 [48]. 
IL-23 is also produced following activation of TLR2 and TLR4 on APCs and induces 
phosphorylation of STAT3 leading to further upregulation of the IL-23 receptor enabling 
Th17 cells to become less responsive to IL-12 and more responsive to IL-23 [49]. IL-17 
produced by Th17 cells includes six IL-17 family members (IL-17A-F) which play an active 
role in inflammatory diseases, autoimmune diseases, and cancer by coordinating local tissue 
inflammation mainly via the induced release of pro-inflammatory cytokines [50].  

1.2.3 Regulatory T cells  
 
Tregs are a collective name given to cells that have the capacity to suppress T cell 
proliferation in vitro and prevent immune pathology in vivo. Initially named suppressor T 
cells [51], they are a small subset (5-10%) of the overall CD4+ T cell population which 
regulate immune responses by maintaining a balance between effector and regulatory T cells 
[52]. Tregs form a part of the control mechanisms that ensure activated immune cells do not 
cause a threat to homeostasis, restraining inappropriate immune responses by creating an 
immunosuppressive threshold. The existence of suppressor T cells in mouse models was first 
suggested by evidence of CD4+ T cells functioning as suppressor cells in an anti-tumour 
response [53], however there remained scepticism surrounding their existence for another 
decade as the cells could not be convincingly characterised. Evidence of the existence of 
these suppressor T cells began to emerge as it was demonstrated that antigen-specific 
suppression could be adoptively transferred by injection of T cells [54]. In 1995  high 
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expression of the IL-2 receptor α chain CD25 in mouse models was recognised as a 
phenotypic marker for CD4+ regulatory T cells [55]. Sakaguchi et al demonstrated that 
elimination of CD4+CD25+ T cells in normal naïve mice resulted in the spontaneous 
development of tumour-specific effector cells and elicited potent immune responses to 
syngeneic tumours in vivo [56]. In mice, FOXP3 was found to be a control gene for Treg cell 
development and subsequent studies confirmed FOXP3 as a specific Treg marker in humans 
also [57,58]. However, within humans, both CD25 and FOXP3 expression are induced 
following T cell activation causing difficulties in identification and isolation of Tregs [59].
On average approximately 30% of CD4 T cells express CD25 with only 1-2% with the 
highest CD25 expression showing suppressive activity. CD127 (IL-7 receptor α-chain), 
although used as a marker of conventional CD4 differentiation, has also been used as a useful 
alternative to CD25 for purification of human Tregs where FOXP3 expression and 
suppressive ability are enriched in CD4+ T cells that express low levels of CD127 [60]. Tregs 
have been recognised as not only having a role in maintaining self-tolerance [61] but also in 
having a regulatory role in the whole immune response, against infectious agents, 
transplantation antigens and they can also favour tumour progression by suppressing anti-
tumour immune responses [62]. 
 
1.2.3.1 Regulatory T cell subsets  
 
Uncertainty remains about the lineages, differentiation factors, antigen specificity and 
mechanisms of action of Tregs as cytokine expression patterns and suppressive modes of 
action of subsets are not mutually exclusive and often overlap. Tregs derived from thymic 
selection are specific for self peptides and have the ability to control autoimmunity [63] 
whereas Tregs that develop within the periphery will also encounter non-self or 
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environmental peptides and have the ability to help prevent tissue pathology during an 
immune response [64].  
Several distinct regulatory T cell populations have been suggested (	) where Tregs 
play a critical role in the generation and maintenance of tolerance in addition to clonal 
deletion and anergy.  In humans, three main subsets of regulatory T cells have been 
described; thymus originating CD4+CD25+ natural Tregs and inducible Tr1s and Th3 cells. 
 
 
 
 
1.2.3.2 Natural T regulatory cells 
 
Classically natural Tregs are thought to actively suppress the proliferation of CD4 Th cells 
through contact-dependent inhibition of IL-2 production [73]. CD4+CD25+ Treg suppressive 
  !"
#$%&'   
CD4+CD25+Foxp3+ (nTreg) Thymus (Mouse  
   and Humans) 
In-vitro: cell-cell contact 
In-vivo: multiple modes of action 
[55] [65] 
CD4+CD25+Foxp3- (Tr1)        In-vitro 
      (Human) 
IL-10? [66] 
CD4+IL-10+Foxp3- (Tr1)      Periphery 
      (Mouse) 
IL-10 [67] 
CD4+TGF-β+ (Th3)      Periphery 
      (Mouse) 
TGF-β [68] 
#$(&   
CD8+CD25+       Thymus 
      (Human) 
TGF-β and CTLA-4 [69] 
CD8+CD28-      Periphery 
      (Human) 
Targeting ILT3 and ILT4 on DCs 
(Immunoglobulin-like transcript) 
[70] 
CD8+CD62L+CD122+  Not determined 
       (Mouse) 
Not determined [71] 
CD8+IL-10+      Periphery 
      (Human) 
IL-10 [72] 
	 	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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function is dependent on activation via their TCR [74] while their inhibitory effect is 
independent of the antigen specificity of the target T cell population. Studies with human 
CD4+CD25+ T cell clones confirmed that they did not produce IL-10 but that they do 
produce TGB-β, which was been implicated in their suppressive function [75]. Recent studies 
have shown that human thymically derived CD4+FOXP3+ T cells follow lineage 
differentiation [76] and can be distinguished using CD45RA/RO expression. 
CD45RA+FOXP3low CD4 T cells are designated as naive/resting Tregs with potent 
suppressive functions and are present in peripheral blood and prevalent in cord blood [77]. 
These naive Tregs proliferate after in vitro TCR stimulation and are highly resistant to 
apoptosis. Tregs with an activated phenotype CD45RA-FOXP3hi also show a suppressive 
phenotype and are terminally differentiated effector Tregs hyporesponsive to apoptotic 
stimuli. The proportions of resting or activated Tregs changes with age as natural resting Treg 
cells are constantly activated by endogenous and exogenous self antigens resulting in a 
predominantly activated Treg population within adults. 
 
As the majority of natural Tregs are found phenotypically in an activated or antigen-primed 
state, it is difficult to phenotypically distinguish nTregs from other activated effector or 
memory T cells. FOXP3 (a forkhead family transcriptional regulator) is a key intracellular 
marker of natural Tregs and essential for their development and function [65]. Under non-
inflamed conditions CTLA-4 (cytolytic T lymphocytes antigen 4) and GITR (a glucocorticoid 
inducible TNF receptor family) are also markers for natural Tregs, however these are also 
upregulated on effector T cells following TCR activation [78]. CTLA-4 is crucial for the 
suppressive function of FOXP3+ Tregs in mice both in vitro and in vivo [79]. CTLA-4 is only 
expressed at high levels by activated CD45RO+FOXP3hi Tregs and can inhibit T effector cell 
activation via regulation of CD80 and CD86 expression by dendritic cells. Another CD4+ 
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related molecule, LAG-3, that binds MHC class II has been shown to be selectively 
upregulated on natural Tregs [80]. The identification of  the constitutive expression of folate 
receptor 4 (FR4), a subtype of the receptor for the vitamin folic acid, by nTregs in high 
amounts has enabled a distinction to be seen between nTregs and naïve or activated T cells 
[81]. Treating mice with an anti-FR4 monoclonal antibody can reduce the numbers of Tregs, 
provoking tumour immunity in tumour-bearing animals whereas similar treatment in healthy 
mice caused autoimmune disease. Combinations of high or low expression of FR4 and CD25 
can distinguish four functionally different CD4+ T cell subpopulations, natural Tregs 
(FR4hiCD25+), effector T cells (FR4loCD25+), memory-like T cells (FR4hiCD25-) and 
naïve T cells (FR4loCD25-).  
 
1.2.3.3 Inducible T regulatory cells  
 
 
Besides naturally occurring CD4+CD25+ Tregs, other Tregs include Tr1 cells secreting large 
amounts of IL-10 [82] and Th3 cells secreting high levels of TGF-β, IL-4 and IL-10 [68]. 
FOXP3 is not expressed by mouse Tr1s and is expressed at lower levels on human Tr1s than 
nTregs [83]. These inducible suppressor cells are derived from conventional CD4+CD25- T 
cells in the periphery by TCR activation without the need for simultaneous co-stimulation 
[84]. Within humans IL-10 producing Tr1 cells can be induced via stimulation of resting 
CD4+ T cells with anti-CD3 and anti-CD46 antibodies [85]. Following activation by antigen-
specificity, Tr1 cells suppressive activity can be enhanced by bystander effects of IL-10 
release [67]. Tr1 cells are characterised by high levels of IL-10, IL-5 and TGF-β and low 
levels of IFN-γ and IL-2 and no IL-4 expression. Tr1s also express activation markers, 
including CD40L, CD69, CD28, CTLA-4 and human leukocyte antigen-DR (HLA-DR) and 
can be induced by immunosuppressive drugs [83] and soluble protein and peptide antigens 
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[86]. Under chronic stimulation Tr1s can also be induced from fully differentiated Th1 and 
Th2 cells secreting IL-10 (detected after 4 hours and reaching a maximum concentration after 
12-24 hours) without any other cytokines [87]. IL-15 supports Tr1 cell proliferation even in 
the absence of TCR activation and in combination with IL-2, significantly enhances the 
expansion of Tr1 cell clones [88].  The addition of IL-15 into Tr1 cell culture enhances the 
production of IFN-γ without a change in phenotype [89].  IL-10 and TGF-β expressing Tr1s 
can also modulate antigen presenting cells and T cells via not only cytokines but also via  
perforin-dependent cytotoxicity as seen in CD4+ T cells, CD14+ monocytes and DCs [90].  
 
Inducible Th3 cells were first identified as murine TGF-β producing CD4+ Tregs and are 
specific for antigens not associated with any danger signals, not presented in the thymus such 
as food antigens, self antigens such as insulin or altered self peptides. Th3 cells suppress 
bystander CD4+ proliferation by IL-10 and TGF-β production [91]. Interestingly, natural 
Tregs also have the ability to directly suppress T cell development, leading to the induction of 
IL-10 secreting Tr1 cells from co-cultured conventional CD4+ T cells [92]. 
 
1.2.4 CD4 T cell plasticity 
 
The previously described effector CD4 T cell subsets were related to the cytokines that they 
produce and the transcription factors expressed. In contrast to the expression of CD4 or CD8, 
transcriptional regulation in peripheral T cells driving gene expression profiles such as those 
encoding chemokine receptors and cytokines is much more variable [93] (	)).  
IL-12 and IFN-γ are important for Th1 cell differentiation, IL-4 drives Th2 cell 
differentiation and TGF-β and IL-6 together induce Th17 cell differentiation. RORγt is the 
transcription factor required for Th17 cell differentiation and is required for IL-17 induction. 
The finding that the Th1 and Th2 cytokines IFN-γ and IL-4 both inhibit induction of IL-17 
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convert into IFN-γ producing Th1 cells or IL-4-producing Th2 cells when stimulated by IL-
12 or IL-4, respectively. Evidence also suggests that Th2 cells can switch to IL-9 producing 
cells in response to TGF-β, controversy remains as to whether Th9 cells are a distinct lineage 
[98]. The local environment, cytokines and cell-cell contact appear to direct the fate of CD4 
T cell subsets.  

1.2.5 CD8 T cells  
 
CD8+ T cells mediate the direct killing of infected host cells expressing endogenous peptides 
derived from viral or bacterial antigens. MHC class I molecules, are expressed on almost all 
somatic nucleated cells, contain an α chain & β2-microglobulin and encode heterodimeric 
peptide-binding proteins, as well as antigen-processing molecules [35]. 
 Classically for endogenously synthesised proteins, the “direct” antigen processing pathway 
occurs within the cytoplasm. Cytosolic proteases, mainly the multi-catalytic proteasome, 
fragment polypeptide substrates into smaller antigenic intermediates, which are then imported 
into the ER by the transporter associated with antigen processing (TAP) [99]. In the ER, 
together with the nascent MHC I molecules, intermediate peptides undergo final trimming by 
proteases [100]. Stable peptides bound to MHC I molecules then leave the ER to enter the 
Golgi and finally reach the cell surface to be presented to circulating CD8 T cells. 
Professional APCs have the ability to carry out cross-presentation where exogenous antigens 
are presented on MHC class I molecules allowing CD8 CTLs to respond to exogenous 
antigens [101].  
Classical cross-presentation depends on two components of the MHC class I pathway, the 
proteasome complex and the ‘transporter associated with antigen presentation’ (TAP) [102]. 
This proteasome dependent pathway involves the transfer of antigen from the phagosome into 
the cytosol [103] where the antigens are transported by the TAP complex into the ER. 
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Antigenic peptides are then bound by MHC class I molecules and transported to the cell 
surface. The phagosome-cytosol pathway is inhibited by mutations in TAP and inhibitors of 
the proteasome. Recently an important finding was that a protein-translocation channel called 
the Sec61 complex is embedded in the ER membrane and imports newly synthesised proteins 
into the ER and exports proteins from it, targeting the proteins for degradation by the 
proteasome [104]. The alternative or proteasome independent pathway for cross presentation 
is also called the exclusive vacuolar pathway. The proteasome-independent pathway has been 
shown to be used by DCs to cross-present OVA peptide (Ovalbumin) suggesting that both 
processing and MHC I loading could occur in the phagosome [105].The study showed 
peptides cross-presented by the TAP independent pathway are produced by proteolysis on the 
phagosome where Cathepsin S is the key protease. The nature of the antigen impacts which 
of these pathways can contribute to cross-presentation in vivo perhaps dependent on whether 
a particular epitope can be generated by endosomal proteases. Once activated T cells release 
the perforin, causing pores to form within the cell membrane, allowing granzymes to enter 
the cell and subsequent activation of the caspase cascade, consisting of cysteine proteases 
which result in cell apoptosis. 
Apoptosis can also be initiated upon engagement of TCR where CTL  activation causes 
expression of the surface protein Fas ligand which can bind to Fas molecules expressed on 
the target cell [106].  Fas-Fas ligand interactions are important for the disposal of non-
essential T lymphocytes during their development. Engagement of Fas with FasL allows for 
recruitment of the death-induced silencing complex (DISC). The Fas-associated death 
domain (FADD) translocates with the DISC, allowing recruitment of procaspases 8 and 10. 
The effector caspases 3, 6, and 7 are then actvivated leading to cleavage of death substrates 
such as lamin A, lamin B1, lamin B2, PARP, and DNAPK and finally resulting in apoptosis. 
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CTLs can also recognise cells expressing altered self-antigens, facilitating the clearance of 
aberrantly transformed cells that could potentially be pathogenic, such as tumour cells. 
 
1.2.5.1 CD8+ regulatory T cells 
 
 
Regulatory T cells have been found to also originate from the CD8+ lineage where the CD8 T 
cells express CD122 and suppress the proliferation and IFN-γ production of both CD8 and 
CD4 target cells [71]. CD122 is the IL- 2 receptor B-chain and CD8+CD122+ Tregs have 
been shown to interact with activated T cells forming active regulatory cells that produce IL-
10 and suppress the target cells [107].  
Plasmacytoid DCs (pDC) from human ovarian tumours have been found to induce CD8 T 
cells expressing IL-10 which inhibit tumour associated antigen (TAA)-specific T-cell 
immunity in vitro [108]. These tumour-associated pDC induced suppressive T cells with the 
phenotype CD8+CD45RO+CCR7+ [109]. Suppressive CD8 Tregs potentially function in 
cancer patients to prevent T effector cell tumour cell killing as DC maturation state can be 
influenced by the tumour environment.  
 
1.2.6 T cell memory subset differentiation 
 
Naive T cells within secondary lymphoid organs are primed by activated APCs to become 
effector cells and to generate long-lived memory cells [110,111].  Stimulation with antigen 
for a prolonged period of at least 7 days [112], and the presence of T helper cells are required 
for memory cell formation [113,114,115]. Priming of T cells induces a differentiation 
program that involves clonal expansion and induction of effector functions where cell surface 
receptors expression influences migration and homing. CD45 is also known as leukocyte 
common antigen, a transmembrane protein tyrosine phosphatase involved in TCR signalling 
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[116]. The CD45 family includes three exons of the primary transcripts including CD45RA, 
RB and RC isoforms. CD45RA denotes naive T cells and CD45RO is located on activated 
and memory T cells which lack RA, RB and RC exons. 
The differentiation pathway for memory subset formation is unclear, classically a linear 
model was suggested whereby naive T cells differentiate into effector cells and finally into a 
memory phenotype (	). Alternatively a divergent pathway may exist where T cells 
become activated without an effector function and give rise to memory cells either directly 
from one intermediate precursor or independently directly from an activated cell [117].  
 
Memory T cells are divided into two main populations dependent on their location, central 
memory T cells (TCM) are found residing in secondary lymphoid organs and are able to 
proliferate whereas effector memory T cells (TEM) are found within the periphery with 
limited proliferation capacity. Sallusto et al first identified differences within human memory 
T cells via CCR7 expression [110]. CCR7 is required for homing to secondary lymphoid 
organs toward a CCL22 gradient and CCR7 expression denotes central memory T cells 
whereas CCR7- expression denotes effector memory T cells which are able to leave 
secondary lymphoid tissues to circulate within the periphery. 
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
	 "!!*',0/	The linear pathway suggests memory T 
cells develop sequentially from effector cells however evidence exists for a divergent pathway where 
activated T cells lacking effector function can also give rise to memory cells. The arrows represent molecular 
and biochemical triggers for memory generation which can potentially occur before formation of an activated 
phenotype, after activation  but prior to effector function or later prior to death. Potentially TCM and TEM can 
arise from one intermediate precursor or independently directly from one effector cell. 
 
Both subsets produce IFN-γ but central memory T cells can also produce IL-2 enabling the 
proliferative capacity compared to effector memory T  cells whereas the enhanced 
cytotoxicity of the effector memory subset can be attributed to increased perforin and 
granzyme B production [118]. During a secondary response to antigen within the periphery 
both antigen dependent and independent mechanisms can re-activate T cells as cytokines 
such as IL-12, IL-18 and IFN-γ via Signal 3 [119,120]. 
While the existence of TEM and TCM subsets has been proven [110], discrepancy remains in 
how to identify each subset, whether this should be via gene expression profiles, activation 
markers or cytokine release. CD44 is a receptor for hyaluronic acid and the most commonly 
used marker for distinguishing effector and memory CD8 and CD4 T cells from naive or 
antigen inexperienced cells. Once activated T cells upregulate CD44 and this expression 
remains high permanently [121]. For identifying murine subsets of memory T cells dual 
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[126]. Adoptively transferred CD8 T cells with and without CD127 expression showed that 
CD8+CD127+ T cells survived in the absence of antigen by homeostatic proliferation and 
thus maintenance via CD127.CD127 down-regulation on T cells occurs during the effector 
phase of T cell activation whereas the formation of memory CD4 and CD8 T cells is 
associated with a CD127 high phenotype, where expression of CD127 determines the 
functional quality of antiviral T cells in both mice and humans [127]. 
 
Within humans a large number of markers can be used to distinguish memory phenotypes of 
CD8 T cells including CD45RA, CD27, CD62L and CCR7. CD27 is a member of the TNF 
receptor family and its ligand CD70 is expressed on
 
the majority of peripheral T cells. 
Activation of T cells via TCR/CD3
 
induces high CD27 surface expression initially [128] 
however prolonged activation causes down-regulation. All CD4+CD45RA+CD45RO- T cells 
express CD27, whereas small numbers of the CD4+CD45RA-CD45RO+ subset
 
are CD27-. 
In contrast, within the CD8+ population CD27 is present on both the CD45RA+ and 
CD45RA- subpopulations. Stimulation with CD3 monoclonal antibodies causes CD27 
expression on both CD4+ and CD8+ subpopulations. CD27 has a functionally distinct role 
from CD28 and combining CD27 and CD28 interactions leads to an additive costimulatory 
effect [129]. Combining CD27 and CD45 expression patterns on T cells can distinguish 
between differentiation states [130]. Within CD8 T cells CD45RA+CD27+ cells are thought 
of as naive T cells, the loss of CD27 (CD45RA+CD27-)  is associated with effector function 
on cells having undergone antigenic stimulation [131]. Loss of CD27 appears irreversible 
which supports a maturation pathway of naive to memory to effector phenotypes as central 
memory T cells show CD27 expression (CD45RA-CD27+). Loss of CD45RA (CD45RA-
CD27-) represents a change to an effector memory function.   
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CCR7 is important for T cell infiltration into secondary lymphoid organs where its ligand 
secondary lymphoid-tissue chemokine (CCL21) is expressed in the high endothelial venules 
of lymph nodes and Peyer's patches and in the T cell areas of spleen and lymph nodes [132]. 
As previously mentioned, human naive and memory T cells can be identified by expression 
of the CD45RA or CD45RO isoforms. Sallusto et al [133] showed that double staining for 
CD45RA and CCR7 shows three subsets of CD4+ cells: one naive CD45RA+CCR7+ and 
two memory subsets, CD45RA-CCR7+ and CD45RA-CCR7-. Within CD8+ T cells, a 
CD45RA+CCR7- phenotype also exists.  
 
Therefore memory subset expression of CD4 and CD8 T cells can be distinguished using the 
same markers; however their relative frequencies differ within peripheral blood and under 
immunological stress such as autoimmunity and cancer. A study by Maldonado et al.
examined the central and effector memory phenotypes of T cell subsets in response to 
rheumatoid arthritis (RA) [134]. Within a cohort of 8 healthy patients the percentage of naive 
(CD45RA+CD62L+) was 46% and only 18% among the CD4 and CD8 populations 
respectively. The percentage of CD45RA-CD62L+ central memory CD4 and CD8 T cells 
was 37% and 6.8% respectively. The effector memory phenotype of CD45RA-CD62L- 
showed the least variation with 17% of CD4 and 24% of CD8 T cells showing this 
phenotype. Interestingly, the percentage of effector cells (CD45RA+CD62L-) T cells within 
the CD4 population was only 1.2% compared to 52% of the CD8 population. The study by  
Maldonado et al showed that within patients with RA T cell maturation tended towards a 
CD45RA–CD62L+ naïve phenotype. 
Another study by Kuss et al. [135] looked at the numbers of effector CD8+CD45RO-CD27- 
T cells in patients with squamous cell carcinoma of the head and neck. The study showed a 
significant increase in the proportion of CD27- cells among CD8+CD45RO- T cells in the 
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patient and hence and increase in effector CD8 T cells. These studies demonstrate that the 
plasticity of the differentiation state of T cell memory subsets is highly dependent on the 
immunological stress within the organism. 
 
1.3 Endothelial cells 
 
 
In order for T cells to target an infection within tissues they need to migrate from the blood 
through the endothelium and into the tissue. Vasodilation and vasoconstriction are controlled 
directly by the endothelium
 
 as is smooth muscle cell proliferation
 
and migration [136]. 
Vasodilation is achieved by the release of nitric oxide (NO), prostacyclin and bradykinin 
[137]. Prostacyclin acts synergistically
 
with NO to inhibit platelet aggregation while 
Bradykinin stimulates production
 
of tissue plasminogen activator (t-PA), forming a role in 
fibrinolysis.
 
Angiotensin II controls vasoconstriction and stimulates production
 
of endothelin 
which together with angiotensin II  allows smooth muscle cell grow [138]. 
The endothelium acts as a selective barrier for leukocyte migration into tissue requiring many 
tightly regulated steps involving cell adhesion molecule/ligand and chemokines/receptor 
interactions. Early phase immune responses occur within 30-90 minutes do not involve 
selectin upregulation but are augmented by histamine which causes vasodilation and changes 
in vascular permeability. Late phase responses of around 3-4 hours following antigen 
challenge involve infiltration of neutrophils, eosinophils and mononuclear cells, with 
granulocytes 6-8 hours. 24-48 hours following antigen challenge mononuclear cells are the 
remaining cells infiltrating tissues.  
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1.3.1 Classical transmigration 
 
The recruitment of leukocytes from blood vessels into underlying tissues is mediated by a 
cascade of events including initial leukocyte tethering and rolling, firm adhesion and 
transmigration through the endothelial cell lining. Cell adhesion molecules expressed by the 
endothelium control each step in the leukocyte extravasation cascade, including selectins, 
integrins and chemokine receptor expression. Initially selectins mediate low affinity binding 
of endothelial E- and P-selectin (CD62-E and CD62-P) to leukocyte L-selectin (CD62-L), P-
selectin ligand (CD24) and PSGL-1 (P-selectin-binding glycoprotein-1), to allow leukocytes 
to roll along the endothelial surface [139]. Addressins such as PNAd (peripheral lymph node 
addressin), CD34, GlyCAM and MAdCAM-1 (mucosal addressin cell adhesion molecule), 
VAP-1 (vascular adhesion protein-1), VCAM-1 (vascular cell adhesion molecule-1) and 
HA/CD44 (hyaluronate) expressed by ECs can also help mediate leukocyte attachment and 
tethering by ligation with leukocyte LFA-1 (leukocyte function associated-1 cell adhesion 
molecule), α4β7 and α4β1 integrins.  
Activation of ECs by cytokines or chemokines in the surrounding environment increases 
ligand expression on ECs and corresponding expression of leukocyte integrins, strengthening 
cell adhesion [140]. The expression pattern of integrins is dependent on the surrounding 
cytokine/chemokine milieu however the main cell adhesion molecules involved in the firm 
adhesion of leukocytes are members of the immunoglobulin gene superfamily: ICAM-1 and -
2 (intercellular adhesion molecule-1 and -2), VCAM-1, MAdCAM-1 and PECAM-1 (platelet-
endothelial cell adhesion molecule-1) binding leukocyte LFA-1, α4β7 and α4β1 integrins. 
Once firmly attached to the endothelium diapedesis of leukocytes across the vessel wall 
occurs mainly via inter-endothelial junctions by PECAM-1 [141], ICAM-2, CD99, JAM-
A/B/C (junctional adhesion molecule) and VE-cadherin (vascular endothelial) [142].  
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PECAM and JAM-A, B and C are members of the immunoglobulin gene superfamily and 
form homophilic interactions between ECs. Under inflammatory conditions such as IFN-γ or 
TNF-α within the micro-environment, these molecules are re-arranged within the cell and 
JAM-A be induced to redistribute to the endothelial apical surface, whilst reducing the 
expression of PECAM-1. Specifically IFN-γ allows redistribution of PECAM-1 to the apical 
surface indicating a role in diapedesis.  
 
1.3.2 MHC expression by endothelial cells 
 
The constitutive expression of MHC class I and upregulation of MHC class II antigens has 
been shown by both human and murine ECs [143]. Human EC strongly express MHC class I 
and class II molecules in vivo,  MHC class I expression is reduced and class II expression is 
lost in vitro [144,145]. Cutaneous microvascular ECs which express high levels of MHC 
class I and II in vivo, perhaps due to low levels of circulating IFN- γ, can be restored in vitro 
via addition of IFN-γ. Whereas IFN-γ impacts both MHC class I and II expression on human 
umbilical vein endothelial cells,  IFN-α/β  has been shown to enhance MHC class I antigen 
expression with no effect on MHC class II [146]. The function of MHC class I and II 
expression by dermal microvascular human ECs is thought to be to present antigen to 
circulating memory T cells. Following contact with T cells, ECs become activated allowing 
increased infiltration of memory and effector T cells via antigen independent transmigration 
[147].  
Lidington et. al. [148] carried out a comparison of primary ECs and endothelial cell lines for 
expression of various cell adhesion molecules and MHC expression. Human adult ECs from 
aorta, coronary artery, pulmonary artery, umbilical artery were all shown to upregulate MHC 
class II in response to IFN-γ. However, human umbilical vein ECs, (HUVEC), were negative 
for MHC class II but constitutively expressed MHC class I, Fas, CD40 and LFA-3. When 
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treated with IFN-γ HUVEC upregulated ICAM-1, MHC class I, Fas, CD40 and LFA-3 and 
induced VCAM-1 and MHC class II expression. The dermal microvascular endothelial cell 
line (HMEC-1) was also studied and showed similar results to the HUVEC primary cultures. 
HUVEC do not express CD80 and, although able to induce cytokine production, are unable to 
differentiate naïve CD4 T cells into Th1 effector cells  [149]. 
Murine lung ECs constitutively express low levels of CD80 molecules and MHC class II 
expression can be induced with culture with IFN-γ [150].  Research investigating the level of 
endothelial MHC class I molecule expression in diabetes-prone mice on CD8 T cell 
migration focused on MHC class I expression in a variety of different tissues and mouse 
strains [151]. The study showed tissue-specific EC heterogeneity in the expression of MHC 
molecules with ECs from aorta, lung, heart and thymus from non-obese diabetic mice 
compared for MHC class II (I-A) and MHC class I (H2-Kd). NOD ECs did not express MHC 
class II whereas MHC class I was expressed on all tissues with higher expression on heart 
ECs and the lowest expression on thymic ECs. In addition MHC class I molecule expression 
was found to differ between NOD (H2-Kd) and Balb/c (H2-Kd) mouse strains with higher H-
2K molecule expression in NOD mice than Balb/c mice. In summary this study showed that 
EC co-stimulation properties in vitro differed depending upon the species, the maturity of the 
T cell, and the vascular bed of origin. 
 
1.3.3 Antigen specific transmigration 
In order for T cells to transmigrate endothelium into tissue, in addition to conventional 
adhesion molecule and chemokine receptor/ligand interactions [152], it has been proposed 
that cognate antigen presentation by ECs to T cells through peptide:MHC and TCR 
interaction is also an important determinant for transmigration and the development of 
chronic inflammation and autoimmunity [147,153]. Indeed, the level of major MHC class I 
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expression on the endothelium in non-obese diabetic mice has been shown to influence islet 
auto-reactive CD8 T cell adhesion and migration [151] and antigen-specific T cells can be 
attracted and retained in tissues via antigen present within the tissue [154].
An in vivo model of HY-specific CD8 T cell transmigration into antigenic and non-antigenic 
tissue showed an accumulation of the male-specific HY antigen-specific CD8 T cells in the 
peritoneal cavity of IFN-γ treated male mice and not untreated male or IFN-γ treated female 
mice [155]. The data suggests that up regulation of H2 molecules by IFN-γ in peritoneal 
mesothelium, 72 hours prior to additions of T cells, led to recruitment of PKH26 labelled HY 
specific T cells in male and not in female mice. Intravital microscopy of the peritoneal 
membrane indicated that cognate recognition enhances diapedesis into tissue without 
affecting rolling and adhesion. Marelli-Berg hypothesised that due to the small molecular size 
of MHC:peptide complexes would mean that TCR triggering would only occur when the two 
cells were in close proximity, i.e. once rolling and adhesion had already occurred and 
therefore antigen recognition does not affect adhesion.  

1.4 Chemokines 
 
Chemokines are secreted proteins involved in immunoregulatory and inflammatory processes 
which play a major role in leukocyte trafficking via their interaction with a group of seven 
transmembrane G protein-coupled receptors (GPCR) [156]. Over 50 chemokines have been 
identified forming a family of heparin-binding cytokines with over 20 receptors, identified by 
the position of cysteine residues (C, CC, CXC and CX3C) near the N termini of each protein.  
Chemokine involvement in leukocyte trafficking has been studied under homeostatic 
conditions and during an inflammatory responses. Chemokines have also been identified 
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within tumour micro-environments and more recently implicated in organ-selective cancer 
metastasis.   
Chemokine receptor and ligand binding causes phosphorylation of C-terminal 
serine/threonine residues that dissociate heterotrimeric G-proteins into α and βγ subunits. This 
inhibits adenylyl cyclase activity, increases the generation of inositol trisphosphate, 
intracellular calcium release and the activation of phosphatidyl inositol 3 kinase (PI3K)/Akt 
cascade and Ras/MAP kinase signalling [157]. During non-inflammatory conditions 
peripheral T cell homeostatic trafficking to lymphoid organs is mediated predominantly by 
CCL19 and CCL21. CCL19 is a small cytokine belonging to the CC chemokine family that is 
also known as EBI1 ligand chemokine (ELC) and macrophage inflammatory protein-3-beta 
(MIP-3-beta). CCL21 is also known as secondary lymphoid-tissue chemokine (SLC) and is 
expressed in the high endothelial venules of lymph nodes and Peyer’s patches, in the T cell 
areas of spleen and in the lymphatic endothelium of multiple organs [132]. CCL19 is  mainly 
expressed in the thymus and lymph nodes [158,159], with lower levels  in the trachea and 
colon and even lower levels in stomach, small intestine, lung, kidney and spleen. CCL19 and 
CCL21, bind to the chemokine receptor CCR7 attracting certain cells of the immune system 
[159], including DCs, B cells and CCR7+ naive and central memory T Cells.  

1.4.1 Chemokine expression in cancer 
 
The tumour microenvironment, which is composed of immune cells, tumour cells, stromal 
cells and the extracellular matrix, is under constant change during the neoplastic process, to 
allow proliferation, survival and migration of tumour cells. Tumours survive and are able to 
spread as they can hijiack signalling pathways used by immune cells favouring tumour 
immune tolerance and resulting in escape from anti-tumour immunity. 
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Chemokine expression in tumours can be investigated from two perspectives, the first being 
chemokine expression within the tumour itself and consequential migration of leukocytes 
bearing the corresponding receptors. In this situation tumour regression can be correlated with 
the type and frequency of leukocyte infiltration. Alternatively, the tumour cells may also 
express chemokine receptors allowing migration to sites of metastasis where the 
corresponding chemokine is present. In vivo a combination of chemokine/receptor expression 
within tumours will affect immune recognition, tumour progression and ultimately patient 
prognosis.  
Tumour associated chemokines are not produced in isolation and chemokine expression 
profiles will exist for different types of cancer. The CXCR4/CXCL12 axis is a key factor in 
tumour metastasis of many cancer types where cancer cells show CXCR4 expression and 
corresponding expression of CXCL12 is seen at sites of tumour metastasis [160,161,162]. 
CXCL12 binds to G-protein-coupled CXCR4 [163]. 
The homeostatic chemokine receptor CCR7 has been shown to be expressed in tumours such 
as breast and oesophageal squamous cancer, where CCR7 expression increases tumour 
metastasis towards the ligand CCL21 [164,165]. In breast cancer patients the chemokine 
CXCL13 and its receptor CXCR5 have been shown to be over-expressed within the tumour 
and in the peripheral blood where expression is associated with metastasis [166]. CCR4 and 
CCR3 expression in adult T cell leukaemia/lymphoma and corresponding ligand expression, 
CCL17 and CCL11 respectively, is associated with reduced survival [167,168]. Curiel et al 
[169] first showed that Tregs expressing CCR4 infiltrate ovarian tumours mediated by 
CCL22/17 expression. 
Chemokines  can affect tumours in four ways; firstly by altering the extent and type of 
leukocyte infiltration, secondly by promoting tumour angiogenesis, thirdly by controlling 
tumour cell metastasis and finally by affecting tumour cell proliferation [170]. 
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1.4.2 Chemokines and leukocyte infiltration into tumours 
 
Curiel et al [169] first showed that Tregs expressing CCR4 preferentially infiltrate ovarian 
tumours in response to CCL22.  CXC chemokines, CXCL9, CXCL10, and CXCL11 are 
induced by IFN-γ and are typical chemoattractants of NK cells and the expression of CXCR3 
on NK cell allows infiltration into tumours expressing CXCL10 [171]. In contrast, to 
infiltration of Tregs, overexpression of these chemokines leads to increased cytotoxic 
responses and long-term anti-tumour immunity.  
CCL2 monocyte chemotactic protein-1 (MCP-1) contributes to the progression of colorectal 
cancer by influencing the number and distribution of tumour associated macrophages (TAMs) 
[172] and the same chemokine leads to NK cell infiltration  into neuroblastomas [173]. 
Tumour infiltration by macrophages is associated with neoangiogenesis and reduced survival, 
whereas the effect of DC infiltration is less clear. DC infiltration is associated with a positive 
clinical outcome in association with their ability to present tumour antigens and induce 
specific anti-tumour T cell responses. However, studies have reported that patients with a 
variety of cancers have impaired DCs [174]. Within non-small cell lung cancer infiltrating 
DCs were kept in an immature state and migrated in response to CCL21 [175]. Moreover, 
recent studies have suggested that, instead of initiating immune responses against tumours, 
DC in the tumour microenvironment may have the ability to suppress the responding T cells 
and induce tolerance [176]. 
CXCL16 had been recently discovered and its receptor CXCR6 is detected on both CD4
 
and 
CD8
 
T cells, and NK cells. A significant correlation between CXCL16 expression by tumour 
cells and the infiltration of T cells has shown a better prognosis in colorectal cancer [177]. 
Within murine models of melanoma and ovarian cancer indicate that the effect of CXCL12 on 
the tumour immune response is dose dependent [178]. Low levels of CXCL12 expression 
allows infiltration T cells into tumours reducing tumour growth, whereas high levels of 
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CXCL12 have been shown to be a biomarker for clinical progression in ovarian cancer, that is 
correlated both the HPV (human papilloma virus) infection and the accumulation of 
FOXP3
+
 T cells within ovarian tumours [179]. Therefore, patient outcome is dependent on 
which subsets of inflammatory cells infiltrate into tumours, subsequently dependent on the 
expression of particular chemokines, either positively or negatively responding to the tumour 
[180]. 

1.4.3 Chemokines and tumour angiogenesis 
 
Angiogenesis is the formation of new capllaries from existing blood vessels and enables 
tumour cell growth and survival.  Angiogenesis is a highly regulated process involving 
chemokines such as CXCL1, -2, -3, -5, -6, -7, and -8 which directly cause chemoattraction of 
ECs and can stimulate angiogenesis in vivo [181]. Chemokines can also be anti-angiogenic 
such as CXCL9 and CXCL10 [182]. The difference in the angiogenic capacity of chemokines 
has been attributed to the amino acids (Glu–Leu–Arg/ELR) immediately amino-terminal to 
the CXC motif (ELR+) which are angiogenic and that ELR− CXC chemokines are angiostatic 
[183].  
Tumour stroma forms an important part of the tumour microenvironment and stromal 
fibroblasts within breast tumours have been shown to produce CXCL12 leading to 
vascularisation by chemoattraction of ECs
 
[184,185]. Hypoxia has also been shown to induce 
CXCL12 expression within primary human ovarian tumour cells by Hypoxia-inducible
 
factor 
(HIF)-1 expression [186]. Tumour angiogenesis promoted by
 
hypoxia, results in the 
expression of angiogenic factors,
 
such as vascular endothelial growth factor (VEGF), IL-8, 
and
 
basic fibroblast growth factor (bFGF).Monocytes are continually recruited into tumours 
and are able to differentiate into tumour associated marcophages (TAMs). Tumour infiltrating 
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TAMs are found to localise in hypoxic areas in response to CCL5 and CCL2 and are thought 
to contribute to tumour angiogenesis via secretion of CXCL8 and VEGF [187].  

1.4.4 Chemokines and cancer metastasis 
 
Cancer metastasis allows tumours to migrate and re-colonise within organs or sites that 
support the growth of cancer cells. Stephen Paget's 1889 proposal was that metastasis 
depended on interactions between selected cancer cells (the 'seeds') and specific organ 
microenvironments (the 'soil'). Whereas Ewing theorised that the patterns of blood flow from 
the primary tumour can predict the first metastasised organs [188]. More recently it is thought 
that cancer cells migrate to specific organ sites as a result of complex signalling between the 
tumour cells and the cells at the organ site.  
Tumour cells use the same chemokine mediated mechanisms to those that regulate leukocyte 
trafficking during the process of metastasis [189]. The CXCR4/CXCL12 axis has been shown 
to be involved in all stages of tumour growth and progression and its role in metastasis is no 
exception. CXCR4 and CCR7 are highly expressed in human breast cancer cells and can 
induce metastasis by enabling tumour cells to migrate via actin polymerisation and 
pseudopodia formation to organs that produce CXCL12 and CCL21 such as lymph nodes, 
bone marrow and lungs [164]. As well as tumour cells migrating to organs as sites of 
metastasis, cancer cells also traffic to lymph nodes under the control of the same lymph node 
homing chemokines as lymphocytes. The expression of CCR7 in gastric cancer cells has 
revealed its critical role in the metastasis to lymphoid organs of gastric cancer cells in 
response to CCL21 [190]. 

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1.5 Immune surveillance 
 
 
The immune surveillance theory was first proposed by Burnet and Thomas who used 
experimental evidence from tumour transplantation models to prove that tumours could be 
repressed by the immune system [191].  Immune surveillance implies that spontaneous 
tumour development can be prevented by the immune system by the elimination of neoplastic 
cells early in their development. Evidence was provided using murine models of cancer, 
formed using methylcholanthrene to initiate spontaneous tumours, whereby tumour formation 
and growth could be measured following depletion of immune cells such as NK and T cells 
[192]. Immunogenic tumours express a range of stress related molecules which act like Toll 
like receptors (TLRs) and alert the immune system to the danger [193,194].  
More recently the immune response to tumours has been termed ‘cancer immunoediting’ and 
can be separated into three 3 phases: (i) elimination, or cancer immune surveillance; in the 
elimination phase, innate and adaptive immunity work together at an early stage to destroy 
developing tumours. When fully effective the immune response during the elimination stage 
can ensure the host remains free of cancer. (ii) equilibrium, a phase of tumour dormancy 
where tumour cells growth and anti-tumour immunity form an equilibrium that halts any 
further tumour expansion; equilibrium is a function of adaptive immunity only as T cells and 
inflammatory cytokines are required to create immunologic equilibrium [195], whereas 
innate cells such as NK cells have been shown to be redundant in this process [192]. During 
the equilibrium phase immune-editing of the tumour can occur due to the constant battle by 
anti-tumour T cell responses to control tumour cell growth and (iii) escape, where tumour 
cells have a reduced immunogenicity or have highly immunosuppressive mechanisms to 
prevent any successful anti-tumour immune responses leading to the appearance of 
progressively growing tumours [196]. Due to the role of T cells within the elimination and 
equilibrium phases of immunoediting, increased infiltration of adaptive immune cells, in 
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particular T cells, into tumours correlates with improved patient survival [197] and CD3+ T 
cell infiltration within tumour associated lymphoid nodules has shown increased survival in 
rectal cancer [198]. A study investigating tumour infiltrating lymphocytes in oral squamous 
cell carcinomas found that the intensity of TILs  was highest in high grade tumours and these 
TILs consisted of FOXP3+ Tregs [199].

1.5.1 Regulatory T cells and human tumours 
 
Treg cells mediate peripheral tolerance by suppressing self-antigen-reactive T cells and have 
been shown to play a role in tumour immunity where tumour rejection has been shown 
following depletion of CD25+ cells [200]. In addition, adoptive transfer of CD4+ T cells 
depleted of Tregs increased anti-tumour immune responses [201]. Higher numbers of Treg 
cells have been found in peripheral blood of a variety of cancers including breast cancer 
[202], colorectal cancer [203], oesophageal cancer [204], gastric cancer [205], lymphoma 
[206], melanoma [203], ovarian cancer [207] and pancreatic cancer [208,209].  
Peripheral Treg cells show potent suppressive activity in vitro and a high frequency of Treg 
cells would dampen tumour antigen-specific immunity in patients with cancer. In ovarian 
cancer, within tumour microenvironments Tregs expressed FOXP3 and inhibited TAA-
specific CD8+ T cell cytotoxicity. Removal of CD4+CD25+ Tregs but not effector cells using 
cyclophosphamide was shown to activate latent high-avidity TAA-specific CD8 T cells that 
had been suppressed by Tregs [210]. Accumulation of Treg cells in the tumour can predict 
reduced patient survival [207]. Studies characterising changes in intra-tumoural Tregs within 
normal breast and pancreatic tissue compared to benign neoplasms found no differences but a 
significant increase in CD4+CD25+ cells in malignant breast and pancreatic tumours [211]. 
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1.5.2 Source of regulatory T cells in the tumour 
 
Regulatory T cells have been proven to be present within the tumour microenvironment due 
to; trafficking, differentiation, expansion and conversion. Treg cells differentiate in the 
thymus, tumour-associated Treg cells may traffic to tumours from the thymus, bone marrow, 
lymph nodes and peripheral blood under the influence of tumour microenvironmental 
chemokines. Treg cells differentiate in the thymus, tumour-associated Treg cells may traffic 
to tumours from the thymus, bone marrow, lymph nodes and peripheral blood under the 
influence of tumour microenvironmental chemokines. [212]. The resulting immature or 
partially differentiated DCs express TGF-β and promote Treg cell proliferation and 
conversion from CD4+CD25- T cells. IL-10 also present supports the differentiation of 
CD4+IL-10+TGF-β+ Tregs and induces Tr1 cells. Therefore tumour microenvironments may 
contain thymus-derived natural Tregs, expanded and converted natural Tregs and locally 
differentiated and expanded Tr1s.  
 
1.5.3 Tumour-associated antigen specificity 
 
Tumour reactive Tregs express markers such as CD25, GITR and FOXP3 typically associated 
with CD4+CD25+ naturally occurring Tregs. Tregs are specific for self-antigens and so may 
be specific for at least one subset of TAA. Human melanoma infiltrating Treg cells have been 
cloned and the target antigen was found to be LAGE-1, a cancer- and testis-specific antigen 
[213]. The fact that in this study LAGE-1 preferentially stimulated Tregs rather than effector 
CD4 T helper cells indicates that the type of antigen, expression level and dose of an antigen 
determines whether CD4 T cells are deleted or express a helper or regulatory phenotype 
[214].  
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Evidence exists for both Treg suppression of TAA-specific T cell priming and effector 
function. In ovarian cancer large numbers of Tregs in the tumour mass but few in tumour-
draining LNs, indicate that Tregs predominantly inhibit extranodal effector functions at this 
stage. Tregs may be present in the draining LNs before clinical manifestation and may block 
TAA-specific T-cell priming during the priming process. Recent studies demonstrated that a 
large proportion of naturally occurring CD4+CD25+ Tregs recognise MHC class II bound 
peptides more efficiently than CD25- T cells [215]. 
Therapeutic applications for targeting Tregsinclude depletion or attenuation of natural Tregs 
using monoclonal antibodies has improved anti-tumour immune responses by targeting Treg 
associated markers such as; CD25, CTLA-4, GITR, TLR4, OX40 and FR4. By targeting 
these Treg associated markers the aim is to enhance anti-tumour responses via depleting 
Tregs and increasing the ratio of effector CD8 and CD4 T cells within the tumour micro-
environment able to carry out anti-tumour cell targeting or by blocking the suppressive 
capacity of Tregs within the tumour. Depletion of Tregs from cancer patients has been carried 
out using Ontak (Denileukin diftitox), a fusion protein comprising IL-2 and diphtheria toxin 
[216]. Within the study a group of patients who had received Ontak was also vaccinated with 
DCs transduced with tumour RNA and showed enhanced T cell responses to tumour antigens 
compared to those receiving vaccine alone. This indicates that depleting Tregs alone is not 
sufficient to induce/recover anti-tumour responses but that depletion in combination with a 
secondary immunisation to prime tumour antigen-specific T cell responses, which would 
otherwise have been suppressed by the presence of Tregs, enhances anti-tumour T cell 
immunity in these patients.  

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1.5.4 Myeloid suppressor cells 
 
Myeloid cells that can also develop into suppressor cells called myeloid derived suppressor 
cells (MDSC) which bring about antigen-specific T cell tolerance by various methods but one 
mechanism is the increased metabolism of L-Arg [217] and these cells can be inhibited in 
mice with inhibitors of Phosphodiesterase-5 [218]. Many human tumours produce the 
immunosuppressive enzymes indolamine -2, 3-dioxygenase (IDO) which prevents the 
activation of T cells [219]. Stereoisomers of 1-methyl-tryptophan can inhibit these enzymes 
and may have a role to play in treatment of patients with cancer [220].  
 
1.5.5 Tumour induced immunosuppressive environment 
 
Tumour cells can also develop resistance to immune cell-mediated death by becoming 
insensitive to apoptotic signals.  Down-regulation of the death receptor, Fas, has been 
reported in a number of human tumours.  Engagement of Fas by its ligand, FasL, normally 
induces cellular apoptosis.  Missense mutations resulting in disrupted Fas signalling have 
been reported in myeloma [221], non-Hodgkin’s lymphoma [222] and melanoma [223].  In 
contrast, a variety of tumours have been reported to express FasL, which induces apoptosis in 
Fas susceptible target cells, such as activated T cells. This has been proposed as a mechanism 
by which tumours may induce activation induced cell death in infiltrating T cells [224].  
Tumour cells have also been reported to block CD8-mediated cytotoxicity through the over-
expression of a serine protease inhibitor that inactivates granzyme B [225]. In a last attempt 
to prevent T cell recognition tumour can lose expression of MHC class I. However, as 
complete loss of MHC class I can be recognised by NK cells, most tumours selectively down 
regulate only a single MHC allele that is the target for the cancer induced T cell response 
[226,227]. Vaccine stimulation of naïve T cells to give a new response to an allele which has 
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not been lost, can effectively overcome this block.  
Although the tumour environment is capable of blocking anti-tumour immunity, in many 
tumours the presence of immune cells is still a strong prognostic factor [228,229,230,231] 
suggesting that it could be externally manipulated to provide an effective therapeutic 
approach. Perhaps potent anti-tumour targeting requires stimulation of new high avidity CD4 
and CD8 T cell responses in combination with depletion of Tregs or neutralisation of 
immunosuppressive cytokines/high dose chemokines. 
 
1.5.6 Migration of T cells in tumours 
 
In order for T cells to target tumours they need to migrate from the blood through the 
endothelium and into the cancer. The alteration of the vasculature within tumour cells to form 
new vessels was proposed by Folkman in 1971 [232] where tumour cells can mediate tumour 
angiogenesis by secreting soluble factors that enhance endothelial cell proliferation, 
migration and tube formation and via direct interactions with endothelial cells. In comparison 
to conventional endothelium tumour endothelium is structurally and functionally abnormal, 
forming highly disorganised and leaky structures [233,234]. The flow of blood through the 
tumour capillaries is slow and even reverse direction as vessel diameter is thinner than 
normal vessels [235]. A comparison of gene expression patterns of endothelial cells derived
 
from blood vessels of normal and malignant colorectal tissues of almost 200 transcripts 
showed
 
that around 50% were differentially expressed, half of which were specifically
 
increased in tumour-associated endothelium [236]. Genes including collagens 4A1, 4A2 and 
1A1, SPARC, THY1 and MMP9 have been shown to be overexpressed on a variety of 
tumour endothelium whereas TEM7, is overexpressed on ECs of all tumour types [237]. 
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1.6 Cancer Vaccines 
 
In order to overcome the suppressive environment of tumours cancer vaccines need to 
stimulate T cell responses. Cancer vaccines come in two types: therapeutic, which are aimed 
at treating an existing cancer, and prophylactic, which are designed to prevent disease.  
 
1.6.1 Prophylactic cancer vaccines 
Preventative prophylactic vaccines aim to prevent cancer by targeting oncogenic infectious 
agents such as viruses which ultimately lead to tumour formation. Gardasil and Cervarix  are 
both prophylactic vaccines against the human papilloma virus (HPV) [238]. Gardasil 
(Merck), also known as Silgard, is specific for several HPV subtypes, subtypes 16 and 18 are 
highly associated with cancer formation in around 70% of cervical [239] and 26% of head 
and neck
 
cancers [240]. Cervarix (GSK) is also designed to prevent infection from HPV types 
16 and 18, but in addition also strains 45 and 31. Cervarix contains an HPV type 16 L1 
protein, HPV type 18 L1 protein [241] and also an adjuvant AS04;3-O-desacyl-4’- 
cmonophosphoryl lipid A (MPL) adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 
[242]. Currently in the UK all girls aged 12 to 13 are able to receive Cervarix.  
In addition to HPV vaccines, the FDA has approved a vaccine for hepatitis B (HBV), Engerix 
B (GSK) as HBV is associated with the initiation of hepatocellular carcinomas (HCC) in both 
adults and children [243]. Engerix B is active against all subtypes of HBV and contains 
Hepatitis B surface antigen produced by recombinant DNA technology in yeast [244]. 
Developing vaccines against oncogenic viruses has the advantage of eliciting strong immune 
responses however the latency or time taken between viral infection and tumour formation 
can impact on the success of prophylactic immunotherapy.  
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1.6.2 Therapeutic vaccines  
Therapeutic vaccines aiming to stimulate potent anti-tumour T cell responses have to 
overcome the immunosuppressive tumour environment and for this reason are often used in 
combination with other cancer treatments such as surgery, to remove primary tumours, 
radiation and chemotherapy. Therapeutic cancer immunotherapy relies on tumour cells 
expressing surface antigens for recognition and initiation of anti-tumour immune responses, 
ideally absent on healthy cells. The molecular identification of antigens recognised 
on human tumour cells by T cells has aided the development of T cell based cancer 
immunotherapy [245] and vaccine classification is based on the genetic mechanisms leading 
to their expression [246]. Most tumour antigens elicit CD8 T cells responses however CD4 T 
cell help and efficient DC activation is also required for effective anti-tumour immune 
responses [247].
Oncofetal antigens are only expressed in fetal tissues and in cancerous somatic cells and to 
date the most widely studied is CEA in colorectal carcinoma [248], whereas over expressed 
accumulated antigens such as HER-2/neu are expressed by both normal and neoplastic tissue 
and can be associated with many types of carcinomas. T cells recognizing HER-
2/neu peptides were initially derived from tumour-infiltrating lymphocytes (TILs) of 
ovarian carcinomas [249].  PRAME is overexpressed in almost all melanomas and in many 
other tumours such as lung carcinomas [250],  Telomerase is a universal tumour antigen due 
to both its expression by the vast majority of tumours and its inherent functional involvement 
in oncogenic transformation [251] and WT1, (Wilms tumour gene 1) a transcription factor 
encoded by a gene that is over expressed in leukaemia [252]. Cancer testis antigens 
are expressed only by cancer cells and adult reproductive tissues such as testis and placenta, 
examples include the gene families MAGE [253], SAGE [254], and BAGE [255]. MAGE 
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expression in many tumours types has been examined and the triggering event seems to be 
demethylation of their promoter, which have a high CpG content [256]. Lineage-
restricted antigens are expressed largely by a single cancer histotype and are also referred to 
as differentiation antigens where they identify tissue differentiation. Within melanoma, 
specific genes include tyrosinase [257], Melan-A/MART-1 [258], Pmel17/gp100 [259], TRP-
1or TRP-2 [260,261,262]. Antigens resulting from mutation are formed when 
antigenic peptides are encoded by genes that show somatic mutations in tumour cells. Several 
point mutations present in antigenic peptides have an oncogenic function such as in 
CDK4 [263],  K-ras [264], p53 [265] and MART-2 in melanomas [266]. Mutated tumour 
antigens show tumour specificity and resistance to immunoselection when the mutated gene 
products are essential for oncogenic processes. However, studies have indicated that T cell 
tolerance can develop rapidly towards tumour-specific antigens even when they are mutated 
[267].
1.6.3 Therapeutic vaccine strategies 
Therapeutic cancer vaccines aim to target existing tumours by either vaccinating non-
specifically against a known tumour antigen or by enhancing a patient’s own anti-tumour 
immune response using patient-specific cells cultured ex vivo. 
	) highlights other therapeutic cancer vaccines currently in late-phase development in 
the European Union or UnitedStates.  
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priming of T cells by fully functional dendritic cells. Provenge (Sipuleucel-T) is designed to 
stimulate T cell immunity to prostatic acid phosphatase (PAP) [269], an antigen expressed in 
prostate cancers [270]. Specifically, Sipuleucel-T is composed of autologous PBMCs 
cultured with a fusion protein (PA2024), which consists of PAP linked to GM-CSF [271]. 
PA2024 has been shown to provide efficient loading and processing of antigen by APCs and 
upregulation of costimulatory molecules [272]. 
To generate mature DCs capable of priming efficient T cell responses DCs can be harvested 
from tumour bearing patients and stimulated ex vivo  to be adoptively transferred back into 
the same patient with the aim of enhancing patient-specific anti-tumour immunity [273]. 
Within melanoma patients a phase III trial failed to show any survival advantage for patients 
immunised with peptide pulsed DC [274]. The failure could be due to ineffective T cell 
priming of T cells once the DCs re-encountered the tumour immunosuppressive environment.   
However by altering the way DCs are stimulated effective responses can be seen in breast 
cancer patients [275] where these DCs had additional stimulation with IFNγ, TNFα and 
CD40 ligand enhancing cytokine release. One huge disadvantage of generating ex vivo 
stimulated patient specific DCs is the cost and time required to generate sufficient numbers 
and quality of cells required for adoptive transfer and subsequent clinical responses [276].   
1.6.5 Whole cell vaccines 
Whole cell vaccines are aimed at presenting a wide variety of tumour rejection antigens 
present on cancer cells to the immune system. Immunising with autologous whole cell 
mixtures derived from patient tumour samples removes the need to identify and isolate these 
mutant gene products for each individual patient. Most of these vaccines involved 
engineering the tumour cells to secrete pro-inflammatory cytokines prior to immunisation, in 
order to improve immunogenicity. A phase III trial of an allogeneic melanoma cell lysate 
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vaccine with IFN-α reported there to be no survival advantages of the vaccine compared with 
treatment with IFN-α alone [277]. Belagenpumatucel-L is a whole cell vaccine containing 
allogeneic non-small-cell lung cancer cells transfected with a plasmid containing a TGFβ2 
antisense transgene [278].Using an antisense gene to inhibit TGFβ2 results have linked 
inhibition of cellular TGFβ2 expression with increased immunogenicity of gene-modified 
cancer cells [279]. AVAX Technologies are developing a whole cell vaccine for the treatment 
of melanoma, M-Vax is being developed using irradiated and modified melanoma cells [280]. 
The advantage of whole cell vaccines is the removal of the need to identify specific tumour 
antigens however a huge selection of antigens would be present on tumour cells and could 
skew T cells responses against immuno-dominant epitopes from housekeeping genes 
stimulating or inducing Tregs further reducing any generation of anti-tumour immunity [281].  
1.6.6 Peptide vaccines 
In direct contrast to whole cell vaccines peptide vaccines aim to generate specific T cells 
responses against known tumour antigens either in the context of MHC class I or class II 
molecules. The advantage in this approach is in focusing the anti-tumour response on one or a 
select few particular antigens with the aim of removing immune competition from competing 
epitopes. In this way the effectiveness of generating specific anti-tumour T cells responses 
can be monitored by identification of these antigen-specific T cells within cancer patients. 
PR1 leukaemia peptide vaccine (The Vaccine Company) is a 9 amino-acid human leukocyte 
antigen (HLA)-A2 restricted peptide derived from proteinase 3 which is a serine proteinase 
overexpressed in leukemic cells and is involved in angiogenesis and metastasis [282]. A trial 
in patients with persistent myeloid leukaemia showed PR1-specific T cell responses in 35 of 
44 (57%) of patients and improved overall clinical response and a trend towards longer event-
free survival. GV1001 is a peptide vaccine targeting telomerase, representing a 16 amino acid 
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hTERT sequence binding both HLA class I and II epitopes, therefore ecapable of stimulating 
both CD8 and CD4 T cell responses. A phase I/II trial has demonstrated GV1001-specific T-
cell responses in more than 50% of pancreatic and pulmonary cancer patients, without 
toxicity [283]. 
The advantage of vaccines based on peptide response epitopes is that they are ideal for large 
scale production. However one problem is their short serum half life as they become rapidly 
proteolytically degraded. A major failure of peptide vaccines is that although generating 
expansions of T cells against immunising peptide, in some cases less than 5% of treated 
patients showed clinical responses [284]. T cells are highly responsive to peptide 
concentration and therefore the correct dose is essential to generate high avidity T cell 
responses, too high a concentration would lead to T cell death and low avidity T cell 
production unable to elicit tumour elimination. 
1.6.7 Protein vaccines 
Protein vaccines are some way between individual peptide vaccines and whole tumour cells 
vaccines. GSK1572932A (GlaxoSmithKline) is an antigen-specific protein vaccine used as 
adjuvant therapy in patients with resectable MAGE-A3 (melanoma-associated antigen 3) 
positive Non-Small Cell Lung Cancer (NSCLC) [285].  MAGE-A3 is a tumour associated 
antigen overexpressed in melanoma, head and neck cancer, and bladder cancer in addition to 
NSCLC. The advantage of using whole proteins as opposed to selective peptides is that 
multiple epitopes can be presented to both CD4 and CD8 T cells, however as mentioned 
previously this can be disadvantageous when immunodominant epitopes stimulate both Tregs 
and Th1 cells [286]. 
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action; firstly, in HLA-B7 negative patients, an allogeneic response would be expected 
against the foreign MHC class I antigen. Secondly, in all patients, ß2 microglobulin may 
recover normal class I antigen presentation increasing tumour antigen presentation. Thirdly, 
in any patient intralesional injection of the pDNA/lipid complex may promote innate pro-
inflammatory responses.   
1.6.8 Inhibition of checkpoint proteins 
 
In a recent phase three trial, Ipilimumab, a human IgG1ĸ monoclonal antibody which is a 
checkpoint protein inhibitor blocking CTLA-4,  was administered with or without a 
glycoprotein 100 (gp100) peptide vaccine and compared to gp100 alone in 676 patients with 
previously treated metastatic melanoma [294]. Ipilimumab is the first agent ever proven to 
improve survival in advanced melanoma has now been approved by the FDA for second line 
therapy in adult patients. Tremelimumab is another human anti-CTLA-4 antibody that has 
been used in phase I and II trials with encouraging results. Out of 39 patients with advanced 
melanoma, two patients had a complete response and two had a partial response. The 
mechanism whereby Tremelimumab was able to elicit anti-tumour responses was shown to be 
due to suppression of Treg activity while also increasing the effector and memory CD4 and 
CD8 T cells populations [295]. This effect was also seen in a murine model whereby CTLA-
4 blockade was seen to alter the balance of Tregs to effector cells favouring anti-tumour 
responses [296]. However Tremelimumab was not as successful as Ipilumimab as a phase III 
trial evaluating the effect of as a first-line treatment compared to conventional treatment 
strategies on patients with advanced melanoma showed no significant difference in overall 
survival due to three deaths in the Tremelimumab treated patients resulting in the study being 
abandoned [297].  
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1.7 Generating an effective cancer vaccine 
 
 An ideal cancer vaccine should induce a strong immune response against the antigen 
expressed only on malignant cells. The failure of antigen specific cancer vaccines is not in 
generating antigen-specific T cells as these can be shown to be present, but that  these CD8 T 
cells are of low avidity and not capable of carrying out effective anti-tumour cytotoxicity. 
Low avidity T cells may also fail to extravasate into tumours or be retained once they have 
migrated [298]. 
1.7.1 T cell avidity 
 
T cell affinity represents the interaction between a TCR and MHC:peptide on APCs. T cells 
show a range of affinities which affect the T cell specificity and activity [299]. The term 
affinity refers to the strength of an interaction between a single receptor and its ligand. 
Whereas avidity is the sum of the strengths of interaction occurring between two cells and is 
determined by affinity, the number of synapses formed, the length of time the synapses are 
engaged, cytokines such as IL-12 and costimulation [300]. The interaction between a T cell 
and a target cell can be measured in terms of its functional avidity which is determined by the 
peptide concentration at which a T cells elicits effector functions and measured by the 
amount of peptide needed to elicit a half maximal response. Subsequently T cells with low 
avidity respond only to high concentrations of peptide. The concentration of an in vitro 
stimulating antigen has been shown to influence the  expansion of  high or low avidity T cells 
[301]. Studies in TCR transgenic mice have shown that any cell can divide to produce further 
cells with different avidities suggesting that avidity can be modulated at the level of a single 
cell [302]. During T cell activation the reorganisation of membrane microdomains (lipid 
rafts) results in the formation of raft-associated molecules at the site of TCR engagement 
[303]. At the immunological synapse the activation of T cells is dependent on lipid 
  
63 
 
raft integrity resulting from the ability of these microdomains to properly localise and 
concentrate signalling molecules in the correct orientation [304].  
Antigen specific CD8 T cells stimulated with various concentrations of peptide can produce 
CD8 T cells with varying avidities where expansion with low-dose peptide (resulting in high 
avidity T cells) enables lysis of target cells sensitised with more than 100 times less peptide 
than CD8 T cells generated with high-dose peptide (resulting in low avidity T cells) [305]. 
The high avidity T cells, recognising low does peptide, when adoptively transferred into 
severe combined immunodeficient mice were up to 1000 times more effective at viral 
clearance than the low avidity T cells however both T cell lines lysed virus-infected targets in 
vitro. Therefore, low dose peptide selects high avidity T cells whereas high dose stimulates 
low avidity responses or even cell death at too high a concentration. 
 
1.7.2 T cell avidity in anti-tumour response 
 
Differences in T cell  avidity correlate with the in vivo anti-tumour efficacy with higher 
avidity T cells leading to better anti-tumour responses [306], [307]. The influence of T cell 
avidity on tumour recognition in vivo was assessed using a murine melanoma model by Zeh 
et al [306]. High avidity T cells specific for tumour antigens TRP-2 or p15E were generated 
by stimulating T cells with very low amounts of antigenic peptide. Adoptive therapy using T 
cells of high and low avidity demonstrated that the high avidity T cells eliminated lung 
metastases from B16 melanoma. Dutoit et al used CD8 T cells clones derived from T cells 
isolated from melanoma patients and showed that an avidity of over 10
-9
M, (the antigen 
concentration at which a half maximal response is achieved), was required for tumour 
recognition and these CD8 T cell clones from spontaneously regressing cancer patients had 
avidities of around 10
-12
M [308].  
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Scancell Holdings Plc developed the ImmunoBody®, a modified DNA vaccine encoding an 
antibody molecule. Complementarity determining regions (CDRs) of the antibody have been 
modified and replaced with unique restriction sites. The ImmunoBody® expression system 
contains cytotoxic CD8 and helper CD4 epitopes within a human IgG1 or mouse IgG2a 
framework, removing the need for adjuvants and stimulating effective T cell responses [309]. 
Vaccination using the ImmunoBody®  has shown anti-tumour immunity as a result of the 
generation of high-frequency and high-avidity T cell responses [307] where no significant 
correlation was found between avidity and frequency suggesting they are independent 
responses. The melanoma antigen tyrosinase related protein 2 (TRP2) was engineered into 
the ImmunoBody® expression system compared to DCs pulsed with HepB/TRP-2 linked 
peptide. The study found that the avidity of TRP-2 specific T cell responses following DNA 
immunisation was up to 10 times higher than with peptide-pulsed DCs. The avidity of T cell 
responses generated by a TRP2/HepB human IgG1 Immunobody DNA vaccine are an 
average of 5x10
-10
M, significantly higher than that of the same peptide immunisation [307], 
and  able to induce tumour lysis in vivo.  
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1.8 Summary 
To summarise, effective cancer vaccines need to stimulate high avidity T cells that can get 
into tumours. The next generation of cancer vaccines need to achieve three essential criteria: 
firstly generating T cells with highly avid recognition of tumour antigens in vivo. Secondly 
these high avidity T cells must be able to infiltrate tumours where trafficking to the tumour is 
dependent on chemokine profiles and potentially antigen recognition required for 
extravasation from the blood. Thirdly, the T cells must be activated sufficiently within the 
tumour, overcoming the suppressive mechanisms at the tumour site to carry out effector 
mechanisms causing tumour destruction. The presence of regulatory T cells within the 
tumours microenvironment highlights the importance of active suppressor mechanisms 
arising both from the tumour and from the immune system itself that can inhibit anti-tumour 
immune reactions in vivo. Work from CTLA-4 inhibition would suggest that altering the 
balance of T effector cells to T regulatory cells can result in clinical benefit. This thesis 
therefore addresses the migration of CD8 and Treg cells into tumours and the chemokine 
effect within the tumour environment in order to further our understanding of how to shift the 
balance to an effective CD8 T cell response.   
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1.8.1 Hypothesis 
 
Due to the growing body of evidence that antigen recognition influences the transmigration 
of T cells the hypothesis for this thesis was that recognition of cognate antigen presented on 
tumour endothelium influences the transmigration and subsequent infiltration of CD8 and 
regulatory T cells into tumours. 
 

1.8.2 Project aims 
 
In order to further analyse factors affecting T cell infiltration into tumours four aims were 
addressed. The aims of the project were: 
 
1) To analyse the importance, in CD8 T cell transmigration, of recognition of peptide: 
MHC on ECs by tumour associated antigen TRP-2 specific CD8 T cells. 
 
2) To analyse the effect of CD8 infiltration into colorectal tumours on the survival and 
clinicopathological characteristics of patients. 
 
3) To analyse the importance of cognate antigen recognition, chemokines and 
inflammation on natural regulatory T cell transmigration.  
 
4) To identify the effect of CXCL12 and CXCR4 within cancer patients on survival and 
correlation with clinicopathological characteristics. 
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Chapter 2: Materials and Methods 

2.1 Mice 
 
All animal work was carried out under a Home Office approved project license. C57BL/6 
mice were purchased from Charles River UK Ltd and were housed in the animal facility at 
Nottingham Trent University. HHD II transgenic mice (Institut Pasteur) were used as an 
HLA-A*0201 transgenic murine model. These mice have a HLA-A*0201/Db transgene 
consisting of the 1 and 2 domains of the HLA-A*0201 linked to the α3 transmembrane 
and cytoplasmic domain of H-2Db, as well as the human β2-microglobulin gene. The mice are 
on a C57Bl/6 x SJL, H-2Db-/- β2m-/- double knockout background. DR4 transgenic mice are a 
transgenic strain containing a hybrid MHC class II molecule (the peptide binding domains of 
human HLA-DR4 and the membrane proximal domains of mouse I-E). All mice were bred in 
house at the animal facility in Nottingham Trent University and were aged between 6 and 12 
weeks. 
 
2.1.1 Peptide 
 
The synthetic TRP-2 peptide used for T cell culture and endothelial pulsing was 
SVYDFFVWL (Department of Biomedical Sciences, Nottingham University, UK) and 
reconstituted in PBS at a stock concentration of 20mg/ml. 
 
2.1.2 Murine cell culture 
 
All cell culture was carried out in a class II safety tissue culture hood using aseptic techniques 
and all reagents were purchased from Sigma (Dorset, UK) unless otherwise stated. Murine 
splenocytes were cultured in RPMI 1640 media was supplemented with 10% NBCS 
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(newborn calf serum) 2mM L-glutamine, 100U/ml Penicillin /Streptomycin, 10mM Hepes 
buffer, 5mM Non essential amino acids, 5mM Sodium Pyruvate  and 5 x 10
-5
M 2-
mercaptoethanol. Murine lung endothelial cells (primary cells) were cultured in Hams-F12 
media, 10% NBCS, 2mM L-glutamine, 100U/ml Penicillin /Streptomycin, 10mM Hepes 
buffer, 5mM Non essential amino acids, 5mM Sodium Pyruvate, 5 x 10
-5
M 2-
mercaptoethanol, 100µg/ml murine EGF (Peprotech, London,UK) and 10µg/ml murine bFGF 
(Peprotech). The B16 melanoma cell line and RMAS TAP-2 deficient murine tumour cell 
line (ATCC) were cultured in RMPI 1640 and 10% NBCS. 

2.1.3 Flow cytometric analysis 
 
For flow cytometric analysis sample cells were placed at 1x10
6 
cells/ml and 100µl used for 
each samples. Each sample was resuspended in 50ul of staining solution containing indicated 
antibodies at described concentrations. For surface staining samples were mixed and 
incubated on ice for 1 hour, washed x2 with PBS and resuspended in 400ul PBS for analysis. 
For intracellular staining, following initial surface staining, samples were resuspended in 
500µl FACs permeabilisation buffer (eBioscience 00-5123-43) for 45 minutes on ice. 
Samples were washed x2 with PBS, resuspended in 50ul intracellular staining solution and 
placed on ice for an hour. Samples washed x2 with PBS and resuspended in 400ul PBS for 
analysis on FACS-calibur flow cytometer using WinMDI 2.8 software.   
 
2.2 Murine lung endothelial cell isolation and culture 
 
To investigate the effect of antigen recognition on T cell transmigration across endothelium 
an in vitro murine model was developed using murine lung endothelial cells (MLECs) as a 
model endothelium and isolated murine T cells for transmigration. 
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2.2.1 Isolation of murine lung endothelial cells 
 
Murine microvascular endothelial cells (MLECs) were isolated from DR4/C57Bl/HHDII 
murine lung tissue by collagenase digestion as shown previously [310]. The lung tissue was 
diced into 1mm
2
 pieces and placed in a solution of 200U/ml collagenase type II (Invitrogen,
Paisley 
UK) in Hanks Balanced Salts Solution (Invitrogen). Lung tissue was incubated in collagenase 
for 1 hour at 37
o
C, shaking vigorously every 20 minutes. MLECs were cultured in 0.2% 
gelatin-coated T75 flasks at 37°C with 5% CO2. At confluence MLECs were detached from 
the culture flasks using 0.1% trypsin in 0.2% EDTA and passaged 1:3.  For use in functional 
assays MLECs were used between passage 4 and 10, activated by culture with a combination 
of 100ng/ml of IFN-γ (Peprotech), 100ng/ml TNF-α (SantaCruz, Heidelberg, Germany) and 
50ng/ml VEGF (SantaCruz) for 24 hours to induce/reduce the expression of cell adhesion 
molecules.  
 
2.2.2 Characterisation of murine lung microvascular endothelial cells. 
 
Murine lung endothelial cells were cultured on the surface of transwell inserts to form a 
monolayer.  ).4 highlights the 3µm pores of the PET transwell insert prior to 
addition of ECs whereas the insert covered with a C57Bl MLEC monolayer is shown in 
)	6	CD31or PECAM-1 (platelet
 
endothelial cell adhesion molecule 1) expression 
has been shown to be a marker of endothelial lineage [311].  
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A.                                                                  B 
    
 
   C.                                                           D.                                                        E. 
              

)		


	


. 
Murine lung endothelial cell monolayer formation, 4 3um pores of a 24 well PET transwell insert. 6 MLEC 
monolayer formation across the insert following coating with 2% gelatin and growth overnight at 37
o
C, 5%CO2. 
#Indirect immunofluorescence staining with anti-CD31mabs (Thick black lines) and flow cytometric analysis 
of  murine lung cells following degradation for 1 hour with collagenase type II, $ The same MLEC cells 
following adherence to 0.2% gelatin coated T25 flask and  following passage 1. Isotyped matched 
immunoglobulin was used as a negative control (thin line). 
 
To ensure that the isolated endothelial cells from murine lungs were indeed derived from an 
endothelial cell lineage the cells were stained by indirect immunofluorescence and analysed 
by flow cytometry. Samples were analysed with anti-murine CD31-PE (eBioscience, 
Hatfield, UK12-0311-81) at 1:50 dilution. Endothelial activation was assessed using anti-
murine antibodies; ICAM-1-FITC (eBioscience, Hatfield, UK 11-0541), VCAM-1-FITC 
(eBioscience 11-1061), ALCAM-PE (eBioscience 12-1661), MHC Class 1-FITC 
(eBioscience 11-5999), MHC Class II-PE (eBioscience 12-5322) and CXCR4-APC 
(eBioscience 17-9991) at 1:50 dilutions. CD31 expression of DR4 murine lung cells 
following degradation in collagenase type II is shown in  )	#. Collagenase 
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degradation causes dissociation of the native collagen that holds the lung tissue together 
allowing retrieval of endothelial cells. CD31 expression increases following preferential 
adherence of endothelial cells to 0.2% gelatin coated T25 tissue culture flasks)	$. 
Finally the same cells at passage 1 following subsequent culture resulting in increased 
numbers of cells expressing CD31 to 80-90% and therefore a purer population of endothelial 
cells)	.  
 
 
2.2.4 Isolation of murine CD4 and CD8 T cells 
 
Murine CD4, CD8 and CD4CD25FOXP3 T cell subsets were isolated using the Miltenyi 
MACs separation system for use in transmigration assays. 
 
Splenocytes were obtained from murine spleens, adhered to tissue culture flasks prior to use 
in transmigration assays to partially enrich for T cells by monocyte adherence and depletion. 
For isolation of CD8 and CD4 T cells murine CD4+ and CD8+ T Cell Isolation Kits 
(Miltenyi130-095-248 and 130-095-236) were used. Splenocytes were labelled with Biotin-
Antibody Cocktail (Miltenyi, Surrey, UK), for CD4 T cell isolation, containing biotin-
conjugated monoclonal antibodies against CD8a, CD11b, CD11c, CD19, CD45R (B220), 
CD49b (DX5), CD105, anti-MHC class II, and Ter-119. For isolation of CD8 T cells the 
antibody cocktail contained anti-CD4 to replace CD8a. T cell populations were obtained by 
negative selection by passage down MS MACS columns (Miltenyi). Purity of the obtained 
CD8 and CD4 population was assessed using Flow Cytometry.   



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2.2.5 Isolation of CD4+CD25+ T cells 
 
Splenocytes were obtained from murine spleens, adhered to tissue culture flasks prior to use 
in transmigration assays to partially enrich for T cells by monocyte adherence and depletion, 
cultured in RPMI 1640 medium supplemented with 10% FCS, 2mM glutamine (Sigma), 
HEPES buffer (Sigma), 2-Mercaptoethanol and 100U/ml penicillin and 50µg/ml 
streptomycin (Sigma) at 37°C with 5% CO2. For isolation of CD4+CD25+ T cells from 
splenocytes a murine CD4+CD25+Regulatory T Cell Isolation Kit (Miltenyi 130-091-041) 
was used. Splenocytes were indirectly magnetically labelled to remove non-CD4+ T cells 
with Biotin-Antibody Cocktail and Anti-Biotin MicroBeads (Miltenyi). This was followed by 
positive selection of CD25+ cells by labelling with anti-CD25-PE antibody. Magnetic 
separation using LD and MS columns, for negative and positive selection was carried out 
respectively. The purity of the obtained CD4+CD25+ T cells was assessed using indirect 
immunofluorescence staining and Flow Cytometric analysis.   
 
2.3 Murine immunisation  
 
To generate anti-tumour specific T responses mice were immunised via gene gun with gold 
bullets coated with plasmid DNA. 
 
2.3.1 Plasmids 
 
The ImmunoBody
TM
 DNA plasmid used in immunisations was a kind gift from Scancell Ltd. 
The ImmunoBody
TM
 construct contains CDRs within the single heavy and light chain vectors 
that had been replaced with unique restriction sites enabling rapid insertion of epitope 
sequences [309]. To generate the human IgG1 TRP2 constructs, oligonucleotides encoding 
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the TRP2 epitope SVYDFFVWL [312] has been incorporated into the CDRH2 or in direct 
replacement of CDRH3.  
 
2.3.2 Preparation of Gold bullets 
 
100 µl 0.05M spermidine (Sigma) was added to 8.3mg 1µm gold particles (Biorad) and 
sonicated. 18 µg DNA was added and the mixture sonicated again. 100 µl 1M CaCl2 was 
added dropwise to the mixture whilst sonicating then tubes were left to stand for 10 minutes 
at room temperature. Gold was spun at 350g in a microfuge. Pellet was washed 3 times by 
resuspending in 1ml dry ethanol and spinning at 350g. Finally, pellet was resuspended in 1ml 
of 0.025mg/ml PVP (Biorad, Hertfordshire, UK). Gold was loaded into Tefzel tubing that had 
previously been pre-dried under nitrogen for 10 minutes, whilst sonicating. Tubing was 
loaded onto the prep-station (Biorad) and left to stand at room temperature for 30 minutes. 
Ethanol was gently aspirated using a syringe, leaving the gold sediment undisturbed. Tubing 
was turned 180° and held for 5 seconds then set to spin on setting 1. After 30 seconds, 
nitrogen was switched on to level 4 and tubing was spun for a further 5 minutes. Bullets were 
cut using the supplied guillotine (Biorad) and stored at 4°C 
 
2.3.3 Immunisation schedule 
 
Mice were immunised 3 times at weekly intervals with DNA coated onto gold particles, 
prepared as previously described. Each mouse received 1 µg DNA/immunisation into the 
shaved abdomen. Hair was removed from the abdomen by shaving before delivery of the 
gold bullets by the Helios Gene Gun (Bio-Rad). 
 

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2.4 Generation of a TRP-2 specific cell line 
 
Splenocytes obtained from immunised mice were used to generate TRP-2 specific T cell lines 
for subsequent use in in vitro transmigration assays across murine lung endothelium and in 
vivo infiltration into tumours. 
 
2.4.1 ELISPOT  
 
 
The Enzyme Linked Immunosorbent Spot (ELISPOT) assay was used to quantify the number 
of cells responding to TRP-2 peptide by assessment of IFN-γ secretion by CD8 T cells within 
the splenocyte population of immunised mice. The ELISPOT kit for mouse IFN- γ (AP 
system), MABTECH (cat # 3321-2A) was used to verify the presence of antigen-specific 
CD8 T cells for CTL generation. 
96 well Multiscreen Immunopore plates with Immobilon-P membrane (Millipore) were 
washed once with 15µl/well 30% ethanol to pre-activate the membrane, then 4 times with 
sterile PBS. Coating antibody (AN18 anti-IFN-γ) was diluted 1:100 in sterile PBS and 50µl 
added into each well. Plates were incubated overnight at 4°C. The following day, coating 
antibody was aspirated and plates were washed 4 times with sterile PBS. Plates were blocked 
with 200µl per well of complete RPMI 1640 10% NBCS 5 x 10-5 M 2-mercaptoethanol (2-
Me) for at least 20 minutes at room temperature. Media was aspirated from the plate then 
immediately, 100µl per well serial dilutions of peptide, prepared in supplemented RPMI 
1640 10% FCS 5 x 10
-5 
M 2-Mercaptoethanol, were added to the plate in triplicate for each 
mouse. 100µl per well PMA (Sigma) (10ng/ml)/Ionomycin (Sigma) (1000ng/ml) was added 
as a positive control and 100µl per well complete RPMI with 2-Me was added as a negative 
control. 5 x 105 splenocytes from immunised mice were added to each well; in 100µl to take 
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the total volume per well up to 200µl. Plates were wrapped in tin foil and incubated for 48 
hours at 37°C 5% CO2.  
Plates were washed 4 times with 0.5% FCS in PBS and 100 µl per well of biotinylated anti-
murine IFN-γdetection antibody was added to each well, diluted 1:1000 in PBS. Plates were 
incubated for 2 hours at room temperature. Detection antibody was removed from the plates 
and plates were washed 4 times with PBS. Streptavidin-AP (AP-conjugate substrate system, 
BioRad (cat # 170-6432) was diluted 1:1000 in 0.5% NBCS in PBS and 100 µl added to each 
well. Plates were incubated for one hour at room temperature. Plates were again washed 4 
times with PBS then a further twice with distilled H2O. Substrate solution was prepared 
according to the manufacturer’s instruction and 100 µl was added to each well. Plates were 
incubated in the dark for 45 minutes then were rinsed with distilled H2O then allowed to dry 
at room temperature overnight. The following day, the number of spots was quantified 
automatically using an automated ImmunoSpot® plate reader from Cellular Technologies 
Ltd. 
 
2.4.1.1 Calculation of funtional avidity 
 
 
The functional avidity of the response is calculated as the peptide concentration at which a 
half maximal response is achieved either in ug/ml of by Molarity (M). Molarity is calculated 
by: Concentration (ug/ml)x1000ml/L/ Molecular Mass = uM 
 
For a nonomer peptide such as TRP-2 a concentration of 1ug/ml equates to a Molarity close 
to 1x10
-6
M.                         
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2.4.2 LPS Blasts 
 
Splenocytes were harvested from syngeneic naïve mice and washed once with complete 
RPMI 10% NBCS. Cells were counted and put into culture at 1 x 10
6
/ml in complete RPMI 
media, 10% NBCS with 5 x 10-
5
M 2-Me, 25µg/ml LPS (Sigma), 7µg/ml dextran sulphate 
(Sigma) and incubated at 37°C, 5% CO2. 48 hours later, LPS blast cells were irradiated at 
3000 rads and washed twice with RPMI 10% NBCS. Cells were counted with trypan blue 
exclusion, resuspended at 2 x 10
7
/ml and pulsed for 1 hour with 10ng/ml TRP-2 peptide at 
37°C. At the end of the incubation period, cells were diluted to 1 x 10
6
/ml ready for use. 
 
2.4.3 Culture of cytotoxic T lymphocytes (CTLs) 
 
Seven days following the final immunisation, splenocytes (5x10
6
/ml) were co-cultured at 
37
o
C with syngeneic, irradiated (3000 rads), peptide-pulsed LPS blasts (0.5 to1x10
6
 cells/ml). 
LPS blasts were obtained as previously described. Prior to use 2x10
7
/ml LPS blasts were 
labelled with 10 ng/mL synthetic peptide for 1 h, washed once with complete media and 
cultured at 5x10
6
/ml. The CD8
+
 T-cell lines, specific for the TRP-2 peptide epitope 
 
SVYDFFVWL presented by H2-K
b
, was maintained in culture by re-stimulation
 
every week 
with LPS blasts from C57Bl mice presenting TRP-2 peptide (10ng/ml) and recombinant
 
interleukin-2 (rIL-2) (20 U/mL).Cultures were assayed forcytotoxic activity on day 6 in a 
51
Cr-release assay.

2.4.4 Phenotyping of CTL lines 
 
Phenotypic analysis of CTL lines was carried out using four colour flow cytometry where 
2x10
5 
cells were used for each condition in 50ul PBS. Samples were analysed with anti-
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murine CD62L-FITC (eBioscience 11-0621), anti-murine CD8-PeCy5 (eBioscience 15-0083) 
and anti-murine CD127-PeCy7 (eBioscience 25-1271) at 1:25 dilution. In addition, anti 
murine TRP-2 specific pentamer PE labelled (ProImmune, Oxford, UK) was added at a 1:10 
dilution.  
 
2.4.5 Chromium release assay 
 
Target cells were passaged 24 hours before the assay. C57Bl MLECs were pre-treated with 
100ng/ml human IFN- γ (Peprotech) to upregulate MHC class I expression for 24 hours. 
Target cells were suspended at 2 x 10
6
/ml in serum free medium containing increasing 
concentrations of TRP-2 peptide and incubated with 1.85mBq 51[Cr] Sodium Chromate 
(Amersham) for 1 hour at 37°C 5% CO2. Cells were washed 3 times with serum free 
medium. Cell lines of central memory, effector or effector memory CTLs were washed once 
and viable cells counted with trypan blue exclusion. Cells were resuspended at 2.5 x 10
6
 per 
ml in supplemented RPMI 1640 10% NBCS. Effector cells were plated out, 50 µl per well, in 
96 well round-bottomed plates. Serial dilutions were performed to obtain the necessary 
effector:target ratios. Supplemented RPMI 1640 10% NBCS media was added to make the 
final volume in each well up to 175 µl per well. After washing with serum free medium, 
viable target cells were counted with trypan blue exclusion and resuspended at 1 x 10
5
 
cells/ml in supplemented RMPI 1640 10% NBCS. 25 µl target cells were added to each well 
of effector cells. Effector cells were incubated with target cells at 37°C 5% CO2 for 4 hours. 
To assess the level of spontaneous release of Chromium, each target cell line was also 
incubated alone in 200 µl of media. To assess maximum release, each target cell line was 
incubated alone in 200 µl media with 25 µl Triton X (Sigma). After 4 hours, 50 µl 
supernatant from each well was transferred to a Lumaplate (Packard) plate. Plates were left to 
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dry at room temperature. The following day plates were read on a Topcount Microplate 
Scintillation Counter (Packard). The percentage specific lysis was determined using the 
following formula: Specific lysis (%) = ((Experimental release – Spontaneous 
release)/(Maximum release – Spontaneous release)) x 100 
 
 
2.5 In vitro transmigration assays 
 
A murine model of T cell transmigration was developed to investigate the effect of antigen-
recognition of peptide presented by endothelial cells in the context of MHC molecules on T 
cell transmigration. 
 
Transmigration assays were carried in Costar Transwell tissue culture inserts (6.5mm 
diameter) with 3.0µm pore size and Polyester membranes ()	4.). Inserts were coated 
with 2% gelatin for 1 hour at 37°C and seeded with 1-2x10
5
 ECs overnight to form a 
monolayer. Where used, monolayers were cultured with 100ng/ml IFN-γ, 100ng/ml TNF-α 
and 50ng/ml VEG for 24 hours prior to transmigration.
 
2.5.1 CD8 T cell transmigration assay 
 
Purified murine CD8 T cells (0.5-2x10
5
) in 200µl RPMI 1640 with 10% NBCS were added to 
the upper chamber, 500µl media per well was added to the lower chamber and left for 24 
hours to migrate through the monolayer. MLEC monolayers of C57Bl (syngeneic) and 
HHDII (allogeneic) were used ()	)). C57Bl ECs were untreated (control) or treated 
with 0.5ug/ml anti-H-2K/Db (Abcam ab64523) for 1 hour prior to transmigration. ECs were 
pulsed with 10ng/ml TRP-2 peptide for 4 hours prior to addition of splenocytes for 
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Splenocytes were derived from a DR4 mouse and analysis by flow cytometry where the cells were detected by 3 
colour flow cytometry for CD4CD25FOXP3 T cells using anti-murine CD4-FITC, CD25-Pe and intracellular 
FOXP3-PeCy7. Scattergrams of FACS analysis for CD4CD25 of the whole splenocyte population is shown in 4 
and 6 represents CD25FOXP3 expression gated on the CD4 T cell population. 
 
 
2.5.4 Analysis of TRP-2 specific CD8 T cell transmigration 
 
Single-cell suspensions of cells recovered from the lower chambers of transwells were 
incubated with all of the following mouse anti-murine monoclonal antibodies: anti-murine 
CD62L-FITC (eBioscience 11-0621), anti-murine CD8-PeCy5 (eBioscience 15-0083) and 
anti-murine CD127-PeCy7 (eBioscience 25-1271) at 1:25 dilution. In addition, anti-murine 
TRP-2 specific pentamer PE labelled (ProImmune) was added at a 1:10 dilution for 60 
minutes on ice. Recordings were made from at least 100,000 cells on a FACS-calibur flow 
cytometer using WinMDI 2.8 software. 
 An example of flow cytometric analysis is shown in )	9 for splenocytes derived from 
a C57Bl mouse immunised with TRP-2 Immunobody
TM
. Within the whole ex vivo splenocyte 
population single staining with anti-CD8-PeCy5 shows 16% of the cells are CD8 positive 
2)	943	 Double staining of the same population with anti-murine CD8-PeCy5 and TRP-2 
specific pentamer (PE) ()	96) highlights only 0.22% of the whole splenocyte population are 
CD8+TRP-2+ T cells. Following CD8 T cells isolation the percentage of CD8 T cells 
increases to around 94% ()	9#) with 2.16% of the population being CD8+TRP-2+ T cells. 
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 )	9$ represents a scattergram for a CTL line stimulated with 10ng/ml TRP-2 and 
rested for 14 days where an effector memory phenotype was identified by CD62L-CD127+ 
expression. Within the effector memory population 22% were CD8+TRP-2+ T cells.  
In this way percentages of total CD8+ and CD8+TRP-2+ T cells within transmigrated 
populations can be assessed by flow cytometric analysis and actual cell counts before and 
after transmigration were used to determine the percentage of each cell subset  transmigrating 
under experimental conditions. 
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Splenocytes were derived from a C57Bl mouse immunised 3 times with TRP-2 Immunobody
TM
 construct via 
gene gun. Scattergrams of FACS analysis for CD8+ and CD8+TRP-2+ expression within the ex vivo splenocyte 
population is shown in 4and6respectively. CD8+TRP-2+ expression within an ex vivo isolated CD8 T cell 
population and 14 day cultured CTL line is shown in # and $ respectively. 
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2.6 Synthesis of TRP-2 knockout B16 lines 
 
 
To investigate the effect of antigen recognition on the in vivo transmigration of TRP-2 
specific CTL lines into B16 tumours a TRP-2 knock-out murine B16 melanoma cell line was 
produced to compare infiltration of T cells against TRP-2+ B16F10 wild type tumours. 
 
The BLOCK-iT
TM 
Inducible Pol II miR RNAi Expression Vector Kit was used (Invitrogen). 
RNA interference (RNAi) describes the phenomenon by which short, homologous RNA 
duplexes induce potent and specific inhibition of eukaryotic gene expression via the 
degradation of complementary messenger RNA (mRNA), and is functionally similar to the 
processes of post-transcriptional gene silencing (PTGS).  
 
TRP-2 or Mus musculus dopachrome tautomerase (Dct), mRNA sequence is shown below 
)	.).











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          Base    Sequence
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2.6.1 DNA plasmid generation 
 
The BLOCK-iT
TM 
RNAi Designer (Invitrogen) was used to generate miR RNAi 
oligonucleotides (oligos), the selected oligos started at 1360: 
CTGTGTAATGGAACCTATGAA, shown in bold in )	.. 
Forward Primer 5’ to 3’ NM_010024_1360 
 
TGCTGTTCATAGGTTCCATTACACAGGTTTTGGCCACTGACTGACCTGTGTAAGAACCTATGAA 
         CAAGTATCCAAGGTAATGTGTCCAAAACCGGTGACTGACTGGACACATTCTTGGATACTTGCCT  
 
Reverse Primer 3’ to 5’ NM_010024_1360 
  
85 
 
Two complementary single-stranded DNA oligonucleotides, encoding the TRP-2 miRNA 
were annealed to generate double stranded (ds) oligos.  The ds oligos were cloned into the 
linearised pcDNA™6.2-GW/EmGFP-miR vector and transformed into One Shot® TOP10 
chemically competent E. coli and select for spectinomycin-resistant transformants. The 
pcDNA™6.2-GW/EmGFP-miR vector that allows the expression of the engineered TRP-2 
pre-miRNA under the control of the strong, Pol II human CMV (cytomegalovirus) promoter 
and Herpes Simplex virus (HSV) thymidine kinase (TK) polyadenylation signal. The coding 
sequence of EmGFP (Emerald Green Fluorescent Protein) is incorporated into the vector such 
that the pre-miRNA insertion site is in the 3’ untranslated (3’UTR) region of the fluorescent 
protein mRNA ()	0). 
 


)	0$14.	)H!.@')!!	
 
2.6.1.1 Generation of double stranded oligonucleotides 
 
To anneal single-stranded (ss) oligonucleotides to generate the double stranded (ds) 
oligonucleotides the lyophilised single-stranded oligonucleotides were used at 200µM each in 
DNase/RNase free sdH2O. 

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4F
Top strand DNA oligo (200 µM)                  
Bottom strand DNA oligo (200 µM)            
10X Oligo Annealing Buffer                        
DNase/RNase-Free Water                            
Total volume                                              
 
The reaction was incubated at 95
o
C for 5 minutes, removed from the heat block and set on the 
laboratory bench at room temperature for 30 minutes to allow the single-stranded oligos to 
anneal. The samples were mixed gently in a microcentrifuge and 1µl of the 50µM annealing 
mixture was added to 99µl H2O (500nM). Subsequently 1µl of this 500nM oligo mix was 
then added to 5µl 10x oligo annealing buffer and 44µl DNase free H2O to make a final 
concentration of 10nM ds oligo stock.  

2.6.1.2 Ligation  
 
Ligation reaction: 5x Ligation buffer                                                           
                              pcDNA6.2GW/GMGFPmiRlinearised                           
                              miR 1360 oligo stock  (10nM)                                      
                              DNase/RNase free H2O                                                  
                              T4 DNA ligase                                                               
 
The ligation buffer was mixed by pipetting and incubated at room temperature for 1 hour and 
then placed on ice. 
 
2.6.1.3 Transformation of E.coli 
 

The ligation reaction was transformed into One Shot® TOP10Chemically Competent E. coli. 
2µl of the ligation reaction was added to 50µlof Shot® TOP10 chemically competent E. coli 
and mixed gently. It was incubated on ice for 30 minutes, heat shocked for 30 seconds at 
42
o
C and transferred back to ice. 250µl of room temperature S.O.C. (super optimal broth) 
medium (Sigma) was added and incubated at 37°C for 1 hour. SOC medium contains 50 and 
5ul 
5ul 
2ul 
8ul 
20ul 
4ul 
2ul 
2ul 
8ul 
1ul 
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150µl from each transformation were spread onto pre-warmed LB agar plates containing 
50µg/ml spectinomycin and incubated overnight at 37°C.  
Plates were assessed for colony growth and 10 individual colonies were selected, picked with 
a sterile pipette tip and placed into universals containing 1.5mls of LB containing 50 µg/ml 
spectinomycin.  Samples were then placed at 37°C overnight.  
Plasmid DNA purification performed using QIAprep Miniprep kits (QIAGEN, Sussex, UK) 
on the 10 clones for sequencing positive transformants to confirm the sequence of the ds 
oligo insert and 15µl of each were sent to Lark Technologies for sequence analysis. 

 
2.6.2 Transfection of B16 cells  
 
DNA plasmid was purified using QIAprep Maxiprep kit and spectrophotometric DNA 
quantification performed. B16 cells were then transfected with the plasmid using 
lipofectamine 2000 reagent (Invitrogen) and cells selected for Blasticidin resistance. 4µg of 
DNA plasmid was added to 250µl of OPIMEM media while 10ul of Lipofectamine 2000 
reagent was added to a further 250µl of OPIMEM media. They were mixed gently and 
incubated at room temperature for 5 minutes. DNA and Lipofectamine were added together 
and incubated at room temperature for 20 minutes. B16 cells, were grown overnight at 
1.5x10
5
 cells/ml in 6 well tissue culture plates (Costar, Sigma). The media was replaced with 
2mls of fresh media and DNA/Lipofectamine complex was added dropwise and mixed gently 
prior to incubation for 24 hours at 37
o
C.
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2.6.3 Analysis of TRP-2 knockdown 
 
Each well was trypsinised and cells replated into 24 well tissue culture plates in fresh 
complete medium containing 10µg/ml Blasticidin. Medium was replaced with fresh medium 
containing Blasticidin every 3-4 days until Blasticidin- resistant colonies were identified 
(generally 10-14 days after selection). Blasticidin-resistant colonies were analysed for 
knockdown of TRP-2 expression by flow cytometric analysis of GFP expression (EmGFP 
excitation 487nm). Intracellular TRP-2 expression was analysed using rabbit anti-murine 
TRP-2 antibody (Abcam, Cambridge, UK, ab74073) and a goat anti-rabbit-PeCy7 secondary 
antibody (SantaCruz). Colonies were selected that showed no/minimal TRP-2 expression 
with the presence of GFP.  

2.7 In vivo TRP-2 specific transmigration assay 
 
To analyse the effect of antigen-recognition on CD8 T transmigration into tumours an in vivo 
model of transmigration was formed using B16 melanoma as a murine tumour model and 
TRP-2 specific CD8 T cells of an effector memory phenotype. 
 
2.7.1 Tumour growth 
 
The B16 tumour cell lines were grown in T75 tissue culture flasks in RPMI 1640 plus 10% 
NBCS at 37
o
C 5% CO2 until confluent. B16 cells harvested by trypsinisation and 
resuspended at 2x10
5 
cells/ml in PBS. C57Bl mice were injected subcutaneously with 2x10
4
 
B16 WT cells on the right flank and 2x10
4
 B16 TRP-2 knockout cells on the left flank. 
Tumour growth was analysed every 2 days and used for analysis of transmigration when they 
reached 500mm
3
.  
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
2.7.2 Labelling and immunisation of CTL line 
 
The CTL line stimulated with LPS blasts and 10ng/ml TRP-2 peptide was rested for 2 weeks, 
harvested and cells placed at 1x10
6
 cells/ml in PBS. 1nM CFSE (diluted from 5nM stock in 
PBS) was added and the cell solution incubated at 37
o
C for 15 minutes. Staining was 
quenched with the addition of ice-cold media for 5 minutes. CTLs were resuspended in PBS 
at 2x10
7
 cells/ml and 500ul was injected by intraperitoneal injection into each tumour bearing 
mouse. 
 
2.7.3 Analysis of in vivo T cell infiltration 
 
T cell infiltration was analysed within TRP-2 positive and negative B16 tumours from the 
same mouse. Tumours, spleens and peripheral blood samples were taken and analysed by 
flow cytometry for CFSE expression to identify adoptively transferred cells. Once identified, 
these samples were analysed with anti-murine CD8-PeCy5 (eBioscience 15-0083) at 1:25 
dilution and anti murine TRP-2 specific pentamer PE labelled (ProImmune, Oxford, UK) at 
1:10 dilution. 
 
2.8 Immunohistochemical staining 
 
Immunohistochemistry (IHC) exploits the specific interaction between an antibody and its 
antigen to estimate expression of that antigen on a section of tissue. This study used formalin 
fixed paraffin embedded (FFPE) tissue for both an ovarian and a colorectal TMA. All tissues 
used the same technique with slight alterations depending on type of tissue and antigen. 

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2.8.1 Colorectal patient cohort 
 
The study population cohort encompasses a consecutive series of 462 archived primary 
invasive colorectal cancer specimens obtained from patients undergoing elective surgical 
resection of a histologically proven primary colorectal cancer at Nottingham University 
Hospitals, Nottingham, UK.  
 
The samples were collected between January 1994 and December 2000 from the established 
institutional tumour bank and were identified from the hospital archives. No cases were 
excluded unless the relevant clinico-pathological material/data were unavailable. The average 
follow-up period was 42 months (range 1-116 months) to ensure a sufficient duration of 
follow-up to allow meaningful assessment of the prognostic value of the markers examined. 
Follow-up was calculated from the date of resection of the primary tumour, and all surviving 
cases were censored for data analysis on December 2003. Patient and tumour characteristics 
for the cohort have been previously published [313]. All patients underwent surgical 
resection; patients with lymph node positive disease routinely received adjuvant 
chemotherapy with 5-flurouracil and folinic acid.  
 
All tumours received following resection in the histopathology lab were incised, fixed 
immediately in formaldehyde and processed through to embedding in paraffin wax, ensuring 
optimal tissue fixation and preservation for histological examination. Tissue microarrays 
were built as described previously [314].  
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2.8.2 Colorectal specimen characteristics 
 
For each tumour, 5µm section slides stained with haematoxylin-eosin were first used to locate 
representative areas of viable tumour tissue. 0.6 mm needle core-biopsies from the 
corresponding areas on the paraffin-embedded tumour blocks were then placed at pre-
specified coordinates in recipient paraffin array blocks using a manual tissue-arrayer 
(Beecher Instruments, Sun Prarie, WI). Array blocks were constructed with between 80–150 
cores in each, with analysis of a single core from each case. Fresh 5µm sections were 
obtained from each TMA block and placed on coated glass slides to allow the 
immunohistochemical procedures to be performed, preserving maximum tissue antigenicity. 
 
2.8.3 Ovarian patient cohort 
 
A total of 360 patients with ovarian cancer were entered in this study, and these consisted of 
patients undergoing a laparotomy for primary ovarian cancer. Information on cancer size, 
stage, presence or absence of residual disease after surgery, histologic type and grade, age at 
diagnosis, and type of adjuvant treatment was collected for all patients. From this original 
population, histologic material was available for analysis in 339 cases. The paraffin-
embedded tissue blocks from these patients dated back from January 1, 1984 until December 
31, 1997. Disease-specific survival was calculated from the operation date until November 
31, 2005 when any remaining survivors were censored. The database was audited to ensure 
validity; there were no major discrepancies with >97% of data available.  
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2.8.4 Ovarian patient characteristics 
 
During the study period, patients with high-grade stage I and stage II to IV disease received 
chemotherapy. The specific chemotherapy varied but reflected the best current practice; most 
recently, this treatment was platinum based. Sixty-two patients participated in the 
International Collaborative Group for Ovarian Neoplasia trials I to IV during which the 
allocated chemotherapy was randomized. Although the study spans a 14 year period, there 
was no significant change in the survival of patients treated in the earlier or latter part of the 
study. This is in line with the unaltered survival of ovarian cancer patients over the last 30 
years [315]. 

2.8.5 Immunohistochemical analysis of CD8 
 
Immunohistochemical analysis of CD8 expression was performed using a routine 
streptavidin-biotin peroxidase method. Tissue array sections were first deparaffinised with 
xylene, rehydrated through graded alcohol and immersed in methanol containing 0.3% 
hydrogen peroxide for 20 minutes to block endogenous peroxidase activity. In order to 
retrieve antigenicity, sections were immersed in 500 mls of pH 9.0 EDTA buffer and heated 
for 10 min in an 800 W microwave at high power, followed by 10 min at low power. 
Endogenous avidin/biotin binding was blocked using an avidin/biotin blocking kit (Vector 
Labs, USA). In order to block non-specific binding of the primary antibody all sections were 
then treated with 100 µl of 1/5 normal swine serum (NSS) in TBS for 15 min. 
CD8 expression was determined using 100 µl of a rabbit polyclonal antibody (ab4055, 
AbCam), recognising a synthetic peptide comprising the 13 C-terminal amino acids of the 
cytoplasmic domain of the CD8 alpha chain, at an optimal concentration of 1:200 in TBS for 
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1 hour at room temperature. Positive control tissue comprised whole sections of colorectal 
cancer tissue. The primary antibody was omitted from the negative control, which was left 
incubating in TBS. 
After washing with TBS all sections were incubated with 100 µl of biotinylated goat anti-
mouse/rabbit immunoglobulin (Dako Ltd, Ely, UK) diluted 1:100 in NSS, for 30 min. 
Sections were washed again in TBS and next incubated with 100 µl of pre-formed 
streptavidin-biotin/horseradish peroxidase (HRP) complex (Dako Ltd, Ely, UK) for 60 min at 
room temperature. Subsequently, visualisation of CD8 expression was achieved using 3, 3'-
Diaminobenzidine tetra hydrochloride (DAB, Dako Ltd, Ely, UK). Finally, sections were 
lightly counterstained with haematoxylin (Dako Ltd, Ely, UK), dehydrated in alcohol, cleared 
in xylene (Genta Medica, York, UK) and mounted with distyrene, plasticiser and xylene 
(DPX – BDH, Poole, UK). 

2.8.6 Immunohistochemical analysis of CXCL12 and CXCR4 
 
Immunohistochemical analysis of active CXCL12 and CXCR4 expression was performed 
using a routine streptavidin-biotin peroxidase method. Tissue array sections were first 
deparaffinised with xylene, rehydrated through graded alcohol and immersed in methanol 
containing 0.3% hydrogen peroxide for 20 minutes to block endogenous peroxidase activity. 
In order to retrieve antigenicity, sections were immersed in 500 mls of pH 9.0 EDTA buffer 
and heated for 10 min in an 800 W microwave at high power, followed by 10 min at low 
power. Endogenous avidin/biotin binding was blocked using an avidin/biotin blocking kit 
(Vector Labs, USA). In order to block non-specific binding of the primary antibody all 
sections were then treated with 100 µl of 1/5 normal swine serum (NSS) in TBS for 15 min. 
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Test sections were incubated with 100 µl of mouse polyclonal antibody, CXCL12/SDF-1 
(MAB350) recognising human CXCL12 (R&D Systems) which was found to show optimal 
staining at a dilution of 1/50 in TBS for 1 hour at room temperature. CXCR4 expression was 
determined using a mouse monoclonal antibody (MAB172, R&D Systems) recognising 
human CXCR4 at an optimal concentration of 1:600 in TBS for 1 hours at room temperature. 
Positive control tissue comprised whole sections of colorectal cancer tissue. The primary 
antibody was omitted from the negative control, which was left incubating in TBS. 
After washing with TBS, all sections were incubated with 100 µl of biotinylated goat anti-
mouse/rabbit immunoglobulin (Dako Ltd, Ely, UK) diluted 1:100 in NSS, for 30 min. 
Sections were washed again in TBS and next incubated with 100 µl of pre-formed 
streptavidin-biotin/horseradish peroxidase (HRP) complex (Dako Ltd, Ely, UK) for 60 min at 
room temperature. Subsequently, visualisation of CXCL12 or CXCR4 expression was 
achieved using 3, 3'-Diaminobenzidine tetra hydrochloride (DAB, Dako Ltd, Ely, UK). 
Finally, sections were lightly counterstained with haematoxylin (Dako Ltd, Ely, UK), 
dehydrated in alcohol, cleared in xylene (Genta Medica, York, UK) and mounted with 
distyrene, plasticiser and xylene (DPX – BDH, Poole, UK). 
 
2.8.7 Evaluation of staining 
 
The tumour cores were first imaged using a NanoZoomer (Hamamatsu, NJ, USA). The cores 
were then assessed at X20 magnification by two observers (AP and RS) in the Nanozoomer 
Digital Pathology viewer (Hamamatsu), both with experience in the analysis of TMAs. Both 
observers were blinded to the clinical and pathological parameters of the case. In the few 
cases (<5%) where there was a discrepancy between the classification of cores a review of 
those cores was performed and a consensus reached. Tumours were classified by H scores 
  
95 
 
where tumours were assessed for high, moderate, low and negative CXCL12 and CXCR4 
expression. For the CD8 staining, a different approach was used due to whole cells present. 
Using the NanoZoomer Slide Viewer, the area of the tumour was measured and number of 
positive cells in each area counted, giving a value of positive cells per mm
2
. 
Following scoring, H score data needed appropriate grouping to facilitate statistical analysis. 
This was most commonly achieved using a binary cut off of either high or low expression 
using the program X-Tile (Yale University, CT, USA) was used to determine low/high 
expression groups.  
 
2.9 Statistical analysis 
 
Statistical analysis of the study data was performed using the SPSS package (version 16 for 
Windows, SPSS Inc., Chicago, IL). Pearson χ
2 
chi squared tests were used to determine the 
significance of associations between categorical variables. Disease-specific survival 
calculations included all patients whose death related to cancer. In contrast, patients whose 
deaths resulted from non-cancer related causes were censored at the time of death. Kaplan-
Meier curves were used to assess factors which influenced survival. The statistical 
significance of differences in disease-specific survival between groups with differing 
expression was estimated using the log-rank test. The Cox proportional-hazards model was 
used for multivariate analysis in order to determine the relative risk and independent 
significance of individual factors. In all cases p-values < 0.05 were considered as statistically 
significant. 
For statistical analysis of T cell transmigration P values were calculated by using two-sided 
Student’s t test; P<0.05 was considered to be statistically significant.  
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Chapter 3: TRP-2 antigen-dependent CD8 T cell transmigration 
 
3.1 Background 
 
Cytotoxic CD8 T cells can recognise tumour antigens and have the potential  to eliminate 
tumour cells in vivo [316]. The endothelium is a gateway for T cell transmigration into 
tumours and it is essential to understand the endothelial barrier and the immunological 
switches that promote transmigration if an effective immunotherapy is to be generated.  
 
T cell trafficking from blood to tissues is a multi-step process including leukocyte tethering 
and rolling, firm adhesion and transmigration through the endothelial cell lining. Several 
studies have shown that recognition of MHC: peptide complexes may also provide a vital 
signal for extravasation [153,317,318,319]. Marelli-Berg et al proposed a ‘shop window 
model’ whereby endothelial cells acquire antigens from the surrounding tissue and present 
them in the context of MHC molecules to circulating T cells within the blood. Cognate 
peptide:MHC recognition allows entry into tissues [318]. However, it remains unclear how 
antigen can be acquired from tissues by endothelial cells and presented on MHC. One 
mechanism that has recently been described is transfer of peptides via gap junctions from the 
underlying tissue to the endothelial cells and then presented on MHC [320]. This would allow 
specific enrichment of the relevant T cells for the tissue. Unlike a viral infection the tumour 
microenvironment may prevent the endothelium displaying the complete architecture of an 
inflamed tissue, perhaps making the role of MHC peptide more vital. As only small amounts 
of peptide are transferred to endothelial cells this may mean that only high avidity T cells 
recognising low levels of cognate MHC: peptide will get sufficient signal to extravasate. As 
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only high avidity T cells clear viral infections and eradicate tumours [305,321,322], the 
selective enrichment by the endothelium would be a distinct advantage.  
In this study an in vitro model is used for transmigration of high avidity antigen-specific CD8 
T cells across murine lung endothelium. The CD8 T cells used to transmigrate were specific 
for a TRP-2(180-188) peptide epitope SVYDFFVWL
 
presented by H2-K
b
. TRP-2 is a 
melanogenic enzyme (dopachrome tautomerase, dct) that is expressed by both melanocytes 
and melanomas and has been identified as a melanoma rejection antigen [262,312]. TRP-
2(180-188) is an epitope identifiedas a shared HLA-A*0201 epitope recognised by both human 
and murine CTLs [323,324]. Murine lung endothelial cells (MLECs) are easy to isolate in 
substantial numbers and were therefore used as a source of endothelial cells. As the lungs 
have been shown to be the primary site of metastasis in melanoma patients [325,326] lung 
endothelium would be an essential barrier for tumour antigen specific T cells to reach 
metastases making lung endothelium a biologically relevant model. 
TRP-2 specific CD8 T cells were derived from mice immunised with a DNA vaccine 
platform called the ImmunoBody
TM
 [309]. The ImmunoBody
TM
 epitope expression system 
represents a plasmid DNA vector encoding an IgG1 human monoclonal antibody in which 
the complementarity determining regions (CDRs) are replaced with T cell epitopes. Upon 
immunisation these T cell epitopes are efficiently processed and presented to break tolerance 
and stimulate high avidity CTL responses capable of anti-tumour activity, prevention of 
metastases and inhibition of already established tumours [306,307]. 
 
By using a novel murine model of TRP-2 specific CD8 transmigration the aim of this study 
was to investigate whether cognate MHC/peptide recognition was required for efficient 
endothelial transmigration. A static transmigration model allows the effect of transmigration 
to be assessed independently of adhesion as the requirement for rolling and tethering is 
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removed. Splenocytes derived from immunised C57Bl mice were used to transmigrate across 
lung endothelium derived from C57Bl wildtype mice and HHDII (human HLA-A*0201) 
transgenic mice forming models of syngeneic and allogeneic transmigration respectively.  
HHDII transgenic mice (Institut Pasteur) were used as they were on the same genetic 
background as C57Bl mice but mis-matched for MHC class I as they have human HLA-
A*0201 class I and no mouse MHC class I molecules. In vivo studies in C57Bl mice 
transplanted with mouse tumours expressing TRP-2 or in which TRP-2 had been knocked out 
confirmed the antigen specificity of transmigration. 
 
The hypothesis is that high avidity T cells may selectively transmigrate across endothelium 
due to cognate MHC:peptide recognition (H-2Kb/TRP-2) confirming that antigen specific 
transmigration is important in CD8 T cell transmigration. Thus we sought to investigate 
whether cross-presentation of specific antigens by the endothelium within tumour 
environmental conditions is one of the requirements for the homing of CTL into tumours.  
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3.2 Results 

3.2.1 Generation of high avidity CD8 T cells recognising TRP-2 peptide. 
 
The effect of cognate peptide:MHC recognition of TRP-2 presented by the endothelium on 
the migration of antigen specific CD8+ T cells was investigated using a murine model of 
transendothelial T cell migration ()	)).  
Previous research has shown that immunisation with the TRP-2 Immunobody construct 
results in high frequency high avidity T cells [305]. CD8 T cells were derived and pooled 
from three C57Bl mice immunised with the TRP-2 ImmunoBody™ construct and the 
presence of TRP-2 specific CD8 T cells was measured in an ELISPOT assay by IFN-γ 
release (	43 with titrating concentrations of TRP-2 peptide. These results confirm 
that the Immunobody generates TRP-2 antigen specific T cells of high avidity and high 
frequency responses were seen. Functional avidity of the response was calculated as the 
peptide concentration at which a half maximal response is achieved.  In this case, for pooled 
splenocytes the maximal response is 700 spots/10
6
 splenocytes and the peptide concentration 
required to achieve half of this response (350 spots) is 1ng/ml TRP-2 peptide or 1x10
-9
M. 
Therefore the avidity was shown to be 1ng/ml (1x10
-9
M) of peptide.  
 
The splenocyte population derived and pooled from 3 mice immunised with TRP-2 
Immunobody™ construct was analysed using four colour FACs with; anti-murine CD62L-
FITC, anti-murine CD8-PeCy5 and anti-murine CD127-PeCy7, anti-murine TRP-2 specific 
pentamer PE labelled Flow cytometry demonstrated that 15% of the initial population were 
CD8+ T cells, following CD8 T cell isolation using MACS separation the purity was around 
95% ()	9). Pentamer staining confirmed that 2.2% of the isolated CD8 T cells were 
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TRP-2 specific and that the majority of these cells were CD62L+CD127+ central memory T 
cells ( 	#). However, this central memory population would not be a true 
representative of CD8 T cells within peripheral blood as central memory, effector and 
effector memory cells are all found in blood. Therefore, the proportion of memory/effector 
subsets present within murine peripheral blood relative to the spleen was determined. 
	6 shows that Flow cytometric analysis of CD8 T cells derived from the spleen of a naive 
C57Bl mice show a predominantly central memory phenotype (70%) whereas CD8 T cells 
within the peripheral blood from the same mouse show 50% effector phenotype (CD62L-
CD127-), 20% central memory and 20% effector memory (CD62L-CD127+).  
 
In order to generate TRP-2 specific CD8 T cells of central memory, effector memory and 
effector phenotypes, CTL lines were derived from the splenocytes of three immunised mice, 
pooled and maintained in culture in the presence of 10ng/ml TRP-2 peptide and IL-2 
(20U/ml).   	# shows the phenotype of one representative cultured CD8+TRP-2 
specific CTL line up to 14 days post-stimulation. The data shows that after the initial 
stimulation, the phenotype switches from a predominantly central memory 
(CD62L+CD127+) to an intermediate phenotype (CD62L+CD127-). Histograms for one 
representative CTL line are shown for days 7 to 14 (	$3	 After 7 days the line was 
predominantly effector CD8 T cells with 85% CD62L-CD127- CD8 T cells (	$). From 7-
14 days the percentage of effector cells decreased as effector memory cells increased 
(CD62L-CD127+) resulting in 70% of the line being effector memory TRP-2 specific CD8 T 
cells and 30% effector at 14 days (	$).  
 For subsequent experiments ex vivo isolated CD8 T cells, of a predominant central memory 
phenotype, were referred to as central memory CD8 T cells and functional avidity was 
assessed via ELISPOT assays. CD8 T cells cultured with peptide for 10-14 days were 
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referred to as effector memory CD8 T cells as determined by flow cytometric analysis prior 
to use in each assay. Effector memory CD8 T cells are determined by a switch from an 
effector phenotype (CD62L-CD127-) to a predominant (CD62L-CD127+) phenotype by 
upregulation of CD127, this occurred between 10-14 days post-stimulation (
	#I$). The percentage of CD8+TRP-2+ T cells within each central memory and effector 
memory population was evaluated prior to each assay by flow cytometry. 
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4Murine IFN-γ Elispot assay showing responses to TRP-2 peptide following vaccination of three C57Bl mice 
with Immunobody
TM
 DNA construct incorporating TRP-2 (DCIB15) via gene gun weekly for 3 consecutive 
weeks. Data in 4 shows the number of spots developed per 10
6
 splenocytes at increasing peptide concentrations 
from 1pg/ml (1x10
-12
M) to 1ug/ml (1x10
-6
M). The functional avidity of the response is calculated as the peptide 
concentration at which a half maximal response is achieved. 6Subset phenotypes of CD8 T cells from the 
spleen and peripheral blood of a naive C57Bl mouse determined by flow cytometry using; anti-murine CD62L-
FITC, anti-murine CD8-PeCy5 and anti-murine CD127-PeCy7 at 1:25 dilution. In addition, anti-murine TRP-2 
specific pentamer PE labelled (ProImmune) was added at a 1:10 dilution for 60 minutes on ice. Recordings were 
made from at least 100,000 cells on a FACS-calibur flow cytometer using WinMDI 2.8 software. #Splenocytes 
derived from C57Bl mice immunised 3 times with TRP-2 Immunobody
TM
 construct via gene gun. The CD8
+
 T-
cell line, specific for the TRP-2 peptide epitope 
 
SVYDFFVWL presented by H2-K
b
, was maintained in culture 
by restimulation
 
every week with LPS blasts from C57Bl mice presenting TRP-2 peptide (10ng/ml) and 
recombinant
 
interleukin-2 (rIL-2) (20 U/mL). The data represents memory subset expression over time for one 
CTL line where each CTL line generated is assessed in the same way for effector memory phenotype generation 
(n>6).$ Shows histograms of CD62L and CD127 expression on gated CD8+TRP-2+ T cells at 7 (), 12 () and 
14 days () post stimulation for one representative line. 
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3.2.2 CTL mediated lysis of target cells via memory subsets of CD8 T cells. 
 
As the CD8 T cells specific for TRP-2 were to be used in transmigration assays with 
endothelial monolayers pulsed with TRP-2 peptide it was vital to determine that these cells 
would not kill endothelial cells as this would alter the integrity of endothelial monolayers. 
	) shows data for a CTL killing assays carried out on separate occasions using CD8 
T cells isolated from splenocytes derived and pooled from three mice immunised with TRP-2 
Immunobody
TM
 and used directly ex vivo (4), of a CD62L-CD127- (effector) phenotype 
following 6 days culture (6) and of a CD62L-CD127+ (effector memory) phenotype 
following 14 days (#) with 10ng/ml TRP-2 peptide pulsed blasts. These represent central 
memory, effector and effector memory CD8 T cells respectively. The TAP-deficient RMAS 
cell line was used as a control.  	)4 and 	)# demonstrate that the central and 
effector memory CD8 T cells did not kill endothelial cells. However, after one week of 
culture, splenocytes that are predominately of an effector phenotype ( 	)63 killed 
resting endothelial cells. Seven days of culture of splenocytes is normal experimental 
conditions which are used to generate a standard 4 hour 51Cr release killing [327].   
Maximum 20% killing was achieved at a 50:1 effector:target ratio which is increased to 
around 40% following endothelial cell activation with IFN-γ and TNF-α (p=0.011). This is 
similar to the level of killing of peptide pulsed RMAS cells. Cytotoxic killing of peptide 
pulsed RMAS and cytokine treated endothelium by effector cells was achieved at 0.1ng/ml 
peptide pulsing whereas for resting endothelial cells 10ng/ml of peptide was required 
(p<0.05). Maximum killing by effector cells of resting and activated endothelial cells was 
achieved at a concentration of 10ng/ml TRP-2 peptide (p<0.05). These results show that 
endothelial cells can be killed by effector CD8 T cells at low levels even in the absence of 
inflammation. These results suggest that effector CD8 T cells can kill endothelial cells 
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whereas central memory and effector memory T cells recognising antigen presented by 
endothelial cells do not. This raises the question as to why effector CD8 T cell populations 
within peripheral blood do not cause extensive endothelial damage. However, to avoid 
destruction of the endothelial monolayer by effector T cells, for our transmigration studies we 
concentrated on studying central and effector memory cell migration. As shown is 
	6 these cells comprise 50% of the peripheral blood population. 

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Splenocytes derived from three C57Bl mouse 
immunised 3 times with TRP-2 Immunobody
TM
 
construct via gene gun were pooled and either 
used directly 4 ex vivo (central memory) or 6 
cultured for 6 days (effector) or # 14 days 
(effector memory) with LPS blasts pulsed with 
10ng/ml TRP-2 peptide. Therefore the assay was 
carried out on separate occasions and the targets 
used were C57Bl endothelial cells with (Square) 
and without stimulation (Triangle) with IFN-γ 
(100ng/ml) and TNF-α (100ng/ml) for 24 hours 
and the endogenous antigen-processing deficient 
RMAS cell line (Diamond). Target cells pulsed 
with peptide concentrations from 0-1000ng/ml 
TRP-2 peptide and 1.85mBq 51[Cr] Sodium 
Chromate for 1 hour and incubated for 4 hours 
with effector cells. The percentage cytotoxicity 
was calculated at a 50:1 effector:target ratio as the 
actual cell counts-spontaneous lysis/maximum 
lysis x 100. P values were calculated by using 
two-sided Student’s t test were carried out for 
each target cell type at varying peptide 
concentrations compared to the control; P<0.05 
was considered to be statistically significant 
where * represents p<0.05 and ** represents 
p<0.001 for n=3. 
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3.2.3 Cognate recognition of ECs enhances transendothelial migration of TRP-2-
specific CD8+ T cells in vitro. 
 
TRP-2 antigen-specific CD8 T cells, of central (CD62L+CD127+) and effector memory 
(CD62L-CD127+) phenotypes were transmigrated across C57Bl and HHDII murine lung 
endothelial cells to form syngeneic (cognate MHC) and allogeneic (non-cognate MHC class 
I) models of transmigration.  For the central memory transmigration assay CD8 T cells were 
isolated from TRP-2 immunised C57Bl mice and the purity for this experiment was around 
80% CD8+ T cells for all mice. For effector memory transmigration, data is an average of 
three separate experiments. Pre and post transmigrated cells were stained for CD8+TRP-2 
pentamer positive T cells. During analysis by flow cytometry the cells were gated on 
leukocyte populations and double stained using anti-CD8-PECy5 and anti-TRP-2 pentamer-
PE labelled antibodies. MLEC monolayers of C57Bl (syngeneic) and HHDII (allogeneic) 
were used. C57Bl ECs were untreated (control) or treated with anti-H-2K/Db for 1 hour prior 
to transmigration to block murine MHC class I and prove the involvement of peptide/MHC 
on transmigration. All ECs were pulsed with 10ng/ml TRP-2 peptide for 4 hours prior to 
addition of splenocytes for transmigration.  
	shows how the percentage transmigration is calculated from the actual numbers of 
CD8+TRP-2+ T cells transmigrating under each condition. The percentage transmigration of 
TRP-2 antigen-specific CD8 T cells was calculated from the absolute numbers of all cells 
having transmigrated and the relative percentages of CD8+TRP-2+ T cells within each 
migrated population relative to cell numbers in the initial population prior to transmigration.  
Within the isolated population of Mouse 1, 2.2% of cells (8640 of 300,000 cells) were 
CD8+TRP-2+, following transmigration across untreated syngeneic endothelium these cells 
made up 2.4% of the migrated population (2187 of 90,000 cells). This equates to 25% 
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transmigration (2187/8640*100) of the CD8+TRP-2+ cells (	). Whereas following 
transmigration across TRP-2 peptide pulsed syngeneic, 5800 TRP-2+ CD8 T cells from an 
initial population of 8640 transmigrated endothelium which equates to 67% transmigration of 
the CD8+TRP-2+ cells	 
	4 shows the percentage transmigration of central memory CD8+TRP-2+ T cells 
across syngeneic resting endothelium was 20±4.9%,  in the presence of TRP-2 peptide 
(10ng/ml) this was significantly increased to 46±6.4% (p=0.039) suggesting antigen specific 
transmigration. In contrast, only low level transmigration (17±1.8%) was seen across 
allogeneic HHDII endothelium and this was not increased with peptide pulsing of the 
allogeneic MHC. To confirm that the migration in response to peptide on syngeneic MHC 
was due to recognition of MHC:peptide  CD8+TRP-2+ T cells where migrated across C57Bl 
MLECs pulsed with peptide in the presence or absence of MHC class I blocking antibody. 
The percentage of transmigrating TRP-2 positive CD8 T cells was reduced from 46±6.4% to 
20±3% (p=0.024) in the presence of blocking antibody. In contrast, as expected for total CD8 
T cell transmigration ( 	4) around 40% of CD8 T cells transmigrated across 
endothelium with and without TRP-2 peptide in the presence or absence of MHC class I 
blocking showing non antigen-specific transmigration.   	6 shows the percentage 
transmigration of CD8+TRP-2+ T cells of an effector memory phenotype under the same 
experimental conditions. Initially, 36±4% of the effector memory CD8 T cells specific for 
TRP-2 migrated through unpulsed syngeneic endothelium. This number increased 
significantly to 49±3.9% (p=0.04) in the presence of TRP-2 peptide and this increase was 
blocked with MHC blocking antibody down to 28±9.6% (p<0.05). There was no peptide 
specific migration through allogeneic endothelium.  This data indicates that recognition of 
TRP-2 peptide on the endothelium enhances transmigration of both central and effector 
memory TRP-2 antigen-specific CD8 T cells. 
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Splenocytes were derived from C57Bl 
mice immunised 3 times with TRP-2 
Immunobody
TM
 construct via gene 
gun. 50,000 isolated CD8 T cells were 
added to each well, 6 wells for each 
condition. 4Transendothelial antigen-
specific central memory CD8 T cell 
migration and 6 antigen-specific 
effector memory CD8 T cell migration 
through MLEC monolayers. For 
central memory transmigration the 
assay was carried out for 3 mice on 
one day whereas for effector memory 
transmigration the data is the average 
of three separate experiments. 
Following transmigration under each 
condition the cells were surface 
stained for CD8+TRP-2+ (4I6) and 
CD8+ (4) positive T cells and 
compared to the initial population. 
MLEC monolayers of C57Bl 
(syngeneic) and HHDII (allogeneic) 
were used. C57Bl ECs were untreated 
(control) or treated with 0.5ug/ml anti-
H-2K/Db for 1 hour prior to 
transmigration. ECs were pulsed with 
10ng/ml TRP-2 peptide for 4 hours 
prior to addition of splenocytes for 
transmigration. Black lines indicate 
the comparison of transmigration 
across C57Bl TRP-2 pulsed 
endothelium to peptide pulsed MHC 
blocked C57Bl and HHDII ECs 
separately. P values were calculated by 
using two-sided Student’s t test; 
P<0.05 was considered to be 
statistically significant. 
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Endothelial 
monolayer used 
in transmigration 
assay 
Mouse Initial 
number of 
cells added 
to 
transwells 
Number of 
CD8+TRP-2+ T 
cells in initial 
population 
Total 
migrated 
cell number 
Number of 
CD8+TRP-2+ T 
cells in migrated 
population 
% Transmigration 
of CD8+TRP-2+ T 
cells 
Untreated EC 
 
1 300000 8640 (2.16%) 90000 2187 (2.43%) 25.31 
(2187/8640*100) 
Untreated EC 
 
2 300000 8040 (2.01%) 65000 2054 (3.16%) 25.54 
Untreated EC 3 300000 7960 (1.99%) 45000 859 
(1.91%) 
10.79 
TRP-2 peptide 
pulsed EC 
1 300000 8640 (2.16) 165000 5800 
(2.9%) 
67.12 
TRP-2 peptide 
pulsed EC 
2 300000 8040 (2.01) 170000 3340 
(1.67%) 
41.54 
TRP-2 peptide 
pulsed EC 
3 300000 7960 (1.99) 150000 3940 
(1.97%) 
49.49 

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Transmigration data is shown for CD8 T cells isolated from three C57Bl mice (M1, M2 and M3) and migrated 
across untreated and TRP-2 (10ng/ml) peptide pulsed C57Bl endothelium. Following transmigration cells from 
the 6 replicates were pooled for analysis. 50,000 isolated CD8 T cells were added to each well giving an initial 
number of 300,000 cells. The number of CD8+TRP-2+ T cells in the initial population is calculated from the % 
of TRP-2+ CD8 T cells determined by flow cytometry. Total migrated cell numbers are the total cells within the 
lower well following transmigration. The number of CD8+TRP-2+ T cells in the migrated population is 
calculated from the % of TRP-2+ CD8 T cells following transmigration determined by flow cytometry. The 
percentage transmigration is calculated from the cell numbers of TRP-2 specific CD8 T cells having migrated 
out of the total TRP-2 specific CD8 T cells within the initial population in each well. 




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3.2.4 Antigen-specific transmigration is dependent on peptide concentration. 
 
The previous experiments demonstrated that CD8+TRP-2+ T cells are preferentially recruited 
across MHC matched, peptide pulsed endothelial cells. To determine if this was affected by 
peptide concentration a gradient of TRP-2 peptide pulsed endothelium was established. The 
hypothesis was that high avidity CTL lines recognising cognate antigen on the endothelium 
would need low peptide concentrations to migrate. ure 	%4shows the avidity of a CTL 
line of an effector memory phenotype, having been stimulated with 0.1ng/ml TRP-2 peptide 
and rested for 14 days was 1ng/ml (1x10
-9
M). The data in  	%6 confirms that 
transmigration of effector memory antigen-specific CD8 T cells, recognising the 
corresponding antigen, was highest at low peptide concentration (0.1ng/ml (p=0.029)), with 
no further enhancement of transmigration at higher levels of peptide. The CD8 T cell line in 
this experiment was cultured in 0.1ng/ml TRP-2 peptide and the data shown in 	%6 
demonstrated 2% transmigration across C57Bl endothelium pulsed with 10ng/ml TRP-2 
peptide. Whereas when CD8 T cells were cultured in the higher concentration of 10ng/ml 
TRP-2 peptide as in  	6 almost 50% transmigration was demonstrated. Therefore 
culturing of CTL lines in with LPS blasts pulsed with 0.1ng/ml in 	%6, as compared 
to 10ng/ml in  	6, shows the same antigen-specific effect on transmigration but 
appears to decrease the overall maximal transmigration. Additional transmigration assays of 
effector memory CD8 T cell lines cultured with varying peptide concentrations have 
indicated differences in antigen specific transmigration (data not shown) however further 
validation is required. Potentially CTL lines cultured in lower peptide concentrations require 
recognition of less cognate peptide on the endothelium to reach a maximal response. 
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Splenocytes were derived from three C57Bl mice immunised 3 times with TRP-2 Immunobody
TM
 construct via 
gene gun and was maintained in culture by restimulation
 
every 2 weeks with splenocytes from C57Bl mice 
pulsed with 0.1ng/ml TRP-2 peptide and recombinant
 
interleukin-2 (rIL-2) (20 U/mL). 4 Murine IFN-γ Elispot 
assay prior to culture of the CTL line showing the number of spots developed per 10
6
 splenocytes at increasing 
peptide concentrations from 1pg/ml to 1ug/ml (1x10
-12
M to 1x10
-6
M). The functional avidity of the response is 
calculated as the peptide concentration at which a half maximal response is achieved. 6 Transmigration of the 
CD8 T cell line having been rested for 14 days, across C57Bl endothelium (6 replicates for each condition, in 
triplicate) pulsed with increasing concentrations of TRP-2 peptide for 4 hours. Results are given as   the 
percentage transmigration of TRP-2 specific CD8 T cells across 4 P values were calculated by using Student’s t 
test; P<0.05 was considered to be statistically significant. 
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3.2.5 Antigen-dependent transmigration occurs more rapidly than antigen-
independent transmigration of CD8 T cells.  
 
Antigen-recognition by CD8 T cells enhances transendothelial migration where cognate 
peptide is presented on the endothelium in the context of MHC Class I. However, migration 
of non-antigen specific CD8 T cells is still seen in this assay. To evaluate whether the 
antigen-specific transmigration follows different time kinetics than conventional antigen-
independent transmigration, CD8+TRP-2+ T cells migration was followed over time 
compared to CD8+ T cells.  	9 shows the percentage transmigration of effector 
memory (CD62L-CD127+) TRP-2 antigen specific CD8 T cells at 2, 4, 6 and 20 hours. The 
data indicates no significant difference in the percentage (50±11%) transmigration of 
CD8+TRP-2+ T cells along the time course, with maximum antigen-specific transmigration 
occurring at 2hr (	94). However, TRP-2 pentamer positive CD8 T cells constituted 
only 5% of the CD8 line population. 	96 shows the percentage transmigration of all 
CD8 T cells and shows significantly increased transmigration at 20 hours than at 2 hours 
(28±1.2% compared to 15±3.1%; p=0.038). This is in contrast to the antigen-specific 
transmigration. Although the level of transmigration of the antigen-specific CD8 T cells did 
not increase over time when the proportion of antigen-specific cells within each migrated 
population was examined these made up a significantly higher percentage of the population at 
2 hours, 14±0.3% compared to 7±1% (p=0.026) at increasing timed intervals (	9#). 
In conclusion the data demonstrated that antigen-dependent transmigration occurred more 
rapidly than antigen-independent transmigration. 



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CD8 T cells were derived and from a C57Bl mouse immunised 3 times with TRP-2 Immunobody
TM
 construct 
via gene gun, stimulated with LPS blasts pulsed with 10ng/ml TRP-2 peptide and rested for 14 days. 50,000 
isolated CD8 T cells were added to each well, 6 wells for each condition 4shows results for transendothelial 
antigen-specific CD8+TRP-2+ T cell migration, of an effector memory phenotype, through MLEC monolayers 
at timed intervals for one CTL line (6 replicates for each condition in triplicate). Following transmigration under 
each condition the cells were surface stained for CD8TRP-2 positive T cells and compared to the initial 
population. ECs were pulsed with 0.1ng/ml TRP-2 peptide for 4 hours prior to addition of CTLs for 
transmigration. 6represents the percentage transmigration of the whole CD8 CTL line at times intervals and #
represents the proportion of antigen-specific cells within each migrated population at each time interval. Black 
lines in # indicate that the transmigration at 2 hours was compared to transmigration at 4, 6 and 20 hours 
separately. P values were calculated by using two-sided Student’s t test; P<0.05 was considered to be 
statistically significant. 
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3.2.6 Antigen-dependent transmigration of central memory CD8 T cells occurs 
more slowly than transmigration of antigen-dependent effector memory CD8 T 
cells. 
 
Following the observation that antigen-dependent transmigration of effector memory CD8 T 
cells occurs more rapidly than antigen-independent transmigration it was of interest to see 
whether  similar kinetics also applied to central memory transmigration or whether these cells 
required longer times. In order to test the hypothesis that antigen-specific effector memory 
CD8 T cells transmigrate more rapidly than central memory cells,  Ex vivo transmigration of 
CD8 T cells isolated from immunised mice was assessed at timed intervals of 2, 4, 6 and 20 
hours.  Indeed as hypothesised, transmigration of central memory CD8+TRP-2+ T cells 
increased from 2 hours (8±0.9%) with a peak at 20 hours (22±2.5%, p=0.002) (	.4). 
The proportion of antigen-specific cells within each migrated population was examined and 
increased significantly from 40±2.5% of the population at 2 hours to 53±3.1% at 20 hours 
( 	.6 p=0.036). This is direct contrast to  	9# where the proportion of 
effector memory CD8+TRP-2+ T cells is highest at 2 hours. These results suggest that central 
memory cells may require time following MHC encounter to allow them to transmigrate. 
Four colour flow cytometry of the migrated population under each condition was carried out 
and the proportion of each memory subset within the antigen-specific CD8+TRP-2+ 
population is shown for each condition in  	.#. Within the initial population of 
CD8+TRP-2+ T cells, 92% were of a central memory (CD62L+CD127+) phenotype, 7% 
were effector memory (CD62L-CD127+) and no cells showed an effector phenotype. After 2 
hours the CD8+TRP-2+ T cells within the transmigrated population were 82% central 
memory, 4% effector memory and 11% were an intermediate phenotype (CD62L+CD127-). 
Absolute cell numbers are shown in 	)and highlight that the increased numbers of 
cells with an intermediate phenotype following 2 hours transmigration have converted from 
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another memory subset as approximately 400 cells were present in the initial population 
whereas 700 and 750 cells were present after 2 and 4 hours respectively, suggesting that 
memory phenotypes can differentiate following transmigration. Interestingly, at the 2 hour 
time-point effector cells (CD62L-CD127-) are present in the transmigrated population (2% or 
150 cells) but are not detected in the initial population or at later time-points and therefore 
they must have differentiated from another subset. At 20 hours the transmigrated population 
of CD8+TRP-2+ T cells contained 84% central memory, 13% intermediate and 3% effector 
memory phenotypes, where cells with an intermediate phenotype were 7 times higher than in 
the initial population (2800 compared to 400). The data here suggests that transmigration of 
memory subsets of antigen-specific CD8 T cells occurs with different time kinetics, where 
those with an effector memory phenotype appear to transmigrate more rapidly than central 
memory phenotypes. In addition the memory phenotypes of antigen-specific CD8 T cells 
change following transmigration perhaps due to antigen-recognition and subsequent T cell 
differentiation.  
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4 Transendothelial antigen-specific CD8+TRP-2+ T cell migration, of ex vivo central memory phenotype, 
through MLEC monolayers at timed intervals. Following transmigration under each condition the cells were 
surface stained for CD8TRP-2 positive T cells and compared to the initial population. ECs were pulsed with 
0.1ng/ml TRP-2 peptide for 4 hours prior to addition of T cells for transmigration. 100,000 isolated CD8 T cells 
were added to each well, 2 wells for each condition, repeated 3 times. 6The proportion of antigen-specific cells 
within each migrated population at each time interval. P values are relative to transmigration at 2 hours and 
calculated by using two-sided Student’s t test; P<0.05 was considered to be statistically significant. # The 
proportion of memory subset phenotypes within CD8+TRP-2+ T cells under each condition.  
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Transendothelial antigen-specific CD8+TRP-2+ T cell migration, of a central memory phenotype, through 
MLEC monolayers at timed intervals. Following transmigration under each condition the cells were surface 
stained for CD8TRP-2 positive T cells and compared to the initial population. ECs were pulsed with 0.1ng/ml 
TRP-2 peptide for 4 hours prior to addition of T cells for transmigration. 100,000 isolated CD8 T cells were 
added to each well, 2 wells for each condition, repeated 3 times.The absolute numbers of memory subset 
phenotypes within CD8+TRP-2+ T cells under each condition are shown where ‘Population’ refers to those 
CD8+TRP-2+ cells of each phenotype in the upper chamber prior to transmigration.  
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3.2.7 Activation by inflammatory cytokines increases cell adhesion molecule and 
MHC expression by murine lung endothelial cells but does not alter antigen 
specific transmigration. 
 
During an immune response inflammation causes endothelial activation and upregulation of 
cell adhesion molecules (CAMs) on the endothelial surface enhancing leukocyte infiltration 
into inflamed tissues. In order to assess the effect of inflammation on TRP-2 specific 
transmigration the effect of inflammatory cytokines was first assessed on murine lung 
endothelial cells. The hypothesis was that inflammatory cytokines increasing cell adhesion 
molecule and MHC expression on the endothelium would enhance CD8 T cell 
transmigration. MLECs were assessed for ICAM, VCAM and ALCAM and MHC expression 
following culture with the inflammatory cytokines IFN-γ and TNF-α at 100ng/ml. C57Bl 
derived MLECs showed a constitutive low level of ICAM-1 (MFI=600) expression (
	04) which peaked at 24 hr following stimulation with IFN-γ and TNF-α (MFI=3000) and 
then decreases at 48 hr and 72 hr, however remaining higher than the basal level. VCAM-1 
expression was not seen on resting endothelium but was induced following 24 hr stimulation.  
However, expression was at a much lower intensity than ICAM-1. In contrast, ALCAM 
expression was present on resting endothelium and diminished on activated endothelium.
CAM expression for HHDII and DR4 derived MLECS, similar to that of C57BL MLECs, is 
shown in 	06 and # respectively. The basal level of ICAM-1 expression for DR4 
mice was similar to C57Bl (MFI=400) and lower for HHDII (MFI=30), however both 
increased following stimulation to 2000 and 75 respectively. The MHC class I expression for 
MLECs is shown in 	0$ and highlights that MHC class I expression was present on 
resting endothelial cells of all types at a low level (MFI of around 200-300) which was 
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greatly increased to around 4000 with 24 hr stimulation with IFN-γ and TNF-α for C57Bl and 
DR4 mice and 400 for HHDII MLECs. 
In order to achieve tethering and rolling T cells must interact with non-specific adhesion 
molecules such as selectins and integrins on the surface of the endothelium; however their 
role in transmigration is less clear. Upregulation of cell adhesion molecules and MHC 
molecules occurs in response to endothelial cell activation by inflammatory cytokines as 
shown in  	0	However activation of endothelium with the inflammatory cytokines 
IFN-γ and TNF-α had no effect on antigen-specific CD8 T cell transmigration (data not 
shown). 
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3.2.8 Antigen-specific transmigration is enhanced by the addition of chemokine 
gradients. 
 
Within the tumour microenvironment chemokine gradients determine both T cell 
infiltration/fugetaxis and tumour cell metastasis. As TRP-2 specific CD8 T cells of an 
effector memory phenotype undergo antigen-specific transmigration across untreated 
endothelium, the effect of two tumour-associated chemokines, CXCL12 and CXCL16 were 
also assessed. The chemokine CXCL16 has been associated with T cell infiltration in 
colorectal cancer [177] and CXCL12 with FOXP3+ cell infiltration in cervical cancer [179]. 
 
The tumour associated chemokine CXCL12 and CXCL16 were used at 100ng/ml to create 
chemokines gradients and transmigration of effector memory TRP-2 specific CD8 T cells 
was measured under each condition. Importantly, the results ( 	() show 
transmigration of TRP-2 specific CD8 T cells is doubled following pulsing of the 
endothelium with TRP-2 peptide under all conditions (p<0.05). In addition, both CXCL12 
and CXCL16 increased antigen-specific transmigration but not antigen-independent 
transmigration (no TRP-2 peptide present on the endothelium).  The level of antigen-
independent transmigration across unpulsed endothelium remained at 27±6.7% 
transmigration with both CXCL12 and CXCL16. Peptide pulsing the endothelium caused the 
percentage transmigration to increase from 20±4.4% to 47±3.9% across unactivated 
endothelium and from 27±6.7% to 57±0.3% with CXCL12 (p=0.03) and 67±1.5% with 
CXCL16 (p=0.01). The ratio of transmigration for peptide/ no peptide for each condition was 
2.3±0.2 highlighting that antigen-specific transmigration of TRP-2 specific CD8 T cells 
occurs independently of chemokine gradients. The ratio between antigen-specific and non-
specific transmigration remains the same while the background level for both can be 
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enhanced by the chemokines CXCL12 and CXCL16, suggesting that the additive effect of 
chemokines occurs independently of TCR ligation. 
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Data for transendothelial migration of antigen-specific effector memory TRP-2 specific CD8 T cell migration 
across C57Bl MLEC monolayers. Effector memory TRP-2+ CD8 T cells were generated by stimulation of 
splenocytes derived from TRP-2 immunised mice, stimulated twice at weekly intervals with 10ng/ml TRP-2 
LPS blasts and rested for 14 days. 100,000 cells were added to each well, 4 wells for each condition. 
Transmigration is shown across non-pulsed endothelium (Black bars) and across 10ng/ml TRP-2 peptide pulsed 
endothelium (White bars). Following transmigration under each condition the cells were surface stained for 
CD8+TRP-2 positive T cells and compared to the initial population. Chemokines were added into the lower 
chamber of transwells at 100ng/ml. Black lines indicate transmigration across TRP-2 pulsed untreated ECs 
compared to the inclusion of CXCL12 and CXCL12 gradients separately. Student’s t test; P<0.05 (n=3) was 
considered to be statistically significant. 
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
3.2.9 Increased antigen-specific transmigration of TRP-2 specific CD8 T cells 
across tumour conditioned endothelium. 
 
In vitro pulsing of endothelium with the melanoma specific TRP-2 peptide has shown to 
increase transmigration of TRP-2 specific CD8 T cells. As this is an artificial system and the 
question remains at to whether melanoma cells are able to transfer TRP-2 peptide to be 
presented by endothelial cells. In order to test whether endothelial cells in contact with 
tumour cells can acquire peptide that can be recognised by antigen specific CD8 cells, 
transmigration assays of TRP-2 specific CD8 cells was tested across endothelium conditioned 
with the murine TRP-2 expressing melanoma cell lines B16F10 ( 	-4). C57Bl 
derived lung endothelial cells were grown on transwell inserts with and without the addition 
of TRP-2 peptide. For B16 conditioning, C57Bl endothelium was grown over the top of a 
monolayer of B16 cells which represents transmigration from the vasculature across the 
endothelium and into the tumour ((B16+EC)4). In addition, a monolayer of B16 cells was 
grown on the top of the C57Bl endothelium representing transmigration from the tumour, 
across the endothelium into the vasculature ((EC+B16)4). The percentage transmigration of 
CD8 and CD8+TRP-2+ T cells across each condition was assessed by Flow cytometry and is 
shown in  	-6 and # respectively. Interestingly, the percentage transmigration of 
antigen non-specific CD8 T cells is reduced across all conditions where the endothelium has 
been in contact with B16 (p<0.05). For antigen-specific transmigration of CD8+TRP-2+ T 
cells, as expected the transmigration is increased across peptide pulsed endothelium from 
32±6% to 73±10.8% (p=0.008) and is also significantly increased across C57Bl endothelium 
with an underlying layer of B16 cells from 32±6% to 51±5% (p=0.04).  
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This data is consistent with the hypothesis that endothelium can uptake antigen from tumour 
cells and present it to T cells however further investigation is required to prove this 
hypothesis. Here the layer of endothelium on the top represents the TRP-2 specific T cells 
transmigrating across vasculature endothelium and into the tumour. Where the B16 
monolayer was reversed and on top of the endothelium antigen-specific transmigration was 
significantly reduced (p=0.017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
4
6



 	- 
 '
 !	
4Diagram to depict the transmigrati
MLECs ((EC+B16)43 and conver
((B16+EC)43. 6Transendothelial 
monolayers under various B16 condit
stained for CD8TRP-2 positive T cel
TRP-2 peptide for 4 hours prior to a
from a C57Bl mouse immunised 3 ti
LPS blasts pulsed with 10ng/ml TRP
30,000 isolated CD8 T cells were ad
transmigration of antigen-specific CD
to transmigration across untreated 
considered to be statistically significa




  EC                EC+TRP-2           EC+B16         
124 

# 
 
" ! " ') " #$( 
on of CD8 T cell across B16F10 melanoma cell mo
sely across MLECs grown over B16F10 melano
CD8+ T cell migration, of an effector memory pheno
ions. Following transmigration under each condition t
ls and compared to the initial population. ECs were 
ddition of CD8 T cells for transmigration. CD8 T ce
mes with TRP-2 Immunobody
TM
 construct via gene 
-2 peptide and rested for 14 days to achieve a CD62L
ded to each well, 2 wells for each condition, repeate
8+TRP-2+ T cells within each migrated population
ECs and calculated by using two-sided Student’s 
nt.  
    B16+EC   EC                EC+TRP-2           EC+B
 

  !
nolayers grown over 
ma cell monolayers 
type, through MLEC 
he cells were surface 
pulsed with 10ng/ml 
lls were derived and 
gun, stimulated with 
-CD127+ phenotype. 
d 3 times. #The % 
. P values are relative 
t test; P<0.05 was 
16             B16+EC 
  
125 
 
3.2.10 Detection of tumour infiltrating TRP-2 specific CD8 T cells. 
 
In vitro transmigration assays presented here have shown that recognition of cognate antigen 
on endothelium in the context of MHC enhances antigen-specific transmigration of TRP-2 
specific CD8 T cells. In order to test whether antigen-specific transmigration also enhances 
CD8 T cell infiltration into tumours an in vivo model of transmigration was required. The 
murine melanoma cell line B16, expresses the melanoma rejection antigen TRP-2 and data 
here would suggest a hypothesis that TRP-2 specific CD8 T cells are able to infiltrate B16 
tumours via tumour vasculature where they recognise TRP-2 peptide presented on the tumour 
endothelium. In order to test this hypothesis firstly the presence of TRP-2 specific CD8 T 
cells needed to be assessed within B16 tumours. A TRP-2 specific CTL line was generated 
from the immunisation of three mice, pooled and cultured twice with 10ng/ml TRP-2 peptide, 
and rested for 14 days (effector memory). The CTL line contained 20% CD8+TRP-2+ T cells 
and was labelled with 1nm CFSE, resulting in 95% of the cells showing fluorescence (
	@4). 1x10
7
 labelled CTLs were injected I.P. into three mice bearing B16 tumours and 
migration allowed to occur for 72 hours. Subsequently the tumours were resected and 
assessed for infiltration of CFSE labelled TRP-2 specific CD8 T cells by flow cytometry. The 
percentage distribution of the injected CFSE labelled CD8+TRP-2+ T cells are shown for 
three tumours of varying sizes in 	@6. The data indicates that approximately 50% of 
the adoptively transferred cells were recovered by resection of the tumour, spleen and 
peripheral blood sample. The tumours varied in size from 440mm
2
 (M1), 600mm
2
 (M2) to 
1280mm
2
 (M3) where the smallest tumour showed the lowest infiltration of CD8+TRP-2+ T 
cells (0.8%) but the largest amount present in the spleen (42%). The largest tumour did not 
show the highest level of CD8+TRP-2+ T cells infiltration, 2% compared to 8% within the 
medium sized tumour. The mouse with the largest tumour showed a larger proportion of 
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antigen-specific CD8 T cells within the blood, 19% compared to 8% and 3 % in the medium 
and small tumours respectively.  
CFSE labelling of adoptively transferred effector memory CD8 T cells  into B16 tumour 
bearing mice enabled the amount of proliferation of CD8+TRP-2+ CFSE labelled T cells to 
be measured within the tumours, spleen and blood to be measured ( 	@#3. The 
largest amount of proliferation was seen for cells collected from murine spleens where 
83±2.3% of adoptively transferred CD8+TRP-2+ T cells proliferated compared to a 
significantly lower level of 67±7.3% within the blood (p=0.04). The amount of proliferation 
having occurred within the tumour was highly variable across the three mice with an average 
of 65±16.8%.  	@$ shows the histograms for immunofluorescence of the CFSE 
labelled CD8+TRP-2+ T cells isolated from the three tumour bearing mice shown in 	@6. 
The high variability in proliferation appears to correlate with tumour CD8+TRP-2+ 
infiltration as the highest amount of proliferation was 94% for M2 which had the highest 
percent of infiltration of CFSE labelled CD8+TRP-2+ T cells, 10% of the total input. The 
lowest amount of proliferation was seen for M3, 36%, which was the largest tumour at 
1280mm
3
.  
In conclusion, adoptively transferred TRP-2 specific CD8 T cells, of a predominantly effector 
memory phenotype, can be detected within the spleens, peripheral blood and tumours of 
mice. The amount of infiltration appears to depend on the tumour size and in addition the 
presence of antigen-specific CD8 T cell presence in the blood positively correlates with 
tumour size. 
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A CTL line was generated from CD8 T cells derived from a C57Bl mouse immunised 3 times with TRP-2 
Immunobody
TM
 construct via gene gun, stimulated with LPS blasts pulsed with 10ng/ml TRP-2 peptide and 
rested for 14 days to achieve a CD62L-CD127+ phenotype. 4Immunofluorescence of the CTL line stained with 
1nM CFSE (Thick black line), unlabelled cells used as a negative control (thin line). 6The distribution of CFSE 
labelled CD8+TRP-2+ T cells having been I.P. injected into three mice. 2x10
4
 B16 cells were injected S.C. into 
the right flank of each C57Bl mouse, after 14 days 1x10
7
 CFSE labelled CTLs were I.P. injected into each 
C57Bl mouse and allowed to migrate for 72 hours before resection of tumours, spleens and a blood sample 
taken. The distribution of labelled cells assessed by 3 colour flow cytometry detecting CFSE labelled cells also 
positive for CD8 and pentamer (TRP-2). #The percentage of CFSE labelled CD8+TRP-2+ T cells having 
proliferated, collected from the spleen, blood and tumours of three C57Bl mice. Students T tests: where p<0.05 
(n=3) considered significant. $Immunofluorescence of CFSE labelled CD8+TRP-2+ T cells isolated from three 
B16 tumours.  
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
3.2.11 The effect of tumour antigen expression on infiltration of antigen-specific 
CD8 T cells into tumours. 
 
A model of transmigration was developed to test whether antigen-specific transmigration of 
TRP-2 specific CD8 T cells occurs in vivo.  The murine melanoma cell line B16, expresses 
the melanoma rejection antigen TRP-2. A TRP-2 knockdown B16 cell line was produced 
using siRNA and the intracellular TRP-2 expression by control B16 and transfected B16 cells 
are shown in 	4	The mean fluorescent intensity is 43.07 for control B16 cells, 
reduced to a MFI of 20.04 following transfection and equating to approximately 90% of the 
transfected B16 cells showing knocked-down TRP-2 expression.  
 It was  hypothesised that TRP-2 specific CD8 T cells would be able to infiltrate TRP-2+ B16 
tumours via antigen-specific transmigration across the tumour vasculature where they 
recognise TRP-2 peptide presented on the tumour endothelium, but would have lower levels 
of infiltration into the B16 tumour with TRP-2 knockout. 
To screen for antigen specific transmigration in vivo, C57Bl mice were injected with B16 
TRP-2+ and B16 TRP-2- in contra-lateral flanks of three mice and when tumours reached 
around 500mm
3
 1x10
7
 CFSE labelled CD8+TRP-2+ cells where adoptively transferred.. 
1x10
7 
CFSE labelled CTLs were injected I.P. into each mouse for a period of 72 hours, all 
tumours were excised and labelled cells enumerated by flow cytometry. As hypothesised 
higher numbers of TRP-2 specific CD8 T cells were found in TRP-2 positive tumours 40,000 
compared to 30,000 for Mouse 1 or 4.5% and 3.5 % of the I.P. injected CFSE labelled 
CD8+TRP-2+ T cells ( 	6). For Mouse 2 25,000 compared to 15,000 were 
detected in B16 TRP-2+ and B16 TRP-2 knock-out tumours respectively equating to 3% and 
1.7% of I.P. injected cells (	#). As analysis was only possible on two mice a paired 
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Student’s T test on the data was not possible however there was a difference between TRP-2 
specific CD8 T cell infiltration into B16 and B16 TRP-2 deficient tumours with a trend 
towards an increase in infiltration into TRP-2+ tumours. The percentage of antigen non-
specific CD8 T cell transmigration was very low in both TRP-2 positive and negative 
tumours ($) at less than 0.5% of the injected CD8 T cells.  
Initial in vivo transmigration data supports the hypothesis as increased transmigration of 
TRP-2 specific CD8 T cells was seen into TRP-2+ B16 tumours. However as this was only 
possible for two samples further validation of this assay is required. 
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4 Indirect intracellular immunofluorescent staining of transfected B16 cells with anti-TRP-2 antibody (thin 
black line) and untransfected (control) B16 cells (thick black line). Isotyped matched immunoglobulin was used 
as a negative control (thick grey line).Infiltration of CFSE labelled TRP-2+CD8+ T cell transmigration was 
assessed by flow cytometry into control B16 tumours (Black bars) and TRP-2 knockout B16 cell line 1360(16) 
(White bars). The actual numbers of TRP-2+CD8+ CFSE labelled T cells are shown for two mice in 6and the 
percentage of TRP-2+CD8+ CFSE  and TRP-2-CD8+ CFSE  labelled T relative to those injected (I.P.) are 
shown in#and$respectively. N=2.
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3.3 Discussion 
 
In order for T cells to enter a tumour they must first transmigrate from the blood into the 
tumour tissue via interaction with the tumour endothelium. Uniquely, our results showed that 
cognate peptide: MHC recognition, enhanced tumour specific CD8 T cell migration. Antigen 
specific CD8 cells migration was enhanced on peptide pulsed, syngeneic endothelial cells but 
not in the presence of an MHC class I blocking monoclonal antibody, in the absence of 
peptide or on peptide pulsed allogeneic MHC. Furthermore, antigen specific transmigration 
was enhanced across endothelium in the presence of tumour cells expressing the cognate 
antigen, whereas, antigen non-specific migration was inhibited. These in vitro results 
translated to in vivo studies with enhanced accumulation and proliferation of antigen specific 
CD8 cells within tumour expressing cognate antigen but not in tumours in the same mice that 
lacked antigen.   
 
Previous research by Marelli-Berg et. al. [319] has shown that memory CD4 T cell 
transmigration across endothelium could increase the recruitment of specific T cells into the 
tissue by cognate recognition of tissue peptide presented by MHC [153,328]. Marelli-Berg 
hypothesised that the endothelium acts as a shop window [318] where tissue derived antigen 
is picked up by endothelial cells (acting as antigen presenting cells), processed and presented 
by MHC molecules. Together with chemokine stimulation migration of antigen-specific T 
cells is favoured into the tissue over non-specific T cells. Subsequent research by Savinov et. 
al. [317] supported this theory and showed antigen recognition to be important for CD8, as 
well as CD4 transmigration. Savinov used pancreas-homing TCR-transgenic insulin-specific 
CD8+ T cells and showed that insulin production and MHC class I expression were necessary 
for trafficking of these CD8 T cells into the pancreas. Interestingly Savinov et. al. also 
showed CD8 T cells demonstrated adhesion to endothelial cells under shear stress in the 
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presence of specific peptide recognition and trafficking in vivo was chemokine dependent but 
occurred in the absence of inflammation. Our data showed antigen-specific transmigration in 
the absence of both chemokine and inflammation in this static model however chemokines 
but not inflammation increased antigen specific migration in this model. This does not 
preclude the fact that inflammation may still be required in vivo to allow rolling and 
adherence of lymphocytes. Indeed, an in vivo model of HY-specific CD8 T cell 
transmigration into antigenic and non-antigenic tissue [155] showed upregulation of H2 
molecules by IFN-γ in peritoneal mesothelium led to recruitment of HY specific T cells in 
male and not in female mice. Intravital microscopy indicated that cognate recognition 
enhances diapedesis into tissue without affecting rolling and adhesion. This led Marelli-Berg 
to hypothesise that due to the small molecular size of MHC: peptide complexes would mean 
that TCR triggering would only occur when the two cells were in close proximity, i.e. once 
rolling and adhesion had already occurred and therefore antigen recognition does not affect 
adhesion.  
  
Interestingly, our data would suggest that T cell immune surveillance occurs more rapidly 
than antigen independent transmigration. When cognate antigen is present within the tissue, it 
is taken up and presented by the endothelium, allowing rapid antigen-dependent 
transmigration of specific CD8 T cells into the tissue. Antigen-independent (non-cognate) 
transmigration occurs much more slowly in this static model where recognition of 
endothelium causes functional changes in T cells such as upregulation of adhesion molecule 
receptors such as CD11a, activation markers (CD69) and costimulation (CD86) receptors 
allowing transmigration to occur [329]. Whether this is physiologically relevant in a flow or 
in-vivo model remains to be determined, although we did see very low numbers of antigen 
non-specific CD8 T cells migrating in a B16 in vivo model. Potentially TCR signalling during 
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antigen-specific transmigration enhances the speed of transmigration due to additional 
activation of T cells via signalling pathways such as the PI3K pathway (phosphoinositide 3-
kinase) (PI3Ks) which control various cell functions, including motility and trafficking [330].  
Antigen-specific transmigration of TRP-2 specific CD8 T cells of an effector memory 
phenotype occurs much more rapidly than for those of a central memory indicating that the 
functional state of the T cell not only alters trafficking patterns, such as central memory T 
cells trafficking to lymphoid organs, but that the speed of transmigration is also affected 
between subsets. An explanation for this could be the expression of costimulatory molecules 
such as CD28, where CD28 mediated signals enhance T cell transmigration via integrin 
clustering and integrin mediated migration [331].  Central memory populations which express 
CD28 [332] may require time to fully activate these signalling effects whereas effector 
memory populations show predominantly low/negative CD28 expression are independent of 
CD28 mediated effects and transmigrate more rapidly.  
 
The guanine nucleotide exchange factor (GEF) Vav-1 plays a role in coupling TCR and 
CD28 to signalling pathways and regulates T cell activation and migration. T cell receptor 
and CD28 induced Vav-1 activity has been shown to be required for the accumulation of 
primed T cells into antigenic tissue [331]. The contribution of TCR and CD28 induced Vav-1 
activity has been assessed on the trafficking and localisation of primed HY-specific CD4 T 
cells. Defects in the migration of Vav-1-/- T cells in vitro were not seen under flow and in the 
presence of chemokines leading to normal recruitment in vivo. In contrast, Vav-1 -/- T cell 
retention into antigen rich tissue was impaired, showing T cells inability to engage in 
sustained TCR and CD28 mediated interactions with tissue resident APCs. In our in vivo 
model we showed proliferation of antigen specific CD8 T cells within small tumours when 
compared to blood or spleen implying that cognate peptide: MHC recognition either by the 
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endothelium or tumour resident APCs gave them an additional boost.  However, in larger 
tumours, proliferation appeared to be reduced implying a more immunosuppressive tumour 
environment. Perhaps due to an increased immunosuppressive environment created by 
infiltration of other cell types such as regulatory T cells and secretion of immunosuppressive 
cytokines such as TGF-β produced by tumour cells and immune cells that can polarise the 
immune response [333]. 
 
Here, cognate peptide: MHC recognition enhanced both antigen specific effector and central 
memory T cells. We were unable to show effector CD8 T cell migration as these cells 
efficiently killed peptide pulsed endothelium. Other studies have shown that endothelial cells 
naturally processing antigens are poor targets for CTLs as they present 50-5000-fold less 
endogenously processed antigenic proteins compared with any other target cell analysed 
[334]. HLA-A2-specific CTL clones killed endothelial cells less efficiently due to the lower 
peptide presentation or suggesting that endothelial cells present
 
a different antigen repertoire 
compared with other cell types. Further investigation into antigen-dependent transmigration 
of CD8 T cells of an effector phenotype is needed to find whether effector CTLs, primed to 
kill target cells expressing TRP-2 peptide, are able to kill endothelium in vivo.  
 
In contradiction to results presented here, Marelli-Berg [335] found that CD8 migration 
across peptide pulsed endothelium decreased under both resting and activated endothelium, 
initiating a stop signal to CD8 T cells. One explanation for the contrast in migratory ability of 
antigen-specific T cells could be the dose of peptide used to pulse the endothelium, which 
was 100nM (100ng/ml for 16 hours). High doses of peptide reduced CD8 transmigration, 
potentially by over-activation and subsequent killing of high avidity CD8 T and therefore use 
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of low doses of peptide in the range of 0.1-10ng for 4 hours are optimal for high avidity 
transmigration. 
 
CD8 T cells vary in antigen specificity and in addition CD8 T cells specific for the same 
antigen can vary in avidity where different peptide concentrations are sufficient for activation 
of effector function [301,305]. Higher avidity CD8 T cells show effector functions when in 
contact with lower peptide concentrations and therefore would be at an advantage during 
recognition of peptide on ECs at low concentrations due to the inefficiency of exogenous 
peptide loading of ECs [336]. Recognition of too much peptide leads to too much signal one 
without costimulation and kills high avidity T cells [337,338].This represents an efficient 
mechanism which would allow those higher avidity antigen specific CD8 T cells, recognising 
low doses of cognate peptide presented by endothelium, to enter tissue rapidly to mount an 
immune response. 
 
Endothelial cells have been characterised as antigen-presenting cells with the ability to cross-
present antigenic peptides to both CD4 and CD8 T cells. However controversy still remains 
as to how endothelial cells acquire tumour antigens. Studies have suggested that endothelial 
cells derive and cross-present antigenic peptides from phagocytosed dead tumour cells [339]. 
Another study has suggested melanoma-derived exosomes allow acquisition of melanoma 
antigen by ECs [340]. However,  more recently melanoma-derived ECs have been shown to 
acquire melanoma antigen following cytosolic exchange of tumour antigens from melanoma 
cells directly via gap junctions allowing the endothelium to cross-present peptides from the 
tumour microenvironment and be eliminated via anti-melanoma CD8 T cells [320]. In this 
study Benlalam et. al showed the importance of the interaction between tumour cells and ECs 
in the formation of gap junctions and that the classical antigen cross-presentation pathways 
  
136 
 
were not involved. Here, co-culture of ECs with B16 cells prior to transmigration 
significantly enhanced the transmigration of TRP-2 specific effector memory CD8 T cells 
while reducing the overall CD8 T cell transmigration. This provided evidence to support the 
idea of gap junctions between tumour cell and ECs as the T cells came into contact with the 
apical side of the endothelium while the B16 tumour cells were underneath. This suggested 
that TRP-2 peptide passed from the B16 cells to ECs via gap junctions and was then 
presented on MHC class I molecules. Potentially, the reduced transmigration is due to 
transmigration being in the direction from the tumour into the vasculature where tumour 
associated conditions prevent T cell migration. To further prove that this increase in 
transmigration across B16 conditioned endothelium is due to TRP-2 peptide uptake via gap 
junctions, an inhibitor of gap junction formation (18GA) could be used in addition to mis-
matched HHDII endothelium. The gap junction inhibitor 18GA, which prevents the 
formation of channels could be used to fully determine whether the uptake of TRP-2 by the 
endothelium was indeed due to transfer within GAP junctions between ECs and B16 cells. 
The implications of this mechanism support the theory that in vivo within TRP-2 expressing 
B16 melanomas, TRP-2 peptide could be obtained by the tumour endothelium and presented 
to TRP-2 specific CD8 T cells within the tumour vasculature. An in vivo adoptive transfer 
experiment was designed to test this theory by adoptively transferring TRP-2 specific effector 
memory CD8 T cells into mice bearing TRP-2+ and TRP-2- B16 tumours and T cell 
infiltration measured. Antigen-specific transmigration in response to a naturally occurring 
tumour antigen showed increased numbers of TRP-2 positive CD8 T cells were found in 
TRP-2 positive tumours. However this pilot data is representative for two mice and requires 
further validation by the group.  
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Antigen specific infiltration of adoptively transferred CD8 T cells has been shown previously 
using in vivo imaging [341].  The study used CT44 hemagglutinin+ (HA+) and CT26 (HA-) 
tumours implanted onto each footpad of Thy1.1 Balb/c mice and after 7 days when the 
tumour had reached around 25mm
2
 
111
In oxine labelled HA specific CD8 T cells were 
injected I.V. and followed over 24 hours. Using SPECT-CT (single photon emission 
computed tomography) to analyse transmigration, the imaging showed that after 2 hours the 
labelled cells had accumulated within the lung, moving down into the kidneys, spleen and 
liver and after 24 hours had preferentially accumulated in the HA positive CT44 tumour. 
Between 7 and 14 days the CTLs controlled the progression of the HA+ CT44 tumours. This 
study proved that HA+ effector CTLs preferentially accumulated within HA+ tumours and 
due to the effector phenotype caused regression in these tumours. The effector phenotype of 
the HA specific CD8 T cells within this study means that these are capable of killing tumour 
endothelium presenting HA antigen and therefore it is impossible to say whether the 
increased transmigration is due to damaged endothelium or enhanced antigen specific 
migration. Within our study the CD8 T cells were of an effector memory phenotype and 
unable to kill endothelium pulsed with TRP-2 peptide. Therefore, the increased TRP-2 
specific CD8 T cell infiltration into TRP-2 positive tumours is likely to be due to TRP-2 
expression on the tumour endothelium leading to increased transmigration. 
 
In conclusion the data here has shown MHC recognition to be important in tumour antigen 
specific CD8 T cell transmigration. In order for tumour antigen specific CD8 T cells to 
infiltrate tumours they must first transmigrate across the tumour endothelium. This 
mechanism suggests that tumour endothelium presenting tumour cell derived antigen peptides 
specifically selects for high avidity potent T cells. This has implications for T cell vaccines as 
adoptively transferred high avidity CD8 T cells specific for certain tumour antigens would 
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require these antigens to be presented on the tumour endothelium in order to infiltrate 
tumours and exert anti-tumour responses. 
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Chapter 4: CD8 T cell infiltration into colorectal tumours 

4.1 Background 
 
Within cancer patients tumour-infiltrating T lymphocytes (TILs) are considered to play 
important roles in anti-cancer immune mechanisms of the tumour bearing host. Increased 
survival times have been correlated with increased T lymphocyte infiltration into melanomas 
and ovarian tumours [228,231]. Animal models have proved that infiltration of tumours by 
tumour-reactive T lymphocytes is essential for efficient tumour regression [342]. CD8 T cells 
are cytotoxic T lymphocytes that recognise particular tumour-associated antigens presented 
on MHC class I molecules at the cancer cell surface and possess the ability to destroy cancer 
cells directly. Results in the previous chapter demonstrated that antigen-recognition of tumour 
antigens presented on endothelium increases antigen-specific CD8 T cell infiltration. 
 
In human cancers, infiltration of cytotoxic CD8 T cells has indeed been shown to enhance 
survival in those cancer patients with high numbers of CD8 T cells per tumour area in 
esophageal carcinoma, colorectal cancer and renal cell carcinoma [343,344,345]. An early 
study in 1998 by Naito et.al showed a significant correlation between the degree of CD8 T 
cell infiltration within tumour cell nests and Dukes’ staging, where both factors significantly 
impacted upon a patients overall survival.   
 
CD4 T cells recognise peptides presented on MHC class II molecules expressed primarily on 
antigen presenting cells. Although most tumour cells do not express MHC class II molecules, 
CD4 T cells can have an effect on anti-tumour responses in the absence of CD8 T cells by 
either directly killing tumour cells or secreting cytokines, such as interferon-gamma (IFN-γ) 
[346], or by activation and recruitment of effector cells such as macrophages and eosinophils 
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[247]. However, another role of CD4 T cells in the immune response to cancer is to prime 
CD8 cells and maintain their proliferation. In addition to CD8 T cell infiltration, CD4 
infiltration is a favourable prognostic factor in non-small-cell lung carcinoma [347]. However 
the role of immune system in the pathogenesis and progression of tumours is a subject of 
controversy and tumour-infiltrating CD4 T lymphocytes have been associated with lymph 
node metastasis and the spread of neoplasia to lymph nodes in patients with early breast 
cancer [348]. Perhaps due to the wide variety of T helper cell subsets encompassed under 
CD4 staining within tumours such as Th1, Th17 and regulatory T cells having opposing 
effects. A recent study of immune regulated genes associated with CD4+ helper T cell subset 
expression within colorectal cancer found that patients with high expression of the Th17 
cluster had a poor prognosis whereas patients with high expression of the Th1 cluster had 
prolonged disease-free survival and none of the Th2 clusters predicted survival [349].  
 
The purpose of the present study was to evaluate the infiltration of T cell subsets in order to 
determine the individual or synergistic role of TILs in colorectal cancer. The expression of 
CD8 within colorectal tumours was investigated using a tumour microarray consisting of 464 
colorectal cancer samples and a detailed database of clinicopathological variables. T cell 
infiltration and subsequent immune responses at the primary tumour site could be used to 
stratify patients for immunotherapy.  
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4.2 Results  
 
4.2.1 Clinical and pathological data of colorectal cancer patients 
The clinic-pathological features of the 462 cases included in the present study are shown in  
%	. 
Variable Categories Frequency of 
total cohort 
(%) 
n=462 
Frequency of 
CD8 stained 
cohort (%) 
n=353 
Gender Male 266 (58) 207(59) 
 Female 199 (42) 146(41) 
Age (years) Median 72 72 
 Range 58-89 57-93 
Status Alive 278(60) 220(62) 
 Dead 184(40) 133(38) 
Tumour Grade Well differentiated 29 (6) 22(6) 
 Moderately 
differentiated 
353 (77) 270(77) 
 Poorly differentiated 71 (15) 53(15) 
 Unknown 8 (2) 8(2) 
Tumour Site Colon 238 (52) 181(51) 
 Rectum 181 (39) 137(39) 
 Unknown 43 (9) 35(10) 
TNM Stage 0 (T) 3 (1) 2(1) 
 1 69 (15) 59(17) 
 2 174 (28) 131(37) 
 3 155 (33) 120(34) 
 4 54 (12) 34(10) 
 Unknown 7 (2) 7(2) 
Extramural Vascular 
Invasion 
Negative 224 (48) 169(48) 
 Positive 128 (28) 94(27) 
 Unkown 110 (24) 90(26) 
Histological Type Adenocarcinoma 392 (85) 301(85) 
 Mucinous carcinoma 51 (11) 39(11) 
 Columnar carcinoma 4 (1) 4(1) 
 Signet ring carcinoma 7 (1) 3(1) 
 Unknown 8 (2) 2(0) 

%		Clinicopathological variables for the patient cohort (n = 462) and cores stained for tumour 
CD8 (n=353). 

Patients had a median follow-up of 37 months (range 0 to 116) and there were slightly more 
male than female patients (58% and 42% respectively). Fifty two per cent of the tumours 
were of colonic origin and 39% of rectal origin, and in 9% of cases, the site was not recorded. 
Well-differentiated tumours comprised 6% of the series, while 77% showed moderate 
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differentiation, and 15% were poorly differentiated. Examination of the standard 
clinicopathological features identified the expected associations between disease-specific 
survival (DSS) and TNM stage (log-rank = 211.37, p < 0.0001), DSS with extramural 
vascular invasion (log-rank = 44.30, p < 0.0001) but not with differentiation (logrank=5.75, 
p=0.12). 

4.2.2 CD8 T cell infiltration of colorectal tumours  
 
Analysis of CD8 T cell infiltration was possible in 353 of the total 462 cores (76%) with the 
remainder not available on the cut slide, being lost during antigen retrieval or not 
demonstrating viable tumour cells in the core. CD8 staining was seen in the tumours and 
within the tumour-associated stroma, only tumour-infiltrating CD8 T cells were scored 
(%	). Of the 353 samples, 114 (32%) were negative for CD8 infiltrating T cells within 
the tumours (%	#.). Cut –points to divide both tumours into low and high expression 
of tumour infiltrating CD8 T cells were determined using the X-tile program (Yale 
University, CT, USA). This provided low/high groups of cells/mm
2
 of 0-20 (low) and 20-
3000 (high) for tumour CD8 expression ( %	$) representing 60% and 40% 
respectively. 










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4B

C                                                                                   D 



%	'

Photomicrographs of colorectal tissue microarray cores immunohistochemically stained for CD8 within the 
tumour 4 and stroma 6. Magnification: x100. # Frequency of CD8 expression in cells/mm
2
. $ Low/high 
groups of cells/mm
2
 0-20 (low) and 20-3000 (high) for tumour infiltrating CD8 T cells within the 353 sample 
cohort of colorectal tumours. 








Mean = 52.19 
S.D. = 144.247 
N = 353 
Mean = 0.4 
S.D. = 0.4 
N = 353 
 
                     Low                                    High 
                                CD8 expression 
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4.2.3 Influence of lymphocyte infiltration of tumours on survival of colorectal 
cancer patients 
 
Kaplan-Meier plots were used to analyse the relationship between low and high expression of 
CD8 positive cells within tumours and disease-specific survival. %	)demonstrates that 
patients with a higher number of CD8 T cells per unit area within tumours expression have 
significantly increased mean survival (p=0.012; 83 months) than those with a lower CD8 
infiltration  (67  months).  
 
 



%	)Kaplan-Meier plot analysis of low/high groups of cells/mm
2
 0-20 (low-black) and 20-3000 (high-
grey) for tumour infiltrating CD8 T cells within the 353 sample cohort of colorectal tumours against patient 
survival. Cum Survival = cumulative survival. The statistical significance of differences in disease-specific 
survival between groups with differing expression was calculated using the log-rank test where p < 0.05 was 
considered as statistically significant.






P=0.012 
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4.2.4 Relationship between CD8 expression and standard clinicopathological 
variables. 
 
The relationship between CD8, expression within colorectal tumours and standard 
clinicopathological variables was measured using the Pearson χ
2
 test. The current cohort of 
colorectal tumour samples have previously been analysed for CD3, STAT-1 and MHC Class I 
expression [350]. Similarly the presence of macrophages or NK cells was enumerated using 
the CD68 or CD16 markers [350] and the expression of BCL2 and p53 have also  previously 
been reported in colorectal cohort [351].  Here, expression of CD8 was significantly 
associated with extramural vascular invasion (p=0.017) Duke’s stage (p=0.045) and CD3 
infiltration (p<0.001), ( %	)). Interestingly CD8 expression was highly significantly 
associated with cytoplasmic Stat-1 expression (p<0.000) but not nuclear Stat-1 expression 
(p=0.322). When analysed against expression of MHC class I and MHC class II expression 
by the tumour cells, CD8 T cell infiltration was associated with MHC class II expression 
(p=0.02) on the tumour but not MHC class I (p=0.488).  
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Variables CD8 T cells 
Gender 0.88 
Tumour Site 0.131 
Tumour Type 0.973 
Tumour Grade 0.220 
Duke’s Stage 0.045 
T Stage 0.138 
Distant Metastases 0.099 
Extramural vascular invasion 0.017 
CD3 T cells  0.0004 
MHC class I 0.488 
MHC class II 0.02 
Stat-1 (nuclear) 0.322 
Stat-1  (cytoplasmic) 0.0001 

%	).Univariate analysis of CD8 expression in correlation with standard clinicopathological variables using 
the Χ
2
 test. Values <0.05 are accepted to be significant. 
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4.2.5 Multivariate analysis of CD8 expression with standard clinicopathological 
variables. 

In order to determine the relative influence of CD8 infiltration into tumours on patient and 
tumour variables known to affect prognosis, a multivariate analysis was performed using the 
Cox proportional hazards model. The variables included were those that have been shown to 
be significantly related to disease specific survival (DSS) on univariate analysis (extramural 
vascular invasion and TNM stage). In this model, extramural vascular invasion (p<0.004) and 
TNM stage (p<0.001) were seen to retain independent prognostic significance (%	.). 
Expression of CD8 T cells within tumours was not seen to be an independent prognostic 
marker (CI 95% 0.949-2.231, p=0.086).  
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









%		The Cox proportional-hazards model was used for multivariate analysis in order to determine the 
relative risk and independent significance of individual factors including CD8 expression. In all cases p-values < 
0.05 were considered as statistically significant. 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 	 P-VALUE 
Lower Upper 
TNM stage 
 1 1     0.001 
 2 1.537 0.661 3.575 
 3 2.634 1.154 6.010 
 4 19.725 8.015 48.544 
Vascular invasion 
absent 1   0.004 
present 2.419 1.599 3.66 
CD8 T cells 
Low 1   0.086 
High 0.687 0.488 1.054  
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4.3 Discussion 
 
Within human tumours T cell infiltration has been shown to predict patient survival 
[343,345,352] potentially as an indication that an anti-tumour immune response is underway. 
Galon et al. [353] used large cohorts of human colorectal cancers to characterise tumour-
infiltrating immune cells by gene expression profiling and in situ immunohistochemical 
staining. The study showed immunological data for the immune cell type, density, and 
location within the tumour samples to be a better predictor of patient survival than the 
histopathological methods currently used to stage colorectal cancer. Here CD8, T cell 
infiltration was analysed within 353 colorectal tumour samples. 
 
The current cohort of colorectal tumour samples have previously been analysed for CD3, 
STAT-1 and MHC Class I expression [350]. Following staining of the cohort for CD3 
expression, of the 355 available tumours, 121 patients (34%) showed low intra-tumoural T 
cells (ITTC) designated as 15cells/mm
2 
or less. Of these, 53 had no T cell infiltration. The 
presence of a high level of intra-tumoural T cells (ITTC) correlated with improved survival 
compared with a low level of ITTC, with a mean difference in survival of 16.3 months 
(p=0.006). Within this current study high numbers of CD8 T cells per unit area of tumour, 
described as those tumours having more than 20 CD8 positive cells per mm
2 
of tumour tissue, 
was shown to predict a better prognosis and increased survival time. This is also in agreement 
with previous studies looking at CD8 T cell infiltration within colorectal tumours [344]. In 
addition, as would be expected, CD8 infiltration correlated with CD3 infiltration (p<0.001) 
and interestingly also correlated with cytoplasmic Stat-1 expression (p<0.001). Stat-1 
expression  has been shown to be important for the efficient expansion of CD8 T cells by 
promoting their survival [354] and in addition Stat-1 expression predicts an IFN-γ mediated 
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immune response, which would enhance MHC expression, including MHC class II, and 
possible extravasation correlating with CD8. 
 
A study by Naito et. al. [344] analysed 131 resected colorectal tumours and separated CD8 T 
cell infiltration into 4 groups; 0, 1-19, 20-50 and >50 cell/mm
2 
and found an inverse 
correlation between CD8 T cell infiltration and Dukes’ staging. One difference between the 
study by Naito and the present study was that the authors found 43% of the tumours to have 
no CD8 infiltration whereas the present study found 32%. Perhaps, a larger cohort of tumour 
samples shows that a higher percentage of tumours have CD8 T cell infiltration. 
 
More recently T cell infiltration within tumours has been assessed via ratios of T cell subsets, 
this is not surprising as CD4 T cells can act to help activate CD8 T cell and FOXP3 
expressing Tregs can work to have opposing effects. Therefore, the relevant ratios of these 
cells within tumours may show a more accurate representation of the immune response 
occurring in patient tumour samples. Within ovarian cancer [352] intraepithelial CD8 T cells 
and a high CD8: Treg ratio showed a favourable prognosis, where Treg staining was denoted 
by CD25+FOXP3+ stained cells. Sato et al also showed that CD4 infiltration alone did not 
predict survival whereas a high CD8+: CD4+ ratio showed improved survival than high 
CD8+ alone. Diederichsen et al studied the prognostic value of the CD4+:CD8+ ratio of 
tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells 
using flow cytometry [355]. Patients with low CD4+/CD8+ ratios had significantly higher 
survival, p=0.046, independent of the Dukes stage and age. Analysis of CD4 and FOXP3 
expression within the tumour samples in this study would allow the CD8: CD4 and CD8: 
FOXP3 ratios to be assessed.  
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In conclusion the presence of intra-tumoural CD8 cells was associated with improved 
survival in colorectal cancer. Activation/memory states and antigen specificity of the 
infiltrating cells and MHC expression by tumour endothelial cells would be useful to 
understand the role of these infiltrating T cell subsets within colorectal cancer. 
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Chapter 5: Antigen-dependent Regulatory T cell transmigration 


5.1 Background 
 
Natural Regulatory T cells constitutively express the interleukin-2 (IL-2) receptor α chain 
(CD25) and the transcription factor forkhead box P3 (FOXP3). Natural Tregs 
(CD4+CD25+FOXP3+) are found phenotypically in an activated or antigen-primed state, 
selected in the thymus by self-MHC recognition  in an affinity range where they appear to 
have either escaped thymic deletion or be positively selected as part of an ‘anti-self’ 
repertoire [356]. Natural Tregs are essential for maintaining peripheral tolerance to self and 
non-self antigens, including tumour-associated antigens and have been detected in high 
numbers in a variety of cancer-bearing patients [169]. Potentially these Tregs result in 
dampening of the anti-tumour immune response by suppressing effector T cell targets, either 
in a contact-dependent manner by competing directly for stimulatory ligands on APCs, by 
scavenging IL-2, or using bystander effects such as secreting suppressive cytokines IL-10 and 
TGF-β. 
The endothelium acts as a selective barrier for leukocyte migration into tissue requiring 
recognition of non-specific adhesion molecules, chemokine gradients and possible cognate 
MHC peptide. Inflammatory cytokines such as IFN-γ and TNF-α have been shown to 
upregulate cell adhesion molecules on the endothelial surface such as ICAM-1 [357] and 
VCAM-1 [358] and also upregulate MHC class II expression by the endothelium [143]. ECs 
have been shown to present endogenous antigen to activated T cells as they possess antigen 
processing machinery including proteasome subunits, TAP proteins and both MHC class I 
and II [359]. In this context normal housekeeping proteins could be presented on MHC class 
  
153 
 
II and be recognised by natural Tregs conditioned in the thymus. This would allow 
recruitment of Tregs to survey normal tissues or to regulate immune responses within tissues. 
High numbers of Tregs have been found within tumours but the key mediators for this 
recruitment remain uncertain. Curiel et. al. [169]first showed that Tregs preferentially move 
to and accumulate within ovarian tumours and ascites, mediated by CCL22/17. Similar 
results have recently been shown in gastric cancer [360]. A study by Shimizu et. al. [361] 
implicated another chemokine, CXCL12, in Treg transmigration. CXCL12 was examined by 
immunostaining tissue specimens from malignant pleural mesothelioma (MPM) and 
malignant peritoneal mesothelioma (MPEM) and was found to be expressed in the cytoplasm 
of all malignant mesothelioma (MM) patients but not in the control groups. CXCR4 mRNA 
was expressed by CD3+FOXP3+CD25+ T cells located adjacent to the border of CXCL12 
expressing epithelial MPM. This research suggested that CXCL12 contributed to tumour-
related inflammation by inducing accumulation of CXCR4-expressing cells with Treg 
markers around MM.   
Selective accumulation of T cells, specifically Tregs, in tumour tissue could be due to an 
increased ability to transmigrate endothelium in response to tumour-associated chemokines 
and/or antigen recognition. It is proposed that T cells recognising highly expressed, high 
affinity epitopes in the thymus are either deleted or differentiated into natural Tregs. The 
hypothesis is that these high affinity self epitopes will be preferentially transferred from 
tissues to endothelial cells by the “shop window” model [317]. The model suggests that tissue 
derived self epitopes would be taken up by the surrounding endothelium and presented in the 
context of MHC class II molecules to circulating CD4 T cells within the blood. Recognition 
of these self-epitopes would allow preferential recruitment of natural Tregs to prevent 
autoimmunity.  
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The hypothesis is that syngeneic transmigration of MHC matched Tregs across ECs from 
DR4 mice would allow the endothelium to present cognate high affinity self peptide in the 
context of the correct MHC.  Whereas, allogeneic transmigration of DR4 Tregs across C57Bl 
endothelium would lead to mis-matched MHC class II, unable to present self-peptides to 
Tregs. This avoids the need to clone and identify the peptide recognised by Tregs.  It is 
therefore anticipated if cognate MHC:peptide is required for Treg migration there should be 
enhanced migration across cells expressing syngeneic MHC when compared to allogeneic 
MHC. 
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5.2 Results 

5.2.1 Natural Regulatory T cell transmigration is not affected by resting syngeneic 
or allogeneic endothelium. 
 
The hypothesis was that regulatory T cells undergo antigen-specific transmigration following 
recognition of self-peptides presented in the context of MHC class II molecules on the 
endothelium. To test this hypothesis splenocytes were derived from naive DR4 mice, which 
contain human MHC class II molecules in replacement of murine MHC class II and were 
migrated within a transwell system across DR4 or C57Bl MLECs forming models of 
syngeneic and allogeneic transmigration respectively ()	). 
 
The transmigrated cells within each population were stained for CD4+CD25+FOXP3+ 
expressing cells by flow cytometry and the percentage transmigration calculated. 
9	42'3represents flow cytometry data for the whole splenocyte population of one naive 
DR4 mouse where around 20% of the cells are CD4+, by gating on the CD4+ T cells 
(9	4233the percentage of CD4CD25FOXP3 T cells within the CD4 population was found 
to be only 1%. Following transmigration, gating on either the whole CD4 T cell population or 
Tregs there was no difference in transmigration of either CD4 or CD4CD25FOXP3 T cells 
across syngeneic when compared to allogeneic endothelium (9	6). Therefore, under 
conditions of no inflammation no antigen-specific transmigration of Tregs was found. This 
may have been due to low levels of MHC class II expressed on resting endothelial cells. 
9	# shows that MHC class II expression was not present on resting C57Bl and DR4 
MLECS but was induced by endothelial activation. The amount of MHC class II expression 
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by DR4 endothelium is lower than that of the C57Bl as the DR4 mice are a transgenic strain 
containing a hybrid MHC class II molecule (the peptide binding domains of human HLA-
DR4 and the membrane proximal domains of mouse I-E). Despite a low basal level the MHC 
class II expression on DR4 endothelium it increased 4 fold following a 24 hour stimulation 
with cytokines IFN-γ and TNF-α. Similar results presented in chapter 3 also showed that 24 
hour stimulation with inflammatory cytokines was sufficient time to up-regulate cell adhesion 
molecule and MHC class I expression on the endothelium.  
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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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
Transendothelial CD4CD25FOXP3 T cell migration through MLEC monolayers. Analysis of splenocytes 
derived from a DR4 mouse is shown in 4 where the cells were detected by 3 colour flow cytometry for 
CD4CD25FOXP3 T cells. 423 represents CD25FOXP3 expression gated in CD4 T cells. Following 
transmigration under each condition the cells were surface stained for CD4 and CD25 and intracellular stained 
for FOXP3 and compared to the initial splenocyte population. MLEC monolayers were derived from DR4 
(syngeneic) or C57Bl (allogeneic) mice. 200,000 cells from DR4 mice were added per well with 6 wells per 
condition. Each experiment was carried out 4 times and the data represents pooled results for all 4. 6 represents 
the percentage transmigration of CD4CD25FOXP3 T cells transmigrating under each condition across either 
syngeneic endothelium (black bar) or allogeneic endothelium (white bars). # shows MHC Class II expression 
for MLECs following 24 hours incubation with IFN-γ and TNF-α 
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5.2.2 Natural Regulatory T cells show higher levels of transmigration across 
activated syngeneic endothelium in the presence of CXCL12. 
 
To answer the question of whether additional signals are required for regulatory T cell 
transmigration, splenocytes from unimmunised mice containing natural Tregs 
(CD4CD25FOXP3) were migrated across syngeneic and allogeneic MLECS ( 9	)) 
under ten experimental conditions ( 9	.) This included migration towards tumour 
associated chemokines such as CCL22 and CXCL12, across endothelium activated with 
inflammatory cytokines IFN-γ and TNF-α and/or pre-treated with the pro-angiogenic factor 
VEGF. 
 
 
 
 
  
 







9	 Isolated splenocytes from DR4 and C57Bl mice were allowed to transmigrate under the 10 conditions 
shown. Control endothelium corresponds to untreated endothelium, IFN-γ, TNF-α and VEGF were used to treat 
endothelial monolayers for 24 hours. The chemokines CXCL12 and CCL22 were present in the media of the 
lower chamber of the transwell during transmigration. 
  
If the initial hypothesis is correct and Tregs do require recognition of self-peptides in the 
context of MHC class II molecules to transmigrate an increased level of transmigration would 
be expected across syngeneic endothelium. Endothelial cells require activation via cytokines 
to upregulate MHC class II expression ( 9	#). When comparing 
 Conditions 
1. Control 
2. IFN-γ (100ng/ml) 
3. IFN-γ and TNF-α (100ng/ml) 
4. CXCL12 (100ng/ml) 
5. CCL22 (100ng/ml) 
6. IFN-γ, TNF-α and CXCL12 
7. IFNγ, TNF-α and CCL22 
8. VEGF (50ng/ml) 
9. VEGF, IFN-γ and TNF-α 
10. VEGF, IFN-γ, TNF-α and CXCL12 
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CD4+CD25+FOXP3+ T cell migration for each syngeneic condition in comparison to 
untreated (control) endothelium the number of Tregs was measured by indirect 
immunofluorescence and flow cytometry on the splenocyte population before and after 
transmigration. A significantly increased transmigration was seen across endothelium treated 
with IFN-γ, TNF-α with a CXCL12 gradient (p=0.02) (9	)43. In contrast, there was 
no significant increase in transmigration of Tregs across any of these conditions on its own or 
in response to CCL22 or VEGF either on their own or in combination with inflammatory 
cytokines. Specific migration of Tregs in response to IFN-γ, TNF-α and a CXCL12 gradient 
was not seen across allogeneic endothelium indicating there was a difference between 
migration across syngeneic and allogeneic MLECs. The number of Tregs transmigrating 
syngeneic endothelium in response to CXCL12, IFN-γ and TNF-α was 8000 compared to 
only 3000 across allogeneic. 9	)6 shows the percentage of CD4CD25FOXP3 T cells 
that transmigrate across syngeneic endothelium in combination with CXCL12 and 
inflammatory cytokines was 45±12%, whereas only 17±5% transmigrated across allogeneic 
endothelium under the same conditions (p=0.029).  9	)# shows the percentage 
transmigration of the whole CD4 population, where no significant difference in 
transmigration was seen across any condition. This provides possible evidence to support the 
theory that peptide recognition is required for Treg migration.  
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5.2.3 Recognition of self antigen presented by MHC on syngeneic endothelium 
increases migration of natural Regulatory T cells. 
 
The hypothesis once again states that MHC: peptide recognition is required for Treg 
transmigration and therefore blocking of MHC class II molecules on the endothelium would 
be expected to decrease Treg transmigration across endothelium. Naive splenocytes 
containing Tregs were migrated across syngeneic and allogeneic MLECS in the presence of 
CXCL12, inflammatory cytokines and the presence or absence of MHC class II anti-HLA-
DR blocking antibody. Absolute numbers of Tregs transmigrating under each condition as an 
average of 3 experiments (each in triplicate) where Tregs were derived from 3 donors are 
shown in 9	. The number of Tregs transmigrating syngeneic endothelium in response 
to CXCL12, IFN-γ and TNF-α was 1400±190 compared to only 500±70 (p<0.05) across 
allogeneic and significantly lower (p<0.05; 800±45 cells) following MHC class II blocking. 
This data verifies that, under conditions of inflammation and CXCL12, Tregs preferentially 
migrate across syngeneic rather than allogeneic MLECS where cognate antigen-recognition 
can only occur in the syngeneic model and this antigen-specific transmigration can be 
blocked by an anti-MHC class II antibody.  
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5.2.4 CXCR4 expression on Regulatory T cells is intracellular until interaction 
with CXCL12. 
 
T cell transmigration towards CXCL12 is known to be dependent on CXCR4 expression on 
the T cells. Data here has shown that Tregs preferentially transmigrate across syngeneic 
endothelium towards CXCL12 and therefore CXCR4 expression was assessed on Tregs by 
flow cytometry. 9	%shows surface staining of CXCR4 and intracellular CXCR4 for 
CD4 T cells (4) and on CD4CD25FOXP3 Tregs (6) prior to transmigration. Only 0.05% of 
the whole CD4 population express CXCR4, at the cell surface whereas, 98% express 
intracellular CXCR4. 10.5% of the Treg population express CXCR4, at the cell surface 
whereas, 43.5% express intracellular CXCR4. This data indicates that chemokine receptor 
expression, particularly in the case of CXCR4, may be intracellular until interaction with 
corresponding chemokines. In addition it also shows that Tregs do not show preferential 
expression of CXCR4 over conventional CD4 T cells. It would be interesting to assess 
CXCR4 expression following transmigration across syngeneic and allogeneic endothelium 
towards a CXCL12 gradient to identify the effect of CXCL12 ligation and transmigration on 
CXCR4 expression.  
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5.2.5 Regulatory T cell transendothelial migration is dependent on a CXCL12 
gradient and reduced under high concentrations. 
 
As Tregs appear to preferentially transmigrate across syngeneic endothelium in response to 
CXCL12, it was hypothesised that this transmigration would be concentration dependent. 
CD4CD25FOXP3 T cells were transmigrated along a CXCL12 gradient  9	94. 
Significantly increased transmigration of Tregs was seen across syngeneic endothelium at 
100ng/ml, (10% to 50% transmigration) but not across allogeneic endothelium showing the 
antigen-specificity in the presence of inflammatory cytokines and CXCL12.  Above 
100ng/ml there was no significant increase in the transmigration of CD4CD25FOXP3 Tregs 
across syngeneic endothelium. 9	96shows the total splenocyte population following 
transmigration across allogeneic and syngeneic endothelium, conditioned with cytokines, in 
response to CXCL12 at 0, 10ng, 100ng and 1µg/ml. The data show an increase in splenocyte 
transmigration along the chemokine gradient, with significantly increased transmigration 
observed at 100ng/ml CXCL12. However there was no difference between syngeneic and 
allogeneic endothelium. In conclusion, both CD4+CD25-FOXP3- and CD4+CD25+FOXP3+ 
T cells follow a CXCL12 gradient that peaks at 100ng/ml however Tregs are the only cell 
type to show antigen-specific transmigration at the peak of transmigration towards CXCL12.  
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5.3 Discussion 
 
Regulatory T cells mediate peripheral tolerance by suppressing self-antigen-reactive T cells 
and high numbers of Tregs have been found in peripheral blood of a variety of cancers 
including breast cancer [362], colorectal cancer [363], oesophageal and gastric cancer [360], 
lymphoma [364], ovarian cancer [169] and pancreatic cancer [208,209]. Vaccination 
strategies to remove the inhibitory effect of Tregs have proven successful; in particular the 
blockade of CTLA-4 has been shown to promote the rejection of pre-implanted B16 
melanomas [365,366]. Combinational therapy blocking both PD-1 and CTLA-4 has shown 
up to 50% regression within B16 melanomas. Combination of CTLA-4 blockade and 
depletion of CD25
+
 Treg cells results in tumour rejection where efficacy of the antitumor 
therapy correlated with an increased frequency of tyrosinase-related protein 2
180–188
–specific 
CTLs detected in the periphery [367]. The effect seen with combination approaches leads to 
an increase in effector T-cell (Teff) infiltration, resulting in highly advantageous Teff: Treg 
ratios with the tumour. The high CD8:Treg ratio resulted from increased CD8 infiltration and 
expansion, impaired conversion of CD4 T cells into Tregs resulting from CTLA-4 blockade, 
and reduced Treg suppression through PD-1 blockade [368]. More recently in a phase III 
study in over 600 metastatic melanoma patients, Ipilimumab which blocks CTLA-4, has been 
shown to improve overall survival in patients with previously treated metastatic melanoma 
[369].  
 
Studies showing the importance of removing the suppressive effects of Tregs for the 
effectiveness of anti-cancer therapies meant that the trafficking of Tregs across endothelium 
and more importantly into tumour tissue was of interest. Having previously shown that 
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antigen recognition is required for CD8 T cell transmigration into tumours, potentially 
antigen recognition may also be required for Treg transmigration into tumours. In order to 
study this transmigration assays under 10 conditions combining the effects of inflammatory 
cytokines and tumour associated chemokines CCL22 and CXCL12 was carried out. Our data 
suggest that Tregs preferentially transmigrate, across murine lung endothelium, towards the 
tumour-associated chemokine CXCL12, in the presence of endothelial cell activation by 
inflammatory cytokines and preferentially across syngeneic rather than allogeneic 
endothelium. Furthermore, the preferential migration across syngeneic endothelium could be 
blocked with an MHC class II binding antibody, demonstrating that Treg transmigration 
across endothelium and therefore infiltration into tissue is antigen-specific and requires MHC 
class II expression by the endothelium.  
 
Marelli-Berg hypothesised that the endothelium acts as a shop window [318] where 
endogenous self antigens and tissue derived antigen is picked up by endothelial cells (acting 
as antigen presenting cells), processed and presented by MHC molecules on the endothelium. 
Together with chemokine stimulation, migration of antigen-specific T cells is favoured into 
the tissue over non-specific T cells potentially selectively recruiting Tregs into tissues to 
prevent autoimmunity.  
 
Beckhove et. al. [370] studied regulatory T cell infiltration in human pancreatic carcinoma 
and showed that tumour endothelium selectively recruited regulatory T cells 
(CD4+CD25+FOXP3+). The study showed increased density of blood vessels in the tumour 
tissue and increased expression of addressins such as CD62-E, ICAM-1/-2, MAdCAM-1, 
VCAM-1 and CD166. Tumour infiltrating Tregs but not tumour-infiltrating CD4+ T cells 
showed differential over-expression of β7 integrin, CD166L and CD62L, showing an 
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increased capacity of Tregs to adhere to and transmigrate selectively into tumour tissue. Our 
data suggests that cognate MHC: peptide recognition of endogenous antigens is a further key 
factor in Treg migration into tissues. 
 
Regulatory T cells develop due to TCR interactions with cognate self-peptide: MHC class II 
complexes, on thymic stromal cells, in an affinity range between positive and negative 
thymic selection [17]. High levels of peptide expression result in deletion of TCR transgenic 
T cells whereas moderate expression results in partial deletion. Of the remaining cells up to 
50% express CD25 and exhibit Treg functions. In addition to recognition of self peptides in 
the thymus, Tregs have been shown to recognise self-peptides bound to MHC class II 
expressed by peripheral antigen presenting cells [371]. By using TCR gene transfer, studies 
have shown that the CD4+CD25+ T cell TCR repertoire was as diverse as the CD4+CD25- 
TCR repertoire, exhibiting a higher frequency of TCRs with enhanced affinity against self-
peptides [372].  This diverse repertoire could enable Tregs to recognise a wide variety of self-
peptides presented by the endothelium and high affinity interactions would further enable 
selective recruitment of Tregs into tissues.  
 
The chemokine CXCL12 is important in T cell trafficking and was first reported in human 
ovarian cancer in 2001 [178,373]. Within the tumour microenvironment stroma and cancer 
cells are the two main components that can produce CXCL12, activated tumour stromal 
fibroblasts produce CXCL12 [185] and contribute to tumour vascularisation by endothelial 
stem cell attraction. Our data showed that Tregs expressed minimal CXCR4 surface 
expression, with the majority being intracellular, supporting previous research that expression 
of the receptor is not confined to the cell
 
surface [374]. Upon activation the
 
amount of cell 
surface expressed CXCR4 on lymphocytes increases
 
two-fold within seconds and is 
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completely down-regulated within
 
the next 2 minutes. Receptor cross-linking caused by 
incubation
 
of cells with anti-CXCR4 mAb was shown to trigger receptor trafficking and the 
receptor is rapidly internalized and recycled to
 
the cell surface. Thus supporting our 
hypothesis that the CXCR4 receptor may be internal until encounter with the endothelium 
where the receptor is trafficked to the cell surface and allows interaction to occur with 
CXCL12, activating signalling cascades which allow the cell to transmigrate.  
 
Antigen-specific Treg transmigration required endothelial activation and subsequent 
upregulation of MHC class II by IFN-γ and TNF-α in addition to a CXCL12 gradient. 
Interestingly, within ovarian cancer cell lines and primary epithelial cancer cells TNF-α 
stimulation is involved in the CXCL12/CXCR4 axis by increasing expression of CXCR4 cell 
surface expression and subsequent migration towards CXCL12 [375]. This role of TNF-α 
within the CXCL12/CXCR4 axis could help to explain the synergy seen with CXCL12 for 
antigen specific Treg transmigration.  
Data here demonstrates that the level of CXCL12 can alter Treg transmigration with peak 
migration at 100ng/ml of CXCL12 and lower levels of transmigration seen at 1µg/ml. 
Previous research using CD4 T cells demonstrated that increasing  the CXCL12 
concentration from 100ng/ml to 1µg/ml inhibited cells responding towards a concentration 
gradient and initiated the movement of T cells away from CXCL12 [376]. Movement away 
was highest at 1 µg/ml CXCL12 for naive and memory CD8 T cells and memory CD4 T 
cells, whereas for naive CD4 cells, migratory activity was higher at 10µg/ml. Movement 
away from CXCL12 (fugetaxis) was significantly greater than chemotaxis for each subset of 
cells. Data presented here showed that all CD4 T cells showed concentration dependent 
transmigration towards a CXCL12 gradient; however Tregs were the only subset to show this 
occurred in an antigen-dependent manner. An in vivo murine tumour study investigated the 
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effect of engineering B16 melanomas to produce CXCL12 at high and low levels and found 
chemo-repellent activity of antigen-specific T cells away from melanoma expressing high 
concentrations of CXCL12 [377].   
 
Results from in vitro transmigration assays has shown natural Tregs preferentially 
transmigrate across syngeneic endothelium under conditions of inflammation and towards a 
CXCL12 gradient. Potentially Tregs use this same antigen-specific mechanism to infiltrate 
tumours by recognition of self-peptides in the context of MHC class II on the tumour 
endothelium. In order to demonstrate this, an in vivo transmigration assay could be carried 
out to assess the contribution of peptide: MHC recognition of Treg infiltration into tumours. 
To achieve antigen-specific Treg transmigration B16 melanomas  could be grown on C57Bl 
and DR4 mice to form models of syngeneic and allogeneic endothelium and isolated CD4 T 
cells from naive C57Bl mice fluorescently labelled with CFSE (1nm) and injected I.P into 
each mouse. The hypothesis would suggest that increased infiltration of natural labelled 
Tregs would be seen in tumours of C57Bl mice where tumours, endothelium and Tregs are 
matched for MHC class II.
 
 MHC recognition is important for CD4 T cell transmigration across endothelium and 
increases the recruitment of specific T cells into the tissue by cognate recognition of tissue 
peptide presented by MHC [153,328]. We have demonstrated that cognate recognition of 
peptides presented by MHC class II aids recruitment of Tregs across endothelium. This 
enhanced T cell transmigration due to MHC/peptide recognition may be due to the TCR 
engagement leading to activation of signalling pathways such as Ras/Rho family of GTPases 
that control cell adhesion molecule activation such as integrins and cytoskeletal 
rearrangements allowing polarisation and motility to be enhanced [378]. Our observation that 
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antigen-specific Treg transmigration occurred in the presence of a CXCL12 gradient is very 
interesting as while TCR signals through initiation of tyrosine kinase cascades, chemokine 
receptors are members of the serpentine receptor family linked to heterotrimeric G proteins 
and potentially a link between the two pathways can occur via Protein Kinase C isoforms 
implicated in downstream regulation. Activation of the TCR with anti-CD3 monoclonal 
antibody elicits
 
a desensitisation effect on CXCR4 activity [379].  
 
The hypothesis was that CXCL12 is involved in antigen-specific transmigration of Tregs 
where it acts to further enhance the TCR signal during antigen-recognition. CXCL12 may 
work synergistically to promote downstream signalling cascades. In addition, the role of 
ZAP-70 on CXCL12 functionality has been assessed in different T-cell lines
 
and in CD4
+
 T 
cells obtained from a patient with ZAP-70 deficiency [380]. Zap-70 is the protein tyrosine 
kinase zeta-associated protein, a key signalling element
 
in T-cell activation. The study by 
Ticchioni et al showed that ZAP-70 is required for CXCL12-induced transendothelial
 
T-cell 
migration and for downstream signalling components including
 
Vav1 and ERKs. Abrogation 
of Vav1 function blocked CXCL12-induced
 
T-cell migration and showed that ZAP-70 plays 
a role in CXCL12 activation of the ERK signalling pathway. CD4 T cells from ZAP-70 
deficient patients resulted
 
in an impairment of transendothelial migration that was reversed by 
the transfection of ZAP-70. CXCL12 stimulates the physical association of CXCR4 and the 
TCR and uses the ZAP-70-binding immunoreceptor tyrosine-based activation motifs 
(ITAMs) of the TCR for signal transduction [381].These studies support the hypothesis
 
that 
chemokine receptor responses can depend upon TCR signalling.  
A study using T cells from patients with chronic lymphocytic leukemia found ZAP-70-
negative
 
samples showed significantly less migration towards CXCL12 compared
 
to T cells 
from ZAP-70-positive samples and that this was not
 
due to defective CXCR4 down-
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regulation [382].  This further supports role for ZAP-70 in migration towards CXCL12 and as 
a potential target to alter T cell subset infiltration into tumours.  
 
Tregs transmigrate across endothelium in a MHC class II restricted manner in the presence of 
inflammatory cytokines and CXCL12. Homeostatically, MHC dependent transmigration of 
Tregs recognising self-antigens into tissues would only occur during infection/inflammation 
and represents a mechanism to enhance the threshold for T cell recognition to prevent 
concomitant autoimmunity. Within tumour microenvironments our results would suggest that 
recognition of naturally presented high affinity self peptides presented by self MHC on 
endothelial cells would preferentially recruit Tregs. Therefore, efficient transmigration of 
Tregs recognising self-peptides presented on the tumour endothelium in combination with 
moderate levels of CXCL12 leads to a suppressive tumour environment and poor prognosis. 
Potentially altering the availability of self-peptides by targeting the MHC class II expression 
on tumour endothelium would help to prevent the infiltration of Tregs, however this may also 
result in reduced antigen-specific transmigration of CD4 effector T cells into tumours. 
However, neutralising CXCL12 within the tumour-microenvironment could have the 
potential to selectively inhibit CD4 and not CD8 T cell migration.  CD4 effector T cells 
would also require MHC class II expression for antigen-specific transmigration into tumours, 
however being an effector population, the CD4 T cells may not depend on CXCL12 
signalling via CXCR4 in the same way as Tregs. Although CXCL12 has been shown to 
enhance tumour metastasis it may also promote Treg recruitment providing a less 
immunogenic environment for the incoming tumour cells. Targeting the CXCL12/CXCR4 
axis has been shown to reduce tumour metastasis [383], in addition neutralising CXCL12 
within the tumour microenvironment would limit Treg antigen-specific infiltration into 
tumours while potentially still allowing effector CD4 and CD8 T cell infiltration. 
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Chapter 6: CXCL12 and CXCR4 expression within tumours 

6.1 Background 
 
Stromal derived factor-1 (SDF-1α, or CXCL12) is a 68-amino acid small (8kDa) cytokine 
belonging to the CXC chemokine family. CXCL12 is constitutively expressed in the bone 
marrow and other tissues including the skin, heart, liver, lung and brain endothelium [384]. 
CXCL12 is a strong chemotactic factor for T cells and monocytes [385] and in B cell 
lymphopoiesis and bone marrow myelopoiesis where its corresponding receptor is CXCR4. 
Data within the previous chapter has highlighted the role of CXCL12 in antigen-specific Treg 
transmigration, this chapter aims to assess the expression levels of CXCL12 and CXCR4 
within colorectal and ovarian tumours relative to clinicopathological variables and overall 
survival of patients. 
 
CXCL12 belongs to the intercrine family, expressed on stromal cells and vascular 
endothelium and induced by pro-inflammatory stimuli such as LPS, TNF and IL-1 and 
hypoxia [186]. CXCL12 binds to G-protein-coupled CXCR4 [163] and plays an important 
role in the regulation of stem/progenitor cell trafficking. This constitutive expression is 
responsible for trafficking and localisation of immature and maturing leukocytes to these 
tissues suggesting a role in immune surveillance [385]. It is also a potent costimulator of CD4 
helper T cells [386]. More recently it has been shown that CXCL12 can act as an anti-
inflammatory chemokines during the inflammatory process by promoting the polarisation of 
helper cells to become antigen specific regulatory cells [387]. CXCL12 is an efficient 
chemoattractant for T cells as it increases adhesion to ICAM-1 (CD54) by up-regulation of 
the binding activity of LFA-1 on the T cells [387]. This is in line with the observation that 
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CXCL12 is a potent chemotactic factor for plasmacytoid dendritic cells and promotes them to 
produce IL-10 [388]. This contradictory role of CXCL12 during homeostasis which  
promotes leukocyte extravasation and immune surveillance, whilst down regulating immune 
responses, during acute inflammation may be explained by concentration effects, with low 
doses promoting inflammation and high doses inhibiting inflammation. This is supported by 
the recent study showing that low doses of CXCL12 are chemotactic for T cells whereas 
higher doses are fugetactic or repellent [376].  
The CXCL12 receptor, CXCR4, is a 352 amino acid rhodopsin-like seven transmembrane G 
protein-coupled receptor [389] and is a co-receptor for HIV entry [390].  CXCL12/CXCR4 
axis plays an important role in the regulation of stem/progenitor cell trafficking [391]. 
AMD3100 is a highly selective CXCR4 chemokine receptor antagonist and has recently been 
approved as a drug (in combination with GM-CSF) for hematopoietic stem cell mobilisation 
from the bone marrow to the blood where they can be collected for autologous stem cell 
transplantation [392,393]. Endothelial cells can express both CXCL12 and CXCR4 and are 
key regulators of angiogenesis [394] and in addition CXC12 and CXCR4 are essential for life 
as mice deficient in either gene are unable to survive past birth [395,396]. 
 
Endothelial cells can express both CXCL12 and its receptor CXCR4 and expression in 
tumour has been shown to be important for tumour progression and metastasis as this 
chemokine/receptor expression has been found to be a key regulator of angiogenesis [394]. 
More recently CXCL12 expression has been shown to be expressed within the tumour 
microenvironment where it impacts upon patient survival. Tumour stroma is an active 
element of the tumour microenvironment and it has recently been shown that in breast cancer, 
activated stroma
 
fibroblasts produce CXCL12 [184] leading to vascularisation by chemotaxis 
of endothelial progenitor cells [185]. The CXCR4/CXCL12 axis has been shown to be a key 
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factor in tumour metastasis of many cancer types where cancer cells show CXCR4 
expression and corresponding expression of CXCL12 is seen at sites of tumour metastasis 
[397].  
Various tumours and in particular the androgen dependent tumours such as prostate, breast 
and ovarian cancers also produce CXCL12 and express CXCR4 [388,398,399,400]. In these 
tumours CXCL12 can have pleiotropic roles in autocrine growth stimulation [373,401], a 
chemoattractant for tumour cells [164,402,403,404,405], contributes to tumour 
vascularisation
 
by endothelial stem cell attraction [185] and can suppress tumour immunity 
[387,388]. Furthermore, expression of CXCR4 and CXCL12 predicts lymph node metastasis 
in colorectal [10] esophageal [406] and breast cancer [407]. CXCR4 has been shown to be a 
predictor of poor survival in Nasopharyngeal carcinoma [408], renal cell carcinoma [409], 
gastrointestinal tumours [161] and ovarian cancer [410]. In contrast, it has been shown that 
endogenous CXCL12 expression in colorectal cancer cell lines provides a barrier to 
metastases by increasing anoikis via activation of a Bim-mediated intrinsic apoptotic pathway 
[411]. Thus expression of CXCL12 could have a correlation with good or poor prognosis. 
Kollmar et. al. [412] used amurine model of established extrahepatic colorectal metastasis 
and showed that CXCL12 promotes tumour cell migration in-vitro and tumour growth of 
established extrahepatic metastasis in vivo due to angiogenesis-dependent induction of 
tumour cell proliferation and inhibition of apoptotic cell death.  
While CXCR4 expression on tumour cells has shown enhanced metastasis towards CXCL12, 
few studies have looked at the expression of both CXCR4 and CXCL12 by tumour cells and 
the relationship with clinicopathological features and survival of patients. In this study a large 
cohort of 292 colorectal and 289 ovarian tumour samples were analysed for CXCL12 and 
CXCR4 expression by tumour cells. Correlations were assessed between chemokine 
expression patterns, patient clinicopathological features and survival. 
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6.2 Colorectal Cancer Results 

6.2.1 Clinical and pathological data of colorectal cancer patients 
 
The clinic-pathological features of the total 462 cases and 292 included in the present study 
are shown in .	.  
Variable Categories Frequency of total 
cohort (%) 
Frequency of 
stained cohort (%) 
Gender Male 266 (58) 169(58) 
 Female 199 (42) 123(42) 
Age (years) Median 72 72 
 Range 58-89 57-93 
Status Alive 278(60) 174(60) 
 Dead 184(40) 118(38) 
Tumour Grade Well differentiated 29 (6) 23(8) 
 Moderately differentiated 353 (77) 220(75) 
 Poorly differentiated 71 (15) 43(15) 
 Unknown 8 (2) 6(2) 
Tumour Site Colon 238 (52) 141(48) 
 Rectum 181 (39) 123(42) 
 Unknown 43 (9) 28(10) 
TNM Stage 0 (Tis) 3 (1) 2(1) 
 1 69 (15) 49(16) 
 2 174 (28) 101(35) 
 3 155 (33) 102(35) 
 4 54 (12) 33(11) 
 Unknown 7 (2) 5(2) 
Extramural Vascular 
Invasion 
Negative 224 (48) 140(48) 
 Positive 128 (28) 81(28) 
 Unknown 110 (24) 71(24) 
Histological Type Adenocarcinoma 392 (85) 249(85) 
 Mucinous carcinoma 51 (11) 32(11) 
 Columnar carcinoma 4 (1) 4(1) 
 Signet ring carcinoma 7 (1) 2(1) 
 Unknown 8 (2) 5(2) 
 
.		Clinicopathological variables for the patient cohort (n = 462) and cores stained for tumour-associated 
CXCL12 (n=292).  
 
The patient cohort was comprised of 226 (58%) males and 196 (42%) females. The median 
age at the time of surgery was 72 years, consistent with a median age at diagnosis of 
colorectal cancer of 70-74 years in the UK. Fifteen percent of tumours arrayed were TNM 1, 
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38% TNM 2, 33% TNM 3 and 12% TNM 4 comparable with recently published national 
figures [413]. The majority of tumours (85%) were adenocarcinomas, and were often of a 
moderate histological grade (77%). Patients had a median follow-up of 37 months (range 0 to 
116) and there were slightly more male than female patients (58% and 42% respectively). 
Fifty two per cent of the tumours were of colonic origin and 39% of rectal origin, and in 9% 
of cases, the site was not recorded. Well-differentiated tumours comprised 6% of the series, 
while 77% showed moderate differentiation, and 15% were poorly differentiated. Evidence of 
extramural vascular invasion was documented in 76% of all tumours. Among all the 
clinicopathological parameters scored, only tumour stage and the presence or absence of 
vascular invasion had strongly significant influence on survival. This is consistent with 
previously published data.  
At the time of censoring for data analysis 49% of patients had died from their disease, 13% 
had died from other causes, and 37% were alive which is comparable with a national average 
of approximately 45% five-year survival for colorectal cancer in the UK [413]. The median 
disease-specific survival was 58.2 months 
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6.2.2 CXCL12 expression in colorectal cancer tissue 
 
Analysis of CXCL12 was possible in 292 of the total 462 cores (63%) with the remainder not 
available on the cut slide, being lost during antigen retrieval or not demonstrating viable 
tumour cells in the core. Due to the large loss of cores, the clinicopathological data for the 
292 samples was assessed to confirm that the stained cohort represented the original cohort 
(Table 1). CXCL12 staining was seen in the cytoplasm of tumour cells (.	). Of the 
292 samples, using an H score system, 20 (7%) were negative (a score of 0) for CXCL12 in 
tumour cells with the majority of tumours having low (104; 35.6% (<=100)) and moderate 
CXCL12 103 (103: 35.3% (<=200)) expression but 65 tumours (22.3% (<=300)) showing 
strong expression. Cut –points to divide both tumours into low and high expression of 
CXCL12 were determined using the X-tile program (Yale University, CT, USA). This 
provided low/high groups of H Score 0-145 (low) and 145-300 (high) for tumour CXCL12 
expression representing 55% and 45% respectively. 























  
180 
 
	.	
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.	7+"'

Photomicrographs of colorectal tissue microarray cores immunohistochemically stained for CXCL12. The level 
of expression ranged from strong (i) to moderate (ii) to weak (iii) to negative (iv). Magnification: x100. 
 
  
181 
 
 
6.2.3 CXCR4 expression in colorectal cancer tissue 
 
Analysis of CXCR4 was possible within the 292 samples of the total 462 cores (63%). 
CXCR4 staining was seen mainly in the nucleus of tumour cells, with the exception of high 
CXCR4 expression which was seen in the nucleus and cytoplasm (.	)). Of the 292 
samples, using an H score system, only 6 (2%) were negative (a score of 0) for CXCR4 
expression on tumour cells with the majority of tumours having low (103; 35.3% (<=100)) 
and moderate CXCR4 (144: 49.3% (<=200)) expression but 39 tumours (13.4% (<=300)) 
showing strong expression. Cut –points to divide both tumours into low and high expression 
of CXCR4 were determined using the X-tile program (Yale University, CT, USA). This 
provided low/high groups of H Score 0-70 (low) and 70-300 (high) for tumour CXCR4 
expression representing 16% and 84% respectively. 
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

 


.	)78'

Photomicrographs of colorectal tissue microarray cores immunohistochemically stained for CXCR4. The level 
of expression ranged from strong (i) to moderate (ii) to weak (iii) to negative (iv). Magnification: x100. 
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6.2.4 Relationship between CXCL12 and CXCR4 expression and survival 
 
Kaplan-Meier plots were used to analyse the relationship between low and high expression of 
CXCL12 and CXCR4 and disease-specific survival. There is a complex relationship between 
CXCL12 expression and survival in colorectal cancer. Patients who express strong or no 
CXCL12 have a poor survival with mean survival times of 50.8 and 55.6 months respectively 
(.	)). In contrast, patients whose tumours express low or moderate levels of CXCL12 
have longer survival times of 81.2 and 73.4 months respectively (p=0.013;  .	4). 
Patients were regrouped into two groups using the X-tile program (Yale University, CT, 
USA). This provided low/high groups of H Score 0-145 (low) and 145-300 (high) for tumour 
CXCL12 expression representing 55% and 45% respectively.Patients with a higher level of 
tumour associated CXCL12 expression showed a significantly reduced mean survival 
(p=0.008; 59 months) than those with a lower level of CXCL12 expression (76 months; 
.	6). Whereas if patients with either no or high expression and patients with low or 
moderate expression where regrouped into two groups forming ‘good’ and ‘bad’ prognosis 
groups, there was an even  stronger association with survival (p=0.003;.	#) 
 
There was no effect on survival of H score groupings for CXCR4 (p=0.882; .	%4
.	). When comparing low and high levels of CXCR4 (.	%6) expression with disease 
specific survival no difference was found (p=0.274). When tumour cell expression of high 
and low CXCL12 was compared to high and low CXCR4 expression (.	%#), patients 
that showed low expression of CXCL12 and low CXCR4, 22 of 194 patients (11%) had the 
best survival (76.4 months), with patients with high CXCL12 and high CXCR4 displaying 
the worst survival (47.3 months), 68 of 124 patients (55%). Patients with high tumour 
CXCL12 and low tumour CXCR4 expression or patients with low tumour CXCL12 and high 
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tumour CXCR4 expression had a similar survival of 59.5 and 62.1 months. Overall there was 
no linear correlation between CXCL12 and CXCR4 however expression patterns showed 
significant effects on survival of colorectal cancer patients (p=0.046). 
 
 
 
 
 
CXCL12 Expression 
Mean survival time (months) 
Estimate 
(months) 
95% Confidence Interval 
Lower Bound Upper Bound 
Negative 50.8 28.9 72.7 
Low  81.2 72.1 90.4 
Moderate 73.4 63.2 83.5 
High  55.6 43.7 67.6 
Overall 72.8 66.7 78.8 

.	)	Mean survival time in relation to CXCL12 expression. 
 


 
 
CXCR4 Expression 
Mean survival time (months) 
Estimate 
(months) 
95% Confidence Interval 
Lower Bound Upper Bound 
Negative 55.4 35.1 75.7 
Low  67.1 57.3 76.9 
Moderate 67.9 59.3 76.5 
High  69.6 53.4 85.8 
Overall 68.4 62.4 74.4 

.		Mean survival time in relation to CXCR4 expression	
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

.		CXCL12 expression in colorectal cancer tissue: correlation with survival.
Kaplan-Meier survival graphs for CXCL12 H scores (A), high versus low CXCL12 (0-145 and 145-300) (B) 
and good (negative and high) versus bad (low and moderate) CXCL12 expression (C). 
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P=0.008 P=0.013 
P=0.003 
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.	%	 CXCR4 expression in colorectal cancer tissue: correlation with survival. 
Kaplan-Meier survival graphs for CXCR4 H scores (A) and high versus low CXCR4 expression (0-70 and 70-300) (B) and 
high and low CXCL12 expression versus high and low CXCR4 expression (C).  
                                                                                                                       









P=0.274 
P=0.046 
P=0.882 
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6.2.5 Relationship between CXCL12 and CXCR4 expression and standard 
clinicopathological variables. 
 
The relationship between CXCL12 and CXCR4 expression within colorectal tumours and 
standard clinicopathological variables was measured using the Pearson χ
2
 test. Expression of 
CXCL12 was significantly associated with Duke’s stage (p=0.021), TNM stage (p=0.037), 
nodal status (p=0.007; distant metastases (p=0.025), TRAIL expression (p=0.013), BCL2 loss 
(p=0.05) and VEGFa expression (p=0.045). CXCR4 was not significantly correlated with any 
clinicopathological variables, with the exception of VEGFc (p=0.017) (.	%). 
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Variable CXCL12 CXCR4 
Histological type 0.672 0.108 
Histological grade 0.129 0.359 
Site 0.939 0.942 
Duke’s stage 0.021 0.298 
TNM stage 0.037 0.415 
Nodal status 0.007 0.694 
Distant metastases 0.025 0.385 
Extramural invasion 0.592 0.734 
P53 0.551 0.316 
Ki67 0.185 0.137 
Bcl2 0.05 0.618 
TRAIL-R2 0.013 0.527 
pAKT 0.119 0.013 
pERK 0.436 0.403 
VEGFa 0.045 0.517 
VEGFc 0.065 0.017 

 .	%. Univariate analysis of CXCL12 and CXCR4 expression in correlation with standard 
clinicopathological variables using the Χ
2
 test. Values <0.05 are accepted to be significant. 
 





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6.2.6 Multivariate analysis of CXCL12 and CXCR4 expression and standard 
clinicopathological variables 
 
In order to determine the relative influence of CXCL12 and CXCR4 alongside other patient 
and tumour variables known to affect prognosis, a multivariate analysis was performed using 
the Cox proportional hazards model. The variables included were those that have been shown 
to be significantly related to DSS on univariate analysis (extramural vascular invasion and 
TNM stage). In this model, extramural vascular invasion (p<0.001) and TNM stage 
(p=0.005) were seen to retain independent prognostic significance (.	9.). Expression of 
CXCL12 by tumour cells was also seen to be an independent prognostic marker (CI 95% 
1.017-2.796, p=0.043). Expression of CXCR4 by tumour cells was not seen to be an 
independent of extramural vascular invasion and TNM, as expected (CI 95% 0.693-2.601, 
p=0.383).  
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





















.	9	Cox multivariate regression analysis of variables in relation to disease specific survival.
The Cox proportional-hazards model was used for multivariate analysis in order to determine the relative risk 
and independent significance of individual factors including CXCL12 and CXCR4 expression. In all cases p-
values < 0.05 were considered as statistically significant. 




 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 	 P-VALUE 
Lower Upper 
TNM stage 
 1 1      <0.001 
 2 2.003 0.714 5.618 
 3 3.948 1.475 10.563 
 4 25.038 8.273 75.778 
Vascular invasion 
absent 1   0.005 
present 2.173 1.259 3.749 
CXCL12 
No or high expression 1   0.043 
Low or moderate expression 1.686 1.017 2.796 
CXCR4 
Low 1   0.383 
High 1.342 0.693 2.601  
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6.3 Ovarian Cancer Results 

6.3.1 Clinical and pathological data of ovarian cancer patients 
 
CXCL12 and CXCR4 expression was analysed on colorectal cancer tissue and now assessed 
in a cohort of ovarian cancer samples. In the current cohort of ovarian cancer patients, the 
mean age at diagnosis was 61 years (range, 24-90). Using the current Surveillance, 
Epidemiology, and End Results (SEER) Program age categorization system, 59% of the 
patients were in group 3 (>60 years at diagnosis), 40% were 30 to 60 years at diagnosis, and 
only 2 of 357 were <30 years. Serous cystadenocarcinoma was the commonest histologic 
type (49%) followed by undifferentiated (15%), endometrioid (12%), mucinous 
cystadenocarcinoma (10%), clear cell (7%), and other types (7%). All patients were treated 
surgically, of which 42% had their masses optimally debulked with no macroscopic disease 
left. Clinicopathologic staging showed that the majority of patients (50%) were stage III 
followed by 27% in stage I, 11% in stage IV, and 11% in stage III. When histologic grading 
was applicable, almost two thirds of the tumours were poorly differentiated (grade 3). 
Twenty-two percent were moderately differentiated, and only 11 were deemed well 
differentiated. All patients' characteristics are summarised in .	.. 
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Variable Categories Frequency of 
total cohort (%) 
Frequency of 
CXCL12 stained 
cohort (%) 
n=289 
Frequency of 
CXCR4 
stained 
cohort (%) 
n=241 
SEER age 
characteristics 
(n=357) 
<30 yrs at diagnosis 
30-60 yrs at diagnosis 
>60 yrs at diagnosis 
2 (1) 
143 (40) 
212 (59) 
2(1) 
112 (39) 
172 (60)  
1 (1) 
92 (38) 
146 (61) 
Macroscopic residual  Absent 143(42) 116 (42) 95 (41) 
disease (n=348) Present 201(58) 161 (58) 136 (59) 
Tumour Grade  Well differentiated (3) 225 (63) 177 (60) 152 (63) 
 Moderately  
differentiated (2) 
73 (20) 62 (22) 51 (21) 
 Poorly differentiated  (1) 39 (11) 34 (12) 28 (12) 
 Unknown 23 (6) 16 (6) 10 (4) 
Tumour FIGO Stage  I 95 (26) 77 (27) 62 (26) 
 II 38 (11) 32 (11) 27 (11) 
 III 175 (49) 141 (49) 118 (49) 
 IV 40 (11) 30 (10) 26 (11) 
 Unknown 12 (3) 9 (3) 8 (3) 
Histological Type  Serous 
Cystoadenocarcinoma 
178 (49) 148 (51) 128 (53) 
Mucinous 
Cystoadenocarcinoma 
35 (10) 29 (10) 22 (9) 
Endometrioid 42 (12) 35 (12) 30 (12) 
Clear cell 25 (7) 20 (7) 18 (8) 
Undifferentiated 54 (15) 39 (14) 31 (13) 
Others 24 (7) 18 (7) 11 (5) 
Adjuvant therapy 
(n=356) 
No 101 (29) 78 (28) 67 (28) 
Yes 249 (71) 204 (72) 168 (72) 

.	.. Clinicopathological variables for the patient cohort (n = 360) and cores stained for both CXCL12 
(289) and CXCR4 (n=241).










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6.3.2 CXCL12 expression in ovarian cancer tissue 
 
Analysis of CXCL12 was possible in 289 of the total 360 cores (80%) with the remainder not 
available on the cut slide, being lost during antigen retrieval or not demonstrating viable 
tumour cells in the core. Due to the loss of cores, the clinicopathological data for the 289 
samples was assessed to confirm that the stained cohort represented the original cohort 
(.	.). CXCL12 staining was seen in the cytoplasm tumour cells (.	93	Of the 
289 samples, 112 (31%) were negative for CXCL12 in tumour cells with the majority of 
tumours having negative or low CXCL12 expression making up 67% of the cohort 
collectively. Cut –points to divide both tumours into low, moderate and high expression of 
CXCL12 were determined using the X-tile program (Yale University, CT, USA). This 
provided low/moderate/high groups of H Score 0-3 (low), 3-90 (moderate) and 90-300 (high) 
for tumour CXCL12 expression  representing 39%, 41% and 20% respectively. When the X-
tile program was used to divide the cohort into 2 groups: low/high groups of H Score 0-10 
(low) and 10-300 (high) for tumour CXCL12 expression represented 55% and 45% 
respectively. 















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Photomicrographs of ovarian tissue microarray cores immunohistochemically stained for CXCL12. The level of 
expression ranged from strong (i) to moderate (ii) to weak (iii) to negative (iv). Magnification: x20, inset x100. 
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6.3.3 CXCR4 expression in ovarian cancer tissue 
 
Analysis of CXCR4 was possible in 241 of the total 360 cores (67%) with the remainder not 
available on the cut slide, being lost during antigen retrieval or not demonstrating viable 
tumour cells in the core. Due to the loss of cores, the clinicopathological data for the 241 
samples was assessed to confirm that the stained cohort represented the original cohort 
(.	.). CXCR4 staining was seen in the nucleus of tumour cells (.	.). Of the 
241 samples, none were negative for CXCR4 in tumour cells with the majority of tumours 
having moderate CXCR4 expression making up 49% of the cohort. Cut –points to divide 
tumours into low, moderate and high expression of CXCL12 were determined using the X-
tile program (Yale University, CT, USA). This provided low/moderate/high groups of H 
Score 0-60 (low), 60-115 (moderate) and 115-300 (high) for tumour CXCL12 expression 
representing 11%, 20% and 69% respectively. When the X-tile program was used to divide 
the cohort into 2 groups: low/high groups of H Score 0-105 (low) and 105-300 (high) for 
tumour CXCL12 expression represented 27% and 73% respectively. 













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
Photomicrographs of ovarian TMA cores immunohistochemically stained for CXCR4. The level of expression 
ranged from strong (i) to moderate (ii) to weak (iii). Magnification: x20, inset x400. 
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6.3.4 CXCL12 and CXCR4 expression in ovarian cancer tissue: correlation with 
survival 
 
Kaplan-Meier plots were used to analyse the relationship between expression levels of 
CXCL12 and CXCR4 and disease-specific survival.   .	04 demonstrates that 
increasing expression of CXCL12 within tumours significantly reduces patient survival 
(p=0.026). Patients with low CXCL12 expression lived a mean of 75.9 months, patients with 
moderate expression a mean of 59.1 months and patients with high expression 24.2 months 
(.	0). .	06 demonstrates that patients with a higher level of tumour associated 
CXCL12 expression have a significantly reduced mean survival (p=0.019; 53 months) than 
those with a lower level of CXCL12 expression (73 months).  
When comparing differing levels of CXCR4 (.	(4) expression with disease specific 
survival, no difference was found (p=0.712). Patients with low CXCR4 expression lived a 
mean of 47.5 months, patients with moderate expression a mean of 74.6 months and patients 
with high expression 58.1 months ( .	(). When comparing low and high levels of 
CXCR4 ( .	(6) expression with disease specific survival no difference was found 
(p=0.525). There was no linear correlation between CXCL12 and CXCR4 expression 
(p=0.409). When tumour cell expression of high and low CXCL12 was compared to high and 
low CXCR4 expression ( .	(#), although no overall significant effect was seen on 
survival, patients that showed low expression of CXCL12 and low CXCR4, 32 of 235 
patients (32%) had the best survival of 82 months, with patients with high CXCL12 and low 
CXCR4 displaying the worst survival, 14 of 235 patients (33%) and a survival time of only 
39 months. Patients with high tumour CXCL12 and high tumour CXCR4 expression or 
patients with low tumour CXCL12 and high tumour CXCR4 expression had a similar 
survival of 66 and 60 months respectively. Overall there was no linear correlation between 
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CXCL12 and CXCR4 and expression patterns showed no significant effects on survival of 
ovarian cancer patients (p=0.173). 
 

 
 
CXCL12 Expression 
MEAN SURVIVAL TIME (MONTHS) 
Estimate 
(months) 
95% Confidence Interval 
Lower Bound Upper Bound 
Low  75.9 59.1 92.6 
Moderate 59.1 45.5 72.6 
High  24.2 13.9 34.5 
Overall 66.6 55.3 77.8 

.	0Mean survival time in relation to CXCL12 H score expression. 
 
 
 
CXCR4 Expression 
MEAN SURVIVAL TIME (MONTHS) 
Estimate 
(months) 
95% Confidence Interval 
Lower Bound Upper Bound 
Low  47.5 22.8 72.1 
Moderate 74.6 45.6 103.7 
High  58.1 46.5 69.7 
Overall 65.1 53.1 77.1 
 
.	(Mean survival time in relation to CXCR4 H score expression. 
















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Kaplan-Meier survival graphs for graded CXCL12 expression (low (0-3) moderate (3-90) and high (90-300)) 
(A) and low versus high CXCL12 expression (low (0-10) and high (10-300)) (B).  

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P=0.019 
 
P=0.712 
 
P=0.173 
 
P=0.026 
 
P=0.525 
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Kaplan-Meier survival graphs for graded 
CXCR4 expression, (low (0-60) moderate (60-
115) and high (115-300) (A) and low versus 
high CXCR4 expression (low (0-105) and (105-
300)) (B). Kaplan-Meier survival graphs for 
graded high and low CXCL12 expression in 
combination with high and low CXCR4 
expression (C). 
 
 
P=0.019 
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6.3.5 CXCL12 and CXCR4 expression in ovarian cancer tissue: correlation with 
clinicopathological features. 
 
The relationship between CXCL12 and CXCR4 expression within ovarian tumours and 
standard clinicopathological variables was measured using the Pearson χ
2
 test. Expression of 
both CXCL12 and CXCR4 was not significantly correlated with any clinicopathological 
variables, including stage (.	-). 
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Variable Χ
2
 test (p value) 
CXCL12 CXCR4 
Tumour FIGO Stage 0.184 0.603 
Tumour Grade 0.865 0.239 
Macroscopic Residual Disease 0.769 0.141 
Adjuvant Therapy 0.144 0.704 
Histological type 0.347 0.658 


 .	-.Univariate analysis of  CXCL12 and CXCR4 expression in correlation with standard clinicopathological 
variables using the Χ
2
 test. Values <0.05 are accepted to be significant


















  
202 
 
6.3.6 Multivariate analysis of CXCL12 and CXCR4 expression with standard 
clinicopathological variables. 
 
In order to determine the relative influence of CXCL12 and CXCR4 and other patient and 
tumour variables known to affect prognosis, a multivariate analysis was performed using the 
Cox proportional hazards model. The variables included were those that have been shown to 
be significantly related to DSS on univariate analysis (macroscopic residual, adjuvant therapy 
and FIGO stage). In this model, macroscopic residual disease (p<0.0001), adjuvant therapy 
(p=0.001) and FIGO stage (p<0.0001) were seen to retain independent prognostic significance 
(.	@). Expression of CXCL12 by ovarian tumours was also seen to be an independent 
prognostic marker (p=0.016). Expression of CXCR4 by ovarian tumours was not seen to be 
independent of macroscopic residual, adjuvant therapy and FIGO stage, as expected (p=0.364; 
 .	).  
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Exp(B) 95.0% CI for Exp(B) p-value 
Lower Upper 
FIGO stage 
Stage 1 1   <0.001 
Stage 2 2.483 1.370 4.501 
Stage 3 5.639 3.235 9.829 
Stage 4 6.047 3.168 11.543 
Macroscopic residual disease 
Absent 1   <0.001 
Present 2.002 1.374 2.917 
Adjuvant therapy 
No 1   <0.001 
Yes 0.493 0.331 0.735 
CXCL12 
Low 1   0.016 
Moderate 1.215 0.892 1.655  
High 1.684 1.180 2.404  
 
.	@	Cox multivariate regression model for CXCL12 expression. CI = confidence intervals. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

.		Cox multivariate regression model for CXCR4 expression. CI = confidence intervals.
 


 
  
Exp(B) 95.0% CI for Exp(B) P-VALUE 
Lower Upper 
FIGO stage 
Stage 1 1     <0.001 
Stage 2 2.633 1.391 4.986 
Stage 3 5.638 3.120 10.189 
Stage 4 5.698 2.878 11.281 
Macroscopic residual disease 
Absent 1   0.002 
Present 1.928 1.284 2.894 
Adjuvant therapy 
No 1   <0.001 
Yes 0.471 0.309 0.719 
CXCR4 
Low 1   0.364 
Moderate 0.667 0.381 1.166  
High 0.796 0.505 1.257  
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6.4 Discussion 
 
The chemokine stromal-derived factor (CXCL12) plays complex roles in tumour 
pathogenesis by either promoting tumour growth, enhancing tumour angiogenesis, 
suppressing tumour immunity  and participating in tumour metastasis via expression of 
CXCR4 [162,414] or by inhibiting metastases by inducing anoikis [411]. However, research 
to determine the source and regulation of CXCL12 expression within the tumour 
microenvironment is limited. Stroma and tumour cells,
 
two main components of the tumour 
microenvironment, can produce CXCL12. CXCL12 regulation within breast and ovarian 
tumours has been attributed to estradiol
 
which activates estrogen receptors and induces the 
production of CXCL12
 
by tumour cells [415]. Hypoxia has also been shown to induce 
CXCL12 expression by primary human ovarian tumour cells where Hypoxia-inducible
 
factor 
(HIF)-1 is the central mediator [186] .  
The CXCL12/CXCR4 axis in human cancers is now becoming an important target
 
for the 
development of novel anti-cancer therapies. In this
 
study, Tissue microarray technology was 
used to assess the expression of CXCL12 and CXCR4 in relation to clinic pathological 
characteristics and overall survival of 292 colorectal and 289 ovarian cancer patients. 

6.4.1 Discussion for Colorectal data  
 
Colorectal cancer (CRC)  accounts for more than 9% of all new cancer cases [413] and is also 
the second most common cause of cancer-related deaths. Despite the recent advances in 
treating cancer, the 5-year survival rate from CRC remains at 50% and 10% for TNM stages 
III and IV respectively. Currently, four treatment options for CRC exist, including surgery, 
chemotherapy, radiotherapy and monoclonal antibody therapy.  
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In this
 
study, Tissue microarray technology was used to assess the expression of CXCL12 and 
CXCR4 in relation to clinicopathology and overall survival of 292 colorectal cancer patients. 
CXCL12 and CXCR4 expression was seen in 93% and 78% of patient samples respectively. 
This study demonstrated  in colorectal cancer that the level of CXCL12 impacted on patient 
survival with patients whose tumours showed no or high CXCL12 expression showing 
reduced disease specific survival (p=0.013). There was a 20 month survival advantage, for 
patients whose tumours lacked or had high CXCL12 expression, when compared to patients 
whose tumours expressed low or moderate levels of this chemokine. 
 
 In agreement with previous studies [160,416], expression of CXCL12 correlated with lymph 
node metastases, tumour stage and survival. However, in our study we show that in a 
multivariate analysis it was shown to confer independent prognostic value. Low or moderate 
expression of CXCL12 correlated with expression of Bcl2 which is consistent with its role in 
anoikis via the intrinsic Bcl-2 pathway [411]. It also correlated with expression of VEGFa 
which is consistent with its role in angiogeneisis. Hypoxia has also been shown to induce 
CXCL12 expression by primary human ovarian tumour cells where Hypoxia-inducible
 
factor 
is the central mediator [186]. Kryczek et al studied CXCL12 in association with VEGF and 
found hypoxia simultaneously induces tumoral CXCL12 and VEGF production [186]. 
Hypoxia-induced signals would be an important factor for initiating and maintaining an 
active synergistic angiogeneic pathway mediated by CXCL12 and VEGF.  
 
In contrast to CXCL12, the expression of CXCR4 within our study, had no significant effect 
on patient survival (p=0.525) or correlation with any other clinicopathological variable. This 
is in contrast with another studies which showed that CXCR4 expression correlated with 
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survival in colorectal cancer patients [410].  This may be a reflection of the differing antigen 
retrieval methods showing greater or less sensitivity of detection. 
 
A study by Yoshitake et al within a sample of 60 colorectal cancer patients indicated that 
nuclear CXCR4 predicted lymph node metastasis in colorectal cancer [160]. Within this 
study, 78% of colorectal cancer patients showed CXCR4 positive tumours, of which 61% 
nuclear CXCR4 expression correlating with significantly more lymph node metastasis than 
those with cytomembrane expression. Another study showed CXCR4 is associated with the 
progression of colorectal carcinoma where high CXCR4 expression is associated with 
metastasis [417]. CXCR4 was positive in 39 cancer tissue specimens (73.6%) and its high 
expression rate (in > 50% of cells) was 45.3%. High CXCR4 expression was associated with 
the vascular and lymphatic vessel invasions (P<0.01), this is in agreement with our 
observation that expression of CXCR4 correlated with VEGF-C expression. Wang et al 
analysed expression of CXCR4 in 388 colorectal clinical samples and showed that CXCL12 
affected the expression of CXCR4 in colon cancer cells [418]. The frequency of cytoplasmic 
and nuclear expression of CXCR4 in colorectal cancers was 35.6% and 36.9%, respectively. 
Nuclear but not cytoplasmic expression of CXCR4 was associated with advanced CRC 
(p<0.001) and lymphovascular invasion. However, as shown in data presented here, in 
multivariate analysis, nuclear expression of CXCR4 did not correlate with patients' outcome. 
Wang et al also showed that in an in vitro study CXCL12 was used to stimulate three 
colorectal carcinoma lines and led to enhanced the CXCR4 nuclear expression. Therefore, the 
explanation for the percentage of tumours expressing CXCR4 between studies could be 
explained by the relative levels of CXCL12 produced by the tumour. Here, with 94% of 
tumours expressing CXCL12 this may result in 98% of tumours expressing CXCR4. One 
explanation for the differences in the effect of CXCR4 on survival between the studies may 
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be the localisation of CXCR4 within the cell. CXCR4 expression is not confined to the cell
 
surface and the CXCR4 receptor may be internal until activation/signalling occurs whereby 
the receptor becomes present at the cell surface and allows interaction to occur with 
CXCL12, activating signalling cascades [374]. Recent studies have shown that 5T4 is one of 
several proteins that are required for functional cell surface expression of CXCR4 in 
differentiating murine embryonic stem cells [419]. As 5T4 is also over-expressed in 
colorectal cancer and is a target for both vaccine and monoclonal antibody therapy it may 
play a similar role in this disease [420]. In our study 100% of the tumours showed nuclear 
staining with 69% strong nuclear and cytoplasmic staining. While in the Yoshitake et al study 
CXCR4 expression was seen either within the nucleus or within the cytoplasm of tumours the 
latter being associated with survival [160].  
A further concern is that CXCL12 can also been shown to bind to CXCR7 [421]. Although it 
is unclear how this receptor signals it has been shown to heterodimerise with CXCR4 and 
alter both the kinetics and dynamics of CXCR4 responsiveness to CXCL12 [422]. Future 
studies should also look for expression of this receptor in colorectal cancer.  
 
 As the CXCR4/CXCL12 pathway has been shown to be involved in the metastasis of tumour 
cells, this has important implications for the survival of colorectal cancer patients where the 
main cause of death is attributed to metastasis of the cancer.  Indeed, in breast cancer high 
levels of expression of CXCL12 were shown in organs representing the first destination for 
breast cancer metastasis [164]. However, we have demonstrated high levels of CXCL12 
expression at the primary site of the tumour to be involved in poor prognosis. This raises the 
question whether chemokines may not just work at target organs but could also be involved 
in the departure of cells from the primary tumours. Indeed, high levels of CXCL12 have been 
shown to be fugetactic to lymphocytes [376], and a B16 melanoma engineered to produce 
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CXCL12 at high levels was found to be chemo-repellent to antigen specific T cells [377]. 
Alternatively, CXCL12 stimulates the production of metalloproteases which are important in 
local tumour invasion [423,424].  In contrast, complete loss of CXCL12 within tumours also 
conferred a poor prognosis on patients. This may reflect the protective role of CXCL12 in 
protecting cells from anoikis or apoptosis triggered by a loss of cellular adhesion to the 
underlying extracellular matrix, a vital role in tumour metastases. As CXCL12 is 
constitutively expressed by colon and is down regulated in adenomas perhaps this initially 
protects tumour cells from anoikis but ultimately the benefits of the tumour promoting 
aspects of CXCL12 make it an advantage to secrete it in moderate amounts. 
 
6.4.2 Discussion for Ovarian data  
 
Ovarian cancer is the fifth leading cause of cancer among women and the leading cause of 
mortality from gynaecologic cancers [425]. Human epithelial ovarian cancer constitutes 
approximately 90% of ovarian malignancies and is thought to arise from the ovarian surface 
epithelium. It can be classified into 4 major categories: serous, mucinous, endometriod and 
clear cell. Each subtype has different clinical, molecular and biological characteristics and 
may represent different diseases [426]. However, the main cause of treatment failure and 
death is metastases. This can be locally within the peritoneum or can be too distant sites such 
as liver and lung. It has been suggested that chemokines involved in lymphocyte homing and 
migration can also be used by tumour cells to metastasise.  In a study of expression 14 
chemokine receptors, only CXCR4 was expressed within ovarian cancer cell lines [427]. The 
only CXCR4 ligand, CXCL12, induced migration, integrin expression, proliferation, and 
invasion. CXCL12 was abundantly expressed within 15/18 ovarian cancer biopsies [428] and 
within ascites from 63 ovarian cancer patients [373].  
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In this
 
study, tissue microarray technology was used to assess the expression of CXCL12 and 
CXCR4 in relation to clinic pathological characteristics and overall survival of 289 ovarian 
cancer patients. This study has the advantage of over 14 years of patient follow up.  CXCL12 
and CXCR4 expression was seen in 69% and 100% of patient samples respectively. This 
study demonstrated  in ovarian cancer that the level of CXCL12 impacted on patient survival 
with patients whose tumours showed moderate or high CXCL12 expression showing reduced 
disease specific survival (p=0.026). There was a 51 month survival advantage, for patients 
whose tumours lacked CXCL12 expression, when compared to patients whose tumours 
expressed high levels of this chemokine. Furthermore, CXCL12 expression was an 
independent predictor of poor survival and was equally expressed by all ovarian tumour 
types. This data contrasts with a smaller immunohistochemical study by Jiang et al using 80 
patients of with a shorter follow up (median 37 months). CXCL12 was detected in 40/44 
(91% of patients) however in this study CXCL12 did not correlate with disease survival 
[410].  This contrasted with our study which analysed 289 patients with a median follow up 
of 167 months (range 95-335 months).  
 
In contrast to CXCL12, the expression of CXCR4 within our study, had no significant effect 
on patient survival (p=0.712) or correlation with any other clinicopathological variable. This 
is in contrast with other studies which showed that CXCR4 expression was an independent 
prognostic factor for poor survival in epithelial ovarian cancer patients [410].  Both these 
studies used lower numbers of patients with less follow up than our study. One explanation 
for the differences in the effect of CXCR4 on survival between the studies may be the 
localisation of CXCR4 within the cell. CXCR4 expression is not confined to the cell
 
surface 
and the CXCR4 receptor may be internal until activation/signalling occurs whereby the 
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receptor becomes present at the cell surface and allows interaction to occur with CXCL12, 
activating signalling cascades [374]. In our study 100% of the tumours showed nuclear 
staining with 69% strong nuclear and cytoplasmic staining. While in the Jiang study CXCR4 
expression was only seen within the cytoplasm of 59% of patients. This may be a reflection 
of the differing antigen retrieval methods showing greater or less sensitivity of detection. 
 
CXCL12 regulation within breast and ovarian tumours has been attributed to estradiol
 
which 
activates oestrogen receptors and induces the production of CXCL12
 
by tumour cells [415]. 
Over 70% of ovarian and breast cancers over-express the oestrogen receptor.  The binding of 
CXCL12 to its receptor CXCR4 is thought to induce proliferation of tumour cells.   In this 
way CXCL12 mediates the cancer cell proliferation action of oestrogen and may be one of 
the reasons for the poor prognosis of patients with high CXCL12 [415].  
 
6.4.3 Overall conclusions 
 
CXCL12 has contradictory roles in immune responses. During homeostasis, tissues 
constitutively express CXCL12 promotes leukocyte extravasation and immune surveillance. 
However, CXCL12 is not produced within normal tissue and it is only induced by pro-
inflammatory mediators such as IL-1 and TNF-α and during hypoxia [186]. Under conditions 
of inflammation it has been shown that CXCL12 can down regulating immune responses 
[429]. It can polarise helper T cells, macrophages and plasmacytoid dendritic cells to secrete 
the immunoregulatory cytokine IL-10 [387,388]. CXCL12 can also promote TNF-α 
expression which can active NK-κB and act back on tumour cells to induce cell surface 
CXCR4 expression. In effect, TNF-α, can amplify the CXCL12 signal [375] and therefore 
suggests that neutralising TNF-α, CXCL12 [429], antagonising CXCR4 [430,431,432,433] or 
inhibiting NK-κB [434] may be effective therapies for cancer.  
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In conclusion, CXCL12 expression levels within colorectal and ovarian tumours impacts on 
survival within patients where increasing CXCL12 expression leads to decreased disease 
specific survival. Expression of CXCL12 was found to be an independent prognostic 
indicator in a large series of patients with all stages of ovarian cancer and colorectal cancer. 
In addition high CXCL12 expression only occurs in a small proportion of ovarian cancers but 
may denote a specific group in which targeting CXCL12 expression as a therapy may be an 
effective target. Chemokine expression profiles are becoming more widely recognised for 
their role in tumour progression and the CXCL12-CXCR4 signalling pathway is becoming an 
attractive target for anti-tumour immunotherapy. CXCR4 has been widely accepted as an 
efficient target for reducing tumour metastasis and antibodies directed against CXCR4 have 
been reported to have effects against both HIV-1 infection and cancer cell migration [435]. A 
small peptide antagonist of CXCR4 has been tested on ovarian cancer cells and shown to 
induce cell death by mitotic catastrophe [436]. CTCE-9908 inhibited ovarian cancer cell 
migration to CXCL12 and caused cell death in CXCR4 positive cells. CTCE-9908 did not 
cause apoptosis or cellular senescence, but induced multi-nucleation, G2-M arrest, and 
abnormal mitosis in ovarian cancer cells.  
 
This study has shown that expression of CXCL12 is an independent prognostic indicator of 
poor survival in ovarian cancer. Furthermore, it identifies a group of ovarian cancer patients 
(20%) and colorectal cancer patients (22%) with high CXCL12 expression in which targeting 
CXCL12/CXCR4 axis may be an effective target. In addition with respect to colorectal 
cancer patients this study has also shown that no or high expression of CXCL12 is an 
independent prognostic indicator of poor survival. Due to the role of CXCL12, at high levels, 
in tumour cell activation, proliferation and migration and in immune cell infiltration targeting 
both CXCR4 and CXCL12 would potentially have synergistic effects on patient survival.  
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Chapter 7: Final Discussion 
 
T cell infiltration into tumours is essential for tumour antigen recognition and tumour cell 
elimination. The aim of this study was to develop a better understanding of T cell infiltration 
into tumours, focusing on two opposing arms of an immune response, anti-tumour CD8 T 
cells and Regulatory T cells. Activated CD4 Th cells are also of importance but could not be 
studied due to the time constraints of the project. The effect of T cell signalling at the 
immunological synapse following interactions between T cells and APCs presenting cognate 
antigen have been well studied. The endothelium is neither a stereotypical APC nor simply a 
passive filter barrier for non-cognate infiltrating T cells. The endothelium can actively 
influence the development of an inflammatory response depending on the functional state of 
both the endothelium and interacting T cells (resting versus recently activated T cells) and the 
type of interactions (cognate versus non-cognate). The hypothesis was that recognition of 
antigens presented in the context of MHC molecules by endothelium aids T cell 
transmigration and hence infiltration into tissues, including into tumours. 
 
The data here highlights the complexity of the tumour microenvironment and potential 
downstream effects on T cell infiltration and tumour metastasis. The presence of CD8 T cells 
within colorectal tumours correlated with improved patient survival. Both CD8 T cells and 
CD4CD25FOXP3 regulatory T cells showed enhanced transmigration across endothelium 
and hence entry into tissues following cognate antigen recognition. Chemokine expression 
profiles, in particular CXCL12, also play a role in this antigen-specific transmigration via 
activation of synergistic signalling pathways but in addition affect the metastatic  potential of 
tumours via CXCR4 expression on the tumours themselves. The interplay between 
expression levels of CXCL12, tumour metastasis and T cell infiltration are summarised in 
0		 
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CD8 infiltration into tumours, as shown here in colorectal tumours, is a good prognostic 
marker for survival. High avidity T cells, recognising and responding to lower amounts of 
cognate antigen, have superior
 
function over low-avidity cells in CD8 CTL-mediated 
immunity
 
against tumours where antigen presentation may be impaired [306]. Therefore, 
there is an advantage of selective/enhanced recruitment of high avidity antigen specific T 
cells into tumours via recognition of cognate antigen on the endothelium. These high avidity 
CTLs recognising low doses of tumour derived antigen on the endothelium would potentially 
be ‘fast-tracked’ into the tumour allowing secondary recognition of the same tumour antigen 
on the tumour cells themselves.  
 
The present study has demonstrated that CD8 antigen-specific transmigration is important for 
infiltration into tumours in response to tumour antigens presented by the endothelium. One 
explanation for the effect of cognate recognition on transmigration is that TCR ligation 
induces a high affinity conformation of T cell surface integrins. TCR engagement has been 
shown to induce high affinity conformational changes in integrins via signalling through 
TCR/CD8 [437,438]. In addition, T cells transiently express CD40 ligand upon TCR 
engagement [439,440]. Upregulation of CD40 ligand following TCR engagement by the EC 
might in turn lead to the ligation of the CD40 on the EC and consequently enhance antigen-
specific T-cell recruitment. CD40 ligation on endothelium leads to upregulation of cell 
adhesion molecules by the endothelium, production of inflammatory cytokines and 
overexpression of VEGF [441,442]. 
 
Transmigration of natural Tregs in response to peptides presented in the context of MHC 
class II molecules requires endothelial activation and subsequent upregulation of MHC class 
II molecules. The data here also suggests that the chemokine CXCL12, in combination with 
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inflammatory cytokines, was also a requirement for antigen-specific transmigration. Analysis 
of CXCL12 expression within colorectal and ovarian tumours has shown increasing levels of 
CXCL12 leads to a poor prognosis and reduced patient survival. Previous research suggests 
that at high levels CXCL12 expression aids tumour cell metastasis, a murine model of 
established extrahepatic colorectal metastasis has shown that CXCL12 promotes tumour 
growth of established extrahepatic metastasis in vivo due to angiogenesis-dependent 
induction of tumour cell proliferation and inhibition of apoptotic cell death [412].  Indeed, at 
high levels, CXCL12 exerts many effects on the tumour microenvironment. CXCL12 and 
CXCR4 expression plays a role in tumour cell metastasis in many tumour types. Regulatory 
T cell activation has been shown to up regulate CXCR4
 
expression and enabling them to 
migrate to the bone marrow in
 
a CXCL12-dependent manner [443], suggesting that bone 
marrow
 
could serve as a functional reservoir for activated Tregs where high levels may 
provide an immune suppressive environment to facilitate bone
 
marrow metastasis. High 
levels of CXCL12 expression have been shown to cause fugetaxis of migrating cells [376] 
and could be used as an immune escape mechanism within tumour where increasing 
concentrations of CXCL12, caused by other factors as previously mentioned, can have an 
additional advantage to the tumour of repelling infiltrating anti-tumour T cells [377]. Due to 
the influence of CXCL12 on Treg transmigration, T cell infiltration into and CXCL12 
expression by tumours was assessed in colorectal tumour samples. Whereas higher CD8 T 
cell infiltration correlated with improved patient survival, FOXP3+ cell infiltration had no 
significant effect and in addition the data showed no significant correlation between either 
CD8 or Treg (FOXP3+) T cell infiltration into tumours and CXCL12 expression by tumour 
cells (data not shown). No correlation between CXCL12 and CD8 T cell infiltration into 
colorectal tumours could be due to antigen-specific CD8 T cell transmigration occurring in 
the absence of chemokines. In order to further investigate the lack of correlation between 
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FOXP3+ T cell infiltration with CXCL12 it would be interesting to look at MHC class II 
expression on the tumour endothelium. Even if CXCL12 was present, without MHC class II 
expression no antigen-specific Treg infiltration would be expected. Another consideration, as 
mentioned previously, is the use of FOXP3 as a marker for regulatory T cells.  
 
TRP-2 specific transmigration was seen for memory subsets of TRP-2 specific CD8 T cells 
and therefore the major issue to be resolved is the interaction between effector CTLs in the 
blood and recognition of cognate peptide on endothelium. Our results show that even under 
little/no inflammation, effector CTLs are able to kill endothelial cells, so why do we not see 
massive destruction to the endothelium in vivo. A simple explanation could lie in the markers 
used to denote effector populations. Here loss of memory markers such as CD62L and 
CD127 are used where perhaps upregulation of ‘effector’ markers would be more 
appropriate. Perforin, granzyme B, and FasL are cytotoxic molecules used by CD8 T 
lymphocytes and natural killer (NK) cells to induce apoptosis [444]. A study looking at these 
activation markers on T cells within 10 healthy patients and emphysema patients showed that 
within the peripheral blood of healthy non-smoking individuals the average percentage of 
CD8 T cells expressing granzyme B was 40% and perforin 60% [445], indicating primed and 
activated CD8 T cell populations do exist in the peripheral blood. Therefore, the mechanism 
for recognition of cognate antigen on endothelium with lack of killing in vivo would have to 
occur at the immunological synapse of the EC: T cell.  
 
Interestingly, TCR ligation upon antigen recognition on the endothelium could enhance 
endothelial cell survival. Chromium release assays are carried out with target endothelial 
cells in suspension and therefore when in a monolayer or in contact with other parenchymal 
cells endothelial cells could have a survival advantage, escaping cytotoxicity. Receptor 
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activator of NFκB (RANK) is highly expressed in endothelial cells of normal adult arterial 
blood vessels, which are not actively involved in angiogenesis and vasculogenesis [446]. The 
ligand for RANK, RANKL molecule is important in bone metabolism. This natural and 
necessary surface-bound molecule found on osteoblasts serves to activate osteoclasts, which 
are the cells involved in bone resorption [447]. However, RANKL is secreted by arterial 
smooth muscle cells and can act in a paracrine manner on RANK expressed on endothelial 
cells and RANKL expression has also been shown on T helper cells [448] where T cell 
activation was reported to induce expression of the RANKL gene [449]. The RANKL protein 
was shown to activate anti-apoptotic kinase PI 3-kinase AKT/ through a signalling complex 
involving SRC kinase and tumour necrosis factor receptor-associated factor (TRAF) 6. T 
helper cells within peripheral blood may therefore be essential in providing RANKL survival 
signals to the endothelium to prevent CD8 T cell cytotoxicity. TCR signalling between T 
cells and ECs, while activating signalling pathways to prepare T cells for transmigration, may 
simultaneously inhibit apoptosis of endothelial cells.  
 
The observation that Tregs but not CD8 T cells require additional activation via chemokines 
to undergo antigen-specific transmigration suggests a threshold for TCR activation is 
required in order to facilitate transmigration across endothelium. Further evidence for this 
comes from the data showing that effector memory TRP-2 specific CD8 T cells transmigrate 
more rapidly than the same cells of a central memory phenotype, potentially requiring 
additional activation prior to transmigration. Therefore, a model of antigen-specific 
transmigration involving thresholds for T cell transmigration can be suggested where the 
threshold required depends on cell type, activation state, amount of available MHC or peptide 
presented by the endothelium and additional activation signals such as chemokine gradients 
and endothelial activation via inflammatory cytokines (0	)).  
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this thesis. Antigen-specific CD8 T cell transmigration again is possible due to MHC class I 
expression, however even in the presence of MHC class II expression the threshold for TCR 
signalling on Tregs following recognition of self-peptides is not enough to allow 
transmigration in the absence of a CXCL12 gradient. The increased endothelial activation 
would also allow non-specific T cell transmigration to occur due to increased adhesion to cell 
adhesion molecules. Under conditions of increased inflammation and a CXCL12 gradient (#) 
both antigen-specific CD8 and Treg transmigration occurs as the CXCL12:CXCR4 signalling 
on Tregs synergises with TCR recognition lowering the threshold for antigen-specific 
transmigration of Tregs and subsequent down-regulation of inflammation.  
 
This model highlights that antigen-specific Treg transmigration, as mentioned previously, 
would occur temporally at a later stage in an immune response than CD8 T cells as 
endothelial activation is required for the induction of MHC class II expression. In addition, 
Tregs appear to require a higher threshold for activation/transmigration via additional 
signalling via chemokines such as CXCL12. Within tissues a higher numbers of self epitopes 
presented to Tregs would aid Treg infiltration over conventional CD8 and CD4 T cells. 
Tumoural hijacking of chemokine networks, such as CXCL12, has advantages for tumour 
cell proliferation, survival and metastasis but in addition could facilitate increased Treg 
infiltration. This could be achieved by lowering the threshold for Treg antigen-specific 
transmigration causing indirect enhanced tumour survival and maintenance of a high Treg: 
CD8 T cell ratio.  
 
T cells continuously circulate between the blood, tissues and lymphatics and this study 
focused on the interaction of T cells with endothelium in order to transmigrate into tissues. 
CD8 T cells were able to recognise TRP-2 presented on resting endothelium in the context of 
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MHC class I molecules which facilitated their transmigration across the endothelium. 
Homeostatically this antigen specific, high avidity CD8 T cell transmigration in the absence 
of or under low inflammation, involving chemokine gradients, shows rapid transmigration 
into tissues as depicted in 0	). Potentially once inside the tissue these CD8 T cells aim 
to eliminate the cause of the infection. The activation of immune responses following CD8 T 
cell recognition of tumour cells could increase inflammation or activate endothelial cells 
directly during transmigration causing upregulation of class II molecules on the endothelium. 
This in turn would lead to infiltration of Tregs recognising self-antigens presented in the 
context of these MHC class II molecules, with the ability to dampen down immune 
responses. 
 
In a tumour situation, the main role of rapid infiltration of high avidity tumour antigen 
specific CD8 T cells would be to kill tumour cells and help control tumour growth. Higher 
avidity CD8 T cells would be able to recognise lower amounts of cognate peptide presented 
by the endothelium, potentially requiring a lower threshold for transmigration across the 
endothelium and more rapidly entering tumour tissue. A model for antigen-specific 
transmigration of high and low avidity CD8 T cells is hypothesised in  0		Under 
conditions of low inflammation, with lower levels of peptide: MHC on endothelial cells there 
will be limited antigen-specific transmigration of low avidity CD8 T cells will occur (4). 
Conversely under the same conditions, high avidity CD8 T cells requiring lower amounts of 
cognate peptide an increase in antigen-specific CD8 T cell infiltration across the endothelium 
would be expected (6). Under high inflammation MHC class I expression by the endothelium 
is enhanced, increasing the amount of peptide presented to antigen-specific CD8 T cells 
resulting in both high and low avidity antigen-specific transmigration (#). 
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to upregulate MHC class II would aid antigen specific Th effector and subsequently Treg 
transmigration into the tumour tissue ultimately controlling anti-tumour responses.  
 
Tumour infiltrating lymphocytes have shown effective recognition and elimination of tumour 
cells following adoptive transfer [453]. The importance of CD4 T cells during the effectors 
phase of the anti-tumour response has been emphasised within tumour, by studies adoptively 
transferring CD4 T cells [454]. Adoptive transfer of CD4 T effectors cells combined with 
CD8 effector cells isolated from tumour draining lymph nodes has provided synergistic 
therapy for mice bearing subcutaneous, intracranial, or advanced pulmonary metastases 
[455]. In addition to augmenting IFN-γ production by CD8 T cells, CD4 T cells infiltrated 
and proliferated extensively in pulmonary tumours, while also stimulating tumour antigen–
specific CD8 T cells. CD8 T cells showed limited intra-tumoral proliferation in the absence 
of CD4 cells. This research highlights the necessity of adoptively transferred CD4 T cells in 
addition to CD8 T cells during the effector phase of immunotherapy.  
 
Although CD4 T cells are vital for high avidity CD8 T cell anti tumour responses [456], 
tumour antigen specific CD4 T cell transmigration was not assessed in this study. Future 
experiments could use the same B16 melanoma model in C57Bl mice could form a model of 
gp100 specific CD4 T cell transmigration. The gp100 protein is expressed endogenously in 
both melanoma and
 
non melanoma cells and processed for presentation of multiple
 
epitopes 
by MHC class II molecules [457]. Due to the requirement for gp100 peptide presentation by 
MHC class II molecules, endothelial activation to upregulate MHC class II would be 
expected to be required for gp100 specific transmigration as required for regulatory T cell 
transmigration. However, as with the TRP-2 specific CD8 T cells potentially the gp100 
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specific T cell may not require chemokine gradients to lower the threshold for transmigration 
as required by Tregs. 
Accurate detection of gp100 specific CD4 T cells following transmigration was not possible 
in this study as ProImmune’s Class II Ultimers™  for detecting these gp100 specific cells do 
not give as accurate results as pentamers used here for TRP-2 positive CD8 T cells. Few 
MHC class II tetramers incorporating peptides from tumours have been developed due to the 
high polymorphism of class II molecules and the low binding capacity to these peptides 
[458]. However, with new generations of class II tetramers are becoming available making it 
possible to test gp100 specific CD4 T cells transmigration. New generation MHC class II 
tetramers specific for the tumour antigen NY-ESO-1 have been developed using molecularly 
defined His-tagged peptides and isolation of folded MHC/peptide monomers by affinity 
purification  prior to tetramerization [459,460]. This technique has allowed the isolation of 
tetramers bound to ESO-speciﬁc CD4 T cells and will potentially advance the production of 
other MHC class II/peptide tetramers specific for tumour antigens.  
 
Adoptive cell therapy with autologous tumour-infiltrating lymphocytes (TIL) has shown 
promising results in metastatic melanoma patients. Disadvantages of this approach are the 
labour-intensive TIL production limiting its widespread applicability.  A phase II clinical trial 
using a new method for TIL production which includes unselected, minimally cultured, bulk 
TILs (Young-TIL) for adoptive transfer [461]. The use of Young-TIL means the treatment is 
not restricted to human leukocyte antigen (HLA)-A2 patients. The trial studied the efficacy 
and toxicity of adoptively transferred Young-TIL following lympho-depleting chemotherapy 
in 20 metastatic melanoma patients. Fifty percent of the patients achieved a measurable 
clinical response including two complete remissions and eight partial responses. The trial 
showed that lympho-depleting chemotherapy followed by transfer of short-term cultured TIL 
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mediated tumour regression in 50% of metastatic melanoma with manageable toxicity. A 
current ongoing phase II trial by Rosenberg et al uses short term cultured CD8 TILs in 
metastatic digestive tract cancers (NCI-10-C-0166). This process may have a major effect on 
cell therapy of cancer as a response was seen in 50% of the patients and perhaps this 
percentage can be further increased by combining adoptive transfer of tumour specific CD4 
alongside CD8 T cells. Interestingly, the TMA data presented here showed 40% of colorectal 
tumours showed high levels of CD8 infiltrating cells which could be the high avidity antigen-
specific T cells able to transmigrate across the tumour endothelium which would potentially 
make up the 50% of patients where TILs are able to be isolated and cultured for subsequent 
adoptive transfer.  
More recently Xu et. al. has further modified the adoptive transfer technique to include CpG 
dinucleotides activation of TILs and CpG administration alongside adoptive transfer [462]. 
TILs from human lung cancer patients were adoptively transferred into autologous tumour 
bearing nude mice. The study showed CpG dinucleotides enhanced the efficacy of adoptive 
cell transfer by modifying Th1 polarisation and infiltration of Th17 cells. Combinational 
therapy combining CpGs with anti-CTLA-4 and PD-1 improved long-term survival and led to 
increased levels of tumour-reactive T cells and reduced numbers of Tregs at the tumour site 
in treatment of murine experimental bladder cancer [463]. Providing further evidence that 
altering the balance of T cell subsets to a higher Th1 based phenotype leads to a better 
prognosis within cancer patients.  
Clinical data suggests that the combination of CTLA-4 blocking antibody with tumour 
antigen vaccination had synergistic activity and administration of ipilimumab has been shown 
in phase III trials to improve survival in 20-25% of metastatic melanoma patients [464]. Anti 
CTLA-4 therapy has been shown to overcome T cell tolerance and help sustain an active 
immune response against cancer cells, if used in combination with adoptive transfer of high 
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avidity, tumour antigen-specific T cells perhaps this 20% increased survival could be 
enhanced. In this way high avidity T cells selectively infiltrating tumours via antigen 
recognition on endothelium could maintain an active state by removal of the suppressive 
effects of CTLA-4 engagement.  Huang et al [465] showed that patients with metastatic 
melanoma treated with the CTLA4 blocking antibody Tremelimumab had enhanced CD8 T 
cell infiltration into tumours in both responding and non responding patients. There were 
similar levels of expression of T cell activation markers (CD45RO, HLA-DR) in both groups, 
and no difference in markers for cell replication (Ki67) or the suppressor cell marker FOXP3. 
Perhaps the non responders had lost target antigen or HLA and therefore showed increased T 
cell infiltration but these T cells were unable to recognise tumour antigens to exert and anti-
tumour response. 
In addition to removing suppressive signalling targeting CTLA-4 interferes with co-
inhibition, whereas targeting co-stimulatory molecules such as CD28 [466], OX40 [467] and 
CD137 [468] has also been shown to elicit anti-tumour responses [469]. The aim of targeting 
co-stimulatory molecules is to increase the numbers of tumour-specific T cells primed to 
elicit anti-tumour responses and to expand this population of memory cells. Other 
combinational strategies could include helping to prevent the immunosuppressive tumour 
microenvironment by targeting other tumour infiltrating immune cells such as myeloid-
derived suppressor cells (MDSCs) which inhibit tumour-specific immune responses via IL-10 
secretion. Targeting MDSCs may allow T cells, having infiltrated the tumour, to be 
effectively re-primed by activated APCs and retained in the tissue to carry out effective anti-
tumour responses.  
Therapeutic implications of the requirement for antigen-specific transmigration mean 
increasing MHC class I expression on the tumour endothelium would be an advantage. An 
alternative form of therapy to attempt to increase antigen-specific transmigration into 
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tumours would be to use targeted therapy to increase specific peptide uptake via the 
endothelium using vehicles such as liposomes containing the peptide of interest.Liposomes 
penetrate tumours spontaneously via the tumour endothelium, leading to known enhanced 
permeability and subsequent drug retention effect  [470]. 
 
In conclusion the requirement for cognate peptide recognition on tumour endothelium shown 
to be important for T cell infiltration into tumours adds another factor to the requirement for 
an efficient T cell vaccine. Understanding the requirements for CD8 infiltration into tumour 
is crucial for the future development of cancer vaccines. High avidity T cells are required to 
infiltrate tumours where low avidity T cells would be unable to recognise sufficient cognate 
antigen on the tumour endothelium being unable to infiltrate into tumour tissue. The effect of 
T cell avidity on the ability to infiltrate and target tumours could be further investigated in the 
same TRP-2 positive B16 model using TRP-2 specific T cell lines of varying avidities 
adoptively transferred into mice bearing tumours with varying TRP-2 expression levels. The 
ideal experimental outcome would be to determine the expression level of tumour antigens 
required for efficient targeting by cognate antigen-specific CTLs. Knowing the ideal T cell 
avidity and antigen expression levels on tumour endothelium required for T cell infiltration 
and subsequent anti-tumour responses could be used to predict patient responses to therapy.  
 
This study highlights that anti-tumour responses require high frequency, high avidity T cells 
that recognise cognate peptide processed by tumour cells, taken up by endothelial cells and 
presented in the context of MHC molecules for efficient T cell infiltration. In addition, 
kinetics, inflammation and chemokine gradients can influence the Teff: Treg ratio. 
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